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ABSTRACT  
 
The advent of deep sequencing has revealed marked differences in microRNA 
(miRNA) expression profiles between cell types. We focus on how miRNAs are 
regulated in embryonic stem cells (ESCs) and their differentiated neural 
progenitor stem cells (NPSCs). We discovered that 60% of miRNAs are regulated 
by transcription. The remaining 40% of miRNAs were transcribed but not 
processed in ESCs. Furthermore, systematic analysis of miRNAs on chromosome 
1 and 2 helped to validate our results. We show that 43% of these miRNAs, 
which are highly expressed in differentiated cell types but poorly expressed in 
ESCs, were transcribed but not processed in ESCs. Therefore we infer that post-
transcriptional regulation of miRNAs is prevalent in ESCs and could potentially 
be a characteristic of this cell type.  
 
Post-transcriptional regulation of miRNAs is also evident in miRNA clusters. 
Clusters of miRNAs are transcribed together however individual mature miRNA 
expression often differs between tissues and even within the same tissue type. 
Following investigation into post-transcriptional regulation, we discovered 
extensive alternative polyadenylation in three different miRNA clusters. We 
suggest that alternative polyadenylation has the potential to influence regulation 
of individual miRNAs within a cluster contributing to their differential 
expression levels.  
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We have also established an improved assay for the novel anti-tumour splicing 
inhibitor, Spliceostatin A (SSA). Prior to our work, there was a disparity between 
the effects of SSA in vitro versus in vivo. In agreement with this, our initial results 
showed that only <25% of genes were affected by SSA, as assayed by RT-PCR. 
However, we demonstrate that the splicing of nascent RNAs was more globally 
inhibited by SSA, indicating that the previous assay had been obscured by the 
large amounts of spliced mRNA already present in cells. The new assay allowed 
us to uncover the effects of SSA on nuclear localization of RNA and to verify these 
effects with another inhibitor, TG003.  
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1.1 RNA 
Ribonucleic acid (RNA) is a nucleic acid polymer that plays a number of crucial 
roles in biological processes across all species. The central dogma of molecular 
biology states that DNA encodes genetic information that is transcribed into 
messenger RNA (mRNA) by RNA polymerase enzymes. Messenger RNAs are 
subsequently translated into proteins by ribosomes (Crick, 1970). This promotes 
the idea that the primary role of RNA is to facilitate the translation of protein. 
However, due to its diverse sequence and biochemical properties, RNAs are 
powerful molecules, with a vital role in cellular processes that extends beyond its 
ability to code for proteins.  
 
RNAs have the capability to form secondary and tertiary structures allowing 
molecular binding interactions and catalytic reactions (Hiriart et al., 2012). Since 
the discovery of RNA in 1868 (Dahm, 2005) our understanding of RNA function 
has been constantly expanding. RNAs have been characterised according to 
function including catalytic and non-coding RNAs which have roles within gene 
regulation, viral transposon defence and epigenetics (Kaikkonen et al., 2011).  
 
Owing to advances in technologies, an abundance of post-transcriptional RNA 
regulation has been discovered including alternative splicing, alternative 
polyadenylation and RNA editing (Du et al., 2009). In addition biochemical 
advancements have allowed analysis of protein-RNA interactions in vivo yielding 
further insights into RNA biogenesis and regulation. The human genome 
sequencing project and several recent high-throughput transcriptomic analyses 
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have revealed that eukaryotes transcribe 90% of their genomes but less than 
10% of genes that encode RNA transcripts get translated into proteins (Martens-
Uzunova et al., 2013, Kaikkonen et al., 2011). In addition, the coding exons of 
these genes account for only 1.5% of the genome (Esteller, 2011).  
 
The functionality of the majority of transcribed non-coding RNAs is still under 
vigorous debate (Ponting and Belgard, 2010), however we are aware that a 
subset of RNAs are not “junk” nor are they simply the intermediary between 
DNA and protein but actually functional end products themselves (Baulcombe, 
2003, Fire, 2007, Licatalosi and Darnell, 2010).  
 
1.1.1 Non-coding RNA 
Although protein-coding genes represent a small percentage of the human 
genome, they remain the most studied, and only recently has the importance of 
some non-coding types of RNAs become apparent.  
 
Previously the function of ncRNA was limited to “infrastructural” roles in protein 
synthesis with ribosomal RNA (rRNA), essential for the structure of ribosomes; 
transfer RNA (tRNA), essential as adaptors between mRNA and amino acids; 
small nuclear RNAs (snRNA), involved in splicing and small nucleolar RNA 
(snoRNA); involved in the chemical modifications of these three precursor 
ncRNAs (Lodish and Porter, 1980, Alberts, 2002, Lodish, 2000).  
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Recently some species of the non-coding RNA fraction have been shown to be 
expressed dynamically during development and regulated by external stimuli 
(Ounzain et al., 2013). This suggested more of a regulatory role for ncRNAs and 
with further technological advancements, their functional capacity in a number 
biological process became obvious (Ounzain et al., 2013). 
 
There are several types of regulatory ncRNA which can be further categorised 
according to size, function and tissue specificity. Long non-coding RNAs 
(lncRNAs) are an abundant class of RNAs, ranging in sizes longer than ~200 
nucleotides. Long ncRNAs share structural characteristics with mRNA however 
they are typically less conserved and expressed less frequently. Current 
publications show lncRNAs to be key modulators of cell biology and some 
lnRNAs are misregulated in several human diseases (Harismendy et al., 2011, 
Hinterseher et al., 2011).  
 
1.1.2 Small non-coding RNA  
MicroRNAs (miRNAs), piwi RNAs (piRNAs) and endogenous small interfering 
RNAs (siRNAs) differ in origin, structure and cell specificity, however all play 
fundamental roles in biology and disease in multiple species (Liu and Paroo, 
2010). What unifies these three small RNAs is their size of about 20-30nts, their 
association with Argonaute (Ago) family proteins and their role in RNAi 
mediated gene regulation (Kim et al., 2009). Germ cell-specific piRNAs are the 
longest in length (24-31nt), with roles in transposon silencing through 
heterochromatin formation or RNA destabilisation (Kim et al., 2009). Small 
19 
 
interfering RNAs are shorter in length (21nts) and derived from long double-
stranded RNA. Small interfering RNA and miRNA share a primary function as 
post-transcriptional regulators of target RNAs.  
 
MicroRNAs are small non-coding RNAs that regulate diverse biological functions 
including cell proliferation, apoptosis, organ development, signal transduction 
and differentiation (Esquela-Kerscher and Slack, 2006, Kloosterman and Plasterk, 
2006). MicroRNAs control biological processes via post-transcriptional 
regulation, which facilitates fine tuning of gene expression. With over 2578 
mature miRNA sequences identified in the human genome (miRBASE, 
http://www.mirbase.org/), miRNAs are the most highly sequenced of all small 
RNA types forming the largest fraction; currently over 60% of total small RNAs 
are miRNAs (Kuchenbauer et al., 2008). Although a lot is still unknown about 
miRNAs, they remain the best understood of the three small RNA classes. 
MicroRNAs are predicted to be encoded by only 1% of the mammalian genome 
therefore it is striking that miRNAs regulate nearly a third of all protein coding 
genes (Li et al., 2009). The global nature of miRNA-directed regulation on 
thousands of genes makes it unsurprising that they play an important role in 
various human diseases (Shah et al., 2009, Hudder and Novak, 2008, Barbato et 
al., 2009). The mechanisms and biogenesis of miRNAs must be better understood 
to acquire knowledge of gene networks and more effective strategies for genetic 
manipulation (Kim et al., 2009).  
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1.2 MICRORNA 
1.2.1 The discovery of microRNAs 
Victor Ambros, Gary Ruvkun and colleagues discovered the first microRNA, Lin-4, 
in Caenorhabditis elegans (C.elegans) twenty years ago (Wightman et al., 1993, 
Ambros, 2004, Lagos-Quintana et al., 2001). The lin-4 gene was discovered to 
control timing of larval development of C.elegans. It does not code for protein but 
instead gets processed into two small RNAs (Lee et al., 1993). Lee et al., (1993) 
observed that one of the RNAs was ~22 nt in length and the other was ~60 nt; it 
was later concluded that the longer ~60 nt RNA was a precursor transcript that 
would fold into a stem loop in order to be processed into the smaller ~22 nt 
RNA. Furthermore it was observed that lin-4 RNAs had antisense 
complementarity to sites in the 3’UTR of the lin-14 mRNA (Lee et al., 1993, 
Wightman et al., 1993). Ruvkun and colleagues established the importance of the 
3’UTR complementarity for the regulation of lin-14 by lin-4 showing a decrease 
in Lin-14 protein without change in the mRNA levels (Wightman et al., 1993). 
This research provided one of the RNA interference models known today in 
which small RNA lin-4 pairs with the 3’UTR of lin-14 to cause translational 
repression (Lee et al., 1993, Wightman et al., 1993).   
 
Over the past two decades since the discovery of small RNAs, this field of 
molecular biology has significantly advanced. Since the first miRNA, lin-4, was 
discovered there have been a further 21,264 miRNA annotated in over 100 
species (miRBASE http://www.mirbase.org/). The importance of miRNAs in 
literally every biological process is becoming known, with roles in regulating 
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developmental timing and signalling pathways, cell death, metabolism and brain 
development (Esquela-Kerscher and Slack, 2006, Kloosterman and Plasterk, 
2006). In addition miRNAs play a part in human pathologies like viral diseases, 
genetic disorders and cancer (Xue et al., 2009, Castellano et al., 2009). 
 
Increasing numbers of mRNA targets of miRNAs are being identified and 
consequently miRNA functions are being experimentally determined helping to 
elucidate miRNA-induced gene regulation (Clancy et al., 2011, Kahai et al., 2009). 
MicroRNA-directed regulation is now known to occur at some of the most crucial 
levels of genome function including chromatin structure, chromosome 
segregation, transcription, RNA processing, RNA stability and translation (Kahai 
et al., 2009). MicroRNAs generally have an inhibitory role in gene expression 
however there have been recent reports of miRNAs causing upregulation of gene 
expression by direct RNA-binding (Kahai et al., 2009).  
 
1.2.2 Stages of miRNA biogenesis  
Approximately half of human miRNA genes are located within the intron of 
protein coding genes; another 40% are located within the intergenic regions of 
non-coding DNA and the remainder is suggested to be located within the exons 
of protein-coding or non-coding genes (Kim et al., 2009, Berezikov, 2011, Lu et 
al., 2008). It is estimated that over half of all human miRNAs are located in 
clusters of tandemly repeated pre-miRNAs, which are transcribed as single 
polycistronic units sharing a promoter. Despite regulation by the same 
transcriptional factors, each miRNA within a cluster can exhibit different cell-
22 
 
type and developmental specific expression patterns (Sotillo and Thomas-
Tikhonenko, 2011). This indicates that miRNAs within clusters can be processed 
individually, though the mechanism driving this remains elusive (Sotillo and 
Thomas-Tikhonenko, 2011).  
 
As illustrated in figure 1.1 miRNA biogenesis begins in the nucleus where the 
majority of primary miRNA (pri-miRNA) transcripts are generated by RNA 
polymerase II (Du and Zamore, 2005). A few miRNAs that associate with Alu 
repeats can alternatively be transcribed by RNA polymerase III (Kim et al., 2009). 
Primary miRNAs are several kilobases long with a 5’ cap structure and a 3’ 
poly(A) tail and many secondary stem-loop structures (Kim et al., 2009). Stem-
loop hairpin precursor miRNAs (pre-miRNA) are processed from the primary 
miRNA by an RNase III enzyme, Drosha and an RNA binding protein cofactor, 
DiGeorge syndrome critical region (DGCR8, also known as “Pasha”) (Lee et al., 
2003, Han et al., 2004, Gregory et al., 2004).  
 
Together Drosha and DGCR8 form a large ~650 kDa microprocessor complex 
which is conserved in animals and essential for embryonic development (Kim et 
al., 2009). It has been reported that pri-miRNA processing by the microprocessor 
may be co-transcriptional, whereby Drosha processing occurs after the 
transcript associates with the splicing machinery, but before the miRNA-
containing intron is removed (Kim and Kim, 2007, Morlando et al., 2008, Kim et 
al., 2009). Some miRNAs located within the introns of protein-coding genes can 
bypass Drosha processing and undergo spliceosome processing of short introns 
into pre-miRNA (mirtrons) (Figure 1.1) (Sotillo and Thomas-Tikhonenko, 2011). 
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Some mirtrons require exonucleolytic trimming at the 5’ and 3’ ends to be 
exported (Sotillo and Thomas-Tikhonenko, 2011, Ladewig et al., 2012).  
 
All pre-miRNAs share a stem-loop structure of about 70 nts with a 2 nucleotide 
overhang at the 3’ end (Sotillo and Thomas-Tikhonenko, 2011). Regardless of 
processing method, Exportin 5 recognises the >14 bp ds-RNA and the short 
3’overhang of the miRNA, so that together with cofactor Ran-GTP they mediate 
the nuclear export of pre-miRNA into the cytoplasm (Kim et al., 2009). In the 
cytoplasm, pre-miRNAs are cleaved again near the terminal loop by another 
RNAse III endoribonuclease, Dicer, producing short (18 nt-25 nt) double-
stranded RNA duplexes (Hutvagner et al., 2001, Sotillo and Thomas-Tikhonenko, 
2011).  
 
Dicer is highly conserved and in humans Dicer interacts closely with TRBP (TAR 
RNA-binding protein) and PACT (protein kinase RNA activator), which do not 
contribute to miRNA processing, but instead aid the formation of the RNA-
induced silencing complex (RISC) (Figure 1.1) (Kim et al., 2009, Sotillo and 
Thomas-Tikhonenko, 2011). The RNA duplex unwinds into separate strands 
where one strand becomes the 18-25 nt mature “guide” miRNA and the other is 
the passenger miRNA “*” strand. It is predicted that the choice of mature miRNA 
is dependent on the themodynamic stability of base pairing of the 5’ end of the 
duplex where the least stable strand unwinds enabling association with Ago 
proteins (Sotillo and Thomas-Tikhonenko, 2011, Khvorova et al., 2003, Kim et al., 
2009). It is also possible that both strands can be processed as functional mature 
miRNAs in comparable amounts. Current literature is vague about the 
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mechanism behind strand selection however at present it is thought that Dicer 
frees the duplex after cleavage and the stable end of the miRNA duplex binds to 
TRBP and the other end associates with one of the Ago proteins (Preall and 
Sontheimer, 2005).  
 
In D. melanogaster and humans it has been shown that multi-functioning Ago 2 is 
also able to remove the passenger miRNA strand by endonucleolytic cleavage 
(Matranga et al., 2005, Miyoshi et al., 2005). In humans, any of the four Ago 
proteins can be recruited by RISC with no obvious preference, however only Ago 
2 can cleave target mRNAs resulting in post-transcriptional gene silencing 
(Sotillo and Thomas-Tikhonenko, 2011, Meister et al., 2004). In C.elegans and 
D.melanogaster the choice of Ago protein is potentially determined by the miRNA 
duplex structure, whereby perfect matches and central mismatches 
preferentially associate with different Ago proteins (Kim et al., 2009). In humans 
there seems to be little difference in the type of associated miRNA duplexes 
suggesting that Ago 1-4 may share similar roles (Kim et al., 2009).  
 
It has recently come to light that not all miRNAs remain in the cytoplasm, miR-
29b, miR-320 and miR-373 accumulate in the nucleus and target mRNA for 
silencing (Hwang et al., 2007, Kim et al., 2008, Place et al., 2008, Liao et al., 2010). 
This implies that miRNAs are able to translocate back into the nucleus after 
processing in the cytoplasm and shows that nuclear mRNAs do not escape 
regulation by miRNAs.  
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During miRNA processing, variations arise due to alternative RNAse III cleavage 
producing isomiRs which are defined as miRNAs with differing 5’ and 3’ ends 
(Lee et al., 2010). During miRNA biogenesis there are several opportunities for 
regulating miRNA expression. A level of control of miRNA expression is essential 
in maintaining normal cell function, as misregulation of mRNAs can result in fatal 
disease (Kim et al., 2009). Consequently studies into the regulation of miRNAs 
could prove to be hugely important in development and disease. 
Figure 1.1 MicroRNA biogenesis. Schematic diagram of canonical miRNA biogenesis 
and mirtron processing. Double black arrows illustrate cleavage sites. (adapted 
from Sotillo and Thomas-Tikhonenko, 2011).  
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1.2.3 MicroRNA regulation of messenger RNA  
The primary role of microRNAs is to regulate target mRNA, a process that is 
dictated by Watson-Crick complementary base pairing of the mature miRNA to 
the mRNA 3’UTR. In animal species miRNA targeting does not require a high 
degree of base-pairing to target mRNA. Therefore miRNAs that are not exactly 
complementary to their mRNA targets can act to inhibit protein synthesis while 
retaining the stability of the mRNA target (Guo et al., 2010, Ambros, 2004). 
However, the extent of complementarity can dictate the precise effect that the 
miRNA may exert on the target mRNA.  
 
It is possible that miRNAs can also regulate target genes by direct cleavage of a 
single phosphodiester bond on the target mRNA between bases 10 and 11, this 
requires 100% complementarity between the miRNA and the target site of the 
mRNA (Elbashir et al., 2001).  The most crucial feature for miRNA-mRNA 
targeting is the presence of a seed region which is normally the 2-8 nucleotides 
of the 5’ end of mature miRNA, which matches with the 3’UTR sequence of the 
mRNA perfectly (figure 1.2). Although there are bulges and mismatches in the 
miRNA-mRNA pairing, perfect base pairing is required in the region that 
associates with Ago (seed region).  
 
On the whole it is thought that perfect base pairing between the miRNA seed and 
the mRNA target can cause destabilisation by three different mechanisms; 
endonucleolytic target cleavage by Ago2, translational inhibition and mRNA 
decay (Sotillo and Thomas-Tikhonenko, 2011).  
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The RISC can inhibit the initiation of target mRNA translation by preventing cap-
recognition by eIF4E (Kiriakidou et al., 2007). Messenger RNAs whose 
translation is cap-independent are reported to be immune to miRNA-mediated 
silencing (Humphreys et al., 2005). This RISC-mediated de-capping is a 
prerequisite to Poly(A) binding protein (PABP)-dependent deadenylation of the 
target mRNA by the deadenylation complex (Giraldez et al., 2006, Wu et al., 
2006). Following deadenylation, the transcript is degraded by cytoplasmic 5’-3’ 
exonuclease XRN1 (Wakiyama et al., 2007).  
 
Translational repression can be induced by upregulating ribosome inhibitory 
proteins e.g. eIF6, which inhibits the joining of the 60S ribosomal units with the 
40S and can also result in mRNA deadenylation (Chendrimada et al., 2007, 
Selbach et al., 2008). Furthermore, it is has been suggested that miRNAs can 
inhibit translational elongation by causing co-translational degradation (Nottrott 
et al., 2006) and/or cause premature ribosome dissociation from the mRNA 
Figure 1.2 Illustration of microRNA seed sequence. A) Sequence and structure of miR-
let-7a, highlighted in blue is the sequence of the mature miRNAs (guide strand on top 
and passenger below) and the red sequence is the 5’ seed sequence of the guide 
miRNA. B) The 8 nt seed sequence (in red) of miR-let-7a binds the 3’UTR of Lin28 with 
perfect complementarity. 
A miR-let-7a 
B 
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(Petersen et al., 2006). The mechanism behind miRNA-mediated translational 
repression is not yet fully clarified and further studies are required to confirm 
current hypotheses.   
 
Global mRNA analyses have led to the discovery of widespread alternative 
polyadenylation (APA) that has functional significance to the regulation of mRNA 
by miRNA. An example of APA regulating miRNA-mRNA interactions occurs in 
muscle stem cells where Pax3, a myogenic regulator, is able to evade miR-206 
regulation in specific cells by producing transcripts with shorter 3’UTRs (Boutet 
et al., 2012). In proliferating cells such as ESCs, mRNAs tend to have shorter 
3’ends making them less susceptible to miRNA regulation conversely 
differentiated cells generate mRNA with long 3’UTRs resulting in higher levels of 
gene regulation. This phenomenon is particularly prevalent in cancer cells which 
have high expression of short 3’UTR mRNAs that are able to evade miRNA 
regulation (Clancy et al., 2011, Mayr and Bartel, 2009).  
 
Bioinformatics and experimental data suggest that a single miRNA may have 
over a hundred mRNA targets and as a result could have a substantial effect on 
gene expression. It is characteristic for mRNA transcripts to be regulated by 
multiple miRNAs and multiple mRNA transcripts can also be targeted by a single 
miRNA (Barbato et al., 2009). Consequently expression profiling of miRNAs is a 
growing trend aiding the identification of miRNAs that regulate a range of 
processes in development, potentially showing promise as miRNA biomarkers of 
disease.  
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1.2.4 MicroRNA evolution and conservation 
MicroRNA genes are evolutionarily conserved across a vast number of species 
and they reside in various locations, either singly or as single transcriptional 
units that encode several miRNAs (Lagos-Quintana et al., 2001, Lau et al., 2001). 
The discovery of conserved microRNA let-7 in worms, flies, and humans led to 
the realization that miRNAs are widespread in animals and evolutionarily 
conserved.  
 
MicroRNAs in animals are possibly distinct from plant miRNAs because although 
there are some similarities, there is limited homology in sequence and structure 
(Zhang et al., 2006, Chapman and Carrington, 2007, Kim et al., 2009). Our 
knowledge about miRNA origin, evolution and conservation is increasing with 
the ever expanding databases of next-generation high throughput sequencing of 
small RNAs. The mirBASE data collection includes miRNAs from over 180 species 
including 368 miRNAs in C.elegans, 2042 in human and 338 in Arabidopsis 
thaliana making miRNAs the largest class of regulatory genes in animals. 
MicroRNAs are known to be present amongst a variety of animal species 
including miR-100 which is shared between eumetazoans indicating that 
miRNAs were present very early on in animal evolution (Berezikov, 2011). 
Conservation observed in 34 miRNAs between two bilaterian lineages, 
protostomes and deuterostomes, indicate that miRNA expansion occured at the 
bilaterian lineages (Berezikov, 2011). Bilaterian animal miRNAs are 
phylogenetically conserved and more than 55% of C.elegans miRNAs have 
human homologues reinforcing the importance of miRNAs throughout evolution 
(Kim et al., 2009, Pasquinelli et al., 2000). There are several theories about the 
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origin of miRNAs and it is known that novel miRNAs are constantly arising 
without evidence of miRNA loss (Berezikov, 2011). Consequently this may help 
explain the emergence of a direct correlation between the number of miRNAs 
and morphological complexity of a species (Berezikov, 2011). 
 
There are several distinct origins of miRNAs however the major source of novel 
miRNAs is by gene duplication (Kim et al., 2009). Over one third of human 
miRNAs are found in “families” meaning they share similar mature miRNA 
sequences and identical (or virtually identical) seed sequences. MicroRNA gene 
families can arise by two types of duplication, local/tandem duplication where 
the duplicate gene remains adjacent to the original miRNA or non-local 
duplication where the new miRNA is located away from the original. Evidence of 
both tandem and non-local duplication can be seen in the human let-7 family 
which can be found in 12 different genomic loci (Kim et al., 2009).  
 
More than half of all human miRNAs are located in the intron of protein-coding 
genes (Rodriguez et al., 2004) and transcribed either sense or antisense to the 
overlapping gene. Intronic miRNAs tend to have arisen later in evolution, being 
more species specific and less conserved (Berezikov, 2011). The hypothesis 
behind this observation is that those introns which are readily transcribed, and 
have an affinity towards forming secondary folding structures could potentially 
be recognised and processed by the miRNA machinery (Berezikov, 2011). 
 
Other sources of miRNA genes can be derived from retrotransposons or DNA 
transposons as well as snoRNAs, tRNAs and pseudogenes (Yuan et al., 2010). 
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With the constant emergence of novel miRNAs it is likely that many novel miRNA 
targets will be determined by chance and often result in deleterious effects. Chen 
and Rajewsky, 2007 suggest that novel miRNAs are subject to transcriptional 
control. They theorise that miRNAs are initially expressed at low levels in 
restricted tissues to reduce random targeting allowing the transcriptome to 
gradually eliminate harmful consequences by natural selection (Chen and 
Rajewsky, 2007). In addition to transcriptional regulation miRNA genes are also 
under post-transcriptional regulation which can result in diversification that is 
important to the evolution of established miRNAs (Chen and Rajewsky, 2007, 
Berezikov, 2011). 
 
Many mature miRNA transcripts can arise from the same hairpin as a result of 
differential processing by Drosha and Dicer enzymes and non-templated 3’ 
nucleotide addition (Lee et al., 2010). These mature miRNAs can vary at the 3’ or 
5‘ ends producing isomiRs (Lee et al., 2010). 3’ isomiRs are common to most 
miRNAs and although they share the same targets their production can be tissue 
specific and biologically relevant. 5’ isomiRs can result in a change in the seed 
sequence resulting in different target predictions (Berezikov, 2011). The 
variation in expressions of dominant isomiRs during evolution is known as “seed 
shifting” and is often evident in distant species (Berezikov, 2011). After 
processing by Dicer the miRNA duplex unwinds resulting in the incorporation of 
only one miRNA strand into RISC. This is thought to be dependent on relative 
thermodynamic stability at the ends of the strands and potentially other 
accessory components. The star or passenger miRNA was thought to be 
degraded however although it is generally less abundant than the guide strand 
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they can still associate with the RISC complex, accumulate in cells to biologically 
relevant levels and regulate target mRNA. Therefore it is possible that the ratio 
of guide to star strand miRNA can be altered. This is known as “arm switching 
and frequently occurs in a variety of species and between tissues making this an 
important mechanism for miRNA selection (Berezikov, 2011).   
 
1.2.5 Transcriptional regulation of miRNAs 
MicroRNA expression is heavily regulated by transcription and like other RNA 
Pol II substrates, transcription factors are involved in the spatial-temporal 
regulation of miRNA gene transcription (Kim et al., 2009). So far 243 
transcription factor-miRNA regulatory relationships have been identified 
bioinformatically and/or experimentally (Wang et al., 2010). Examples include 
the transcription factor and tumour suppressor p53, which is known to activate 
the miR-34 family (He et al., 2007). Furthermore during myogenesis, 
transcription factor myogenin and MYOD1 bind miR-1 and miR-133 loci and 
induce gene transcription (Chen et al., 2006, Rao et al., 2006).  
 
MicroRNA genes are also exposed to epigenetic regulation, which is often altered 
in cancer cell lines. This can be seen in the miR-203 locus, where DNA 
methylation of this gene is common in T-cell lymphoma but not in normal T 
lymphocytes (Bueno et al., 2008). A study by Suzuki et al. 2011 combined miRNA 
expression data, chromatin signature and histone modifications in colorectal 
cancer cells to identify 47 miRNAs in 37 gene transcription units that are under 
epigenetic control (Suzuki et al., 2011).  
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1.2.6 Post-transcriptional regulation of miRNAs 
Differential expression of miRNAs can be seen across different cell and tissue 
types as well as different developmental stages and there is an abundance of 
evidence that suggests transcriptional regulation alone does not account for the 
regulation of all miRNAs (Ryazansky et al., 2011, Siomi and Siomi, 2010, Davis 
and Hata, 2009, Thomson et al., 2006, Newman and Hammond, 2010, 
Obernosterer et al., 2006).  Developmental timing and external stimuli can 
dictate miRNA expression resulting in a number of outcomes. This includes 
global down-regulation of miRNA expression in tumour cell lines; differential 
expression of individual miRNAs within clusters; expression of single miRNA 
strands and differential miRNA isomer expression (van Kouwenhove et al., 2011, 
Bernstein et al., 2003, Murchison et al., 2005). Post-transcriptional regulation is 
an important mechanism for the regulation of messenger RNA, as evident by the 
expanding repertoire of interfering RNAs. As a result it is not surprising that it 
would also play a large part in the regulation of miRNA themselves.  
 
The complexity of miRNA biogenesis lends itself to post-transcriptional 
regulation at multiple stages, leading to either elevated or reduced miRNA 
expression. MicroRNA regulation may be governed by proteins involved in 
miRNA processing, nuclear export and variations in the miRNA transcript itself 
as a result of SNPs or processing irregularities (Wu et al., 2008).  
 
Microprocessor levels can differ between cell types and in diseases such as 
prostate and ovarian cancer, where Drosha and Dicer expression is known to 
vary (Shiohama et al., 2003, Ambs et al., 2008, Merritt et al., 2008). This implies 
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that the miRNA processing machinery itself is under post-transcriptional control. 
The microprocessor is strictly regulated through a combination of negative and 
positive feedback loops. For example the microprocessor is able to cleave DGCR8 
mRNA hairpins reducing DGCR8 expression, and DGCR8 protein is able to 
stabilise Drosha protein providing regulatory feedback loops (Han et al., 2009).  
 
Drosha forms a complex with DEAD-box RNA helicases P68 and P72 and nuclear 
factors NF90 and NF45 (Gregory et al., 2004). These components have been 
proven to affect processing efficiency of specific miRNAs (Davis et al., 2008, 
Fukuda et al., 2007, Slezak-Prochazka et al., 2010, Suzuki et al., 2009, Yamagata 
et al., 2009). Endogenous p68 regulates miRNA expression under different 
stimuli by interaction with various proteins including SMAD transcription factors 
to facilitate the processing of pri-miRNA 21 and p53 to enhance expression of 
several pri-miRNAs in response to DNA damage (Slezak-Prochazka et al., 2010). 
It is known that p53 plays a large role in the regulation of miRNAs promoting 
recruitment of the microprocessor to the target pri-miRNAs (Suzuki et al., 2009). 
Regulation by p68/p72 can also cause down-regulation of a group of pri-miRNAs 
upon estrogen receptor alpha (ERα) stimulation (Yamagata et al., 2009). 
NF90/NF45 have also been shown to regulate miRNA biogenesis, as over 
expression of these proteins result in the accumulation of pri-let-7a-1, pre-miR-
21 and pri-miR-15a~16-1, however the mature miRNA levels remain constant, 
suggesting a compensatory feedback mechanism is in place to restore mature 
miRNA expression (Sakamoto et al., 2009).  
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The low levels of pre-miRNA expression compared to mature and primary 
miRNA expression implies that Dicer efficiently processes pre-miRNA (Lee et al., 
2008). Dicer associates with TRBP, PACT and Ago to facilitate RISC assembly. 
TRBP phosphorylation mediated by the mitogen-activated protein kinase 
(MAPK) signalling pathway results in stabilisation of RISC. This results in 
elevated expression of growth promoting miRNAs (e.g. miR-17 and miR-92) and 
down-regulation of growth-inhibiting miRNAs (e.g. miR-let-7a) (Paroo et al., 
2009). Overexpression of Ago proteins is also known to upregulate the 
expression of specific mature miRNA (Diederichs and Haber, 2007).   
 
Primary and precursor miRNAs may have multiple conformations caused by 
base pair mismatches of the stem structure and internal loops; the choice of 
conformation determines successful Drosha-DGCR8 processing (Ma and Huang 
2010).  The terminal loop of miRNA precursors contains key sites for several 
RNA binding proteins which stabilises a specific structure either aiding or 
diminishing Drosha-DGCR8 processing (Ma and Huang 2010).  
 
During differentiation of mouse and human ESCs, mature miR-let-7 expression is 
enhanced whilst the primary transcript remains constant. The expression of the 
inhibitory RNA binding protein, Lin28 was discovered by biochemical 
purification of associated complexes and mass spectrometric analysis. In humans, 
two isoforms of Lin28 are generated, cytoplasmic Lin28 (or Lin28a) and Lin28b 
which is mainly localised to the nucleolus. Lin28 alone is able to inhibit the 
processing of both the primary and precursor miRNAs and Lin28b is able to bind 
the pri-miRNA in the nucleolus causing repression of mature miR-let-7 
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expression in ESCs and various cancer cell types (see figure 1.3). Both Lin28 and 
Lin28b bind to the terminal loop of precursor and/or primary miR-let-7 and 
block processing of these transcripts. Lin28 substrates are targeted by terminal 
uridyl transferase (TUTase) Zcchc11/TUT4 and subjected to 3’uridylation of the 
precursor and primary transcripts resulting in its degradation because Dicer 
cannot cleave the precursor miRNA with such an elongated 3’ tail (Thornton and 
Gregory, 2012, Heo et al., 2008). Lin28b substrates are unable to be processed by 
the microprocessor complex by a mechanism that still remains unknown 
(Thornton and Gregory, 2012).  To add to the complexity of miR-let-7 regulation, 
Lin28 itself is a target of miR-let-7, culminating in a complex double feedback 
loop (Thornton and Gregory, 2012). 
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Figure 1.3 Schematic of Lin28-mediated control of let-7 biogenesis. Left: When Lin28 
is absent miRNA-let-7 is processed through the canonical miRNA biogenesis 
pathway. Right: Lin28 blocks miR-let-7 processing by Dicer in the cytoplasm through 
direct binding with the terminal loop of pre-miR-let-7 and recruits the terminal 
uridyl transferase (TUTase) Zcchc11/TUT4 to catalyze the addition of a 3′ 
oligouridine tail, marking pre-let-7 for degradation. Lin28b is expressed primarily in 
the nucleolus and binds to pri-let-7, blocking the activity of the microprocessor 
complex through an unknown mechanism. Reproduced from (Thornton and 
Gregory, 2012) 
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Lin28 is the first of a rising number of RNA binding proteins which have been 
discovered to associate with the terminal loop of miRNAs and regulate their 
expression. This reveals a potent method for regulation of specific miRNAs. 
Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is an RNA binding 
protein that assists Drosha-DGCR8 in the processing of miR-18a (Guil and 
Caceres, 2007). hnRNP A1 binds the terminal loop and the stem region resulting 
in the relaxation of the primary miRNA which facilitates processing by the 
microprocessor (Michlewski et al., 2010, Michlewski et al., 2008). Pri-miR-18a is 
located within the miR-17~19 cluster however hnRNP A1 does not affect the 
other members of the cluster which might explain the differences in expression 
of the individual miRNAs. In addition hnRNP A1 also binds to pri-let-7a-1 and 
pri-miR-101-1 suggesting that hnRNP A1 may regulate the expression of several 
miRNAs (Slezak-Prochazka et al., 2010).  
 
KH-type splicing regulatory protein (KSRP) is a component of the 
microprocessor complex and RISC. KSPR binds to the terminal loop of primary or 
precursor transcripts and induces the expression of a cohort of miRNAs 
including miR-21, miR-let-7a and miR-16 (Trabucchi et al., 2009). 
 
The expression of Arsenic Resistance protein 2 (Ars2) is linked to the 
proliferation of cells during mammalian embryonic development and Ars2 
associates with Drosha and DGCR8 to regulate miRNA processing of miR-let-7 
and miR-21 (Gruber et al., 2009). The mechanism behind Ars2 regulation is not 
fully known and its conservation is still to be confirmed in humans. 
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It is probable that there are many RNA binding proteins involved in the 
regulation of miRNAs by association with the terminal loop. Approximately 14% 
of terminal loop sequences across vertebrates are conserved (Michlewski et al., 
2008). Michlewski et al. (2008) demonstrate that pri-miRNAs with conserved 
terminal loops are down-regulated by overexpression of antisense loop oligos 
conversely non-conserved pri-miRNA were unaffected by the antisense loop 
oligos (Michlewski et al., 2008). This suggests that there is a genuine role of 
conserved terminal loops in primary miRNA processing.   
 
Exportin 5 interacts exclusively with pre-miRNAs recognising the >14 b double 
stranded region and the 2 nt 3’ overhang. Knockdown of exportin 5 results in a 
decrease in both precursor and mature miRNA expression, indicating that 
exportin 5 has a role in stabilising the precursor transcript (Yi et al., 2003). 
Exportin 5 is a rate limiting factor for miRNA production as knockdown and 
over-expression coincides with reduction or elevation of miRNA expression 
respectively (Yi et al., 2005, Lund et al., 2004). It has been shown that export of 
pre-miR-31 is tissue specific and in situ hybridisation for pre-miR-31 showed 
cytoplasmic localisation in HS766T cells however in MCF7 cells pre-miR-31 
accumulated in the nucleolus (Lee et al., 2008). 
 
Changes in miRNA genes or miRNA transcripts can also result in altered miRNA 
processing. Single nucleotide polymorphisms (SNPs) and point mutations in the 
pri-miRNA sequence could alter the secondary structure inhibiting processing of 
the miRNA. Mutations in 5 out of 42 specific miRNA genes were found in 15% of 
patients with chronic lymphocytic leukemia (Calin et al., 2005). Moreover a 
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mutation in the miR-15a~16-1 gene, 7 bp downstream from pre-miR16-1 causes 
reduced mature miRNA expression (Calin et al., 2005). MicroRNA 146 and miR-
125a are known to have reduced expression due to SNPs located on one of the 
strands in the double stranded stem of the pre-miRNA (Jazdzewski et al., 2008, 
Duan et al., 2007). This introduces a bulge in the pri-miRNA hairpin resulting in 
disruption of Drosha processing (Jazdzewski et al., 2008, Duan et al., 2007). 
These studies highlight the importance of secondary structure in the biogenesis 
of miRNAs however, it is important to note that changes to miRNA folding by 
mutations, are incredibly rare (Jazdzewski et al., 2008, Duan et al., 2007).  
 
RNA editing plays a widespread role in miRNA sequence alteration and has a 
large effect on miRNA processing. RNA editing is carried out by adenosine 
deaminases acting on RNAs (ADARs) (Valente and Nishikura, 2005). ADAR 
editing is a well-known mechanism for post-transcriptional miRNA regulation in 
mammals where primary miRNAs are subject to adenosine – inosine conversion 
by adenosine deaminases. Inosines are similar to guanosine in structure and are 
recognised as such, therefore the sequence and the structure of the RNA is 
altered. (Valente and Nishikura, 2005)  The sites subject to ADAR editing are 
often located on the double stranded stem of the pri-miRNA resulting in the 
suppression of processing of the pri-miRNA by Drosha and DGCR8 (Yang et al., 
2006, Valente and Nishikura, 2005).  
 
Primary miR-22 was the first miRNA discovered to undergo ADAR editing at 
sequence positions near the Drosha cleavage site however, the role of miR-22 
editing is still unknown (Luciano et al., 2004). ADAR editing of pri-miR-142 
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resulted in reduced Drosha processing of the transcript and cleavage in vitro by 
Tudor-SN, which specifically degrades inosine-containing dsRNAs (Scadden, 
2005, Yang et al., 2006). ADAR editing can occur after primary to precursor 
miRNA processing, causing inhibition of Dicer processing. Edited pre-miR-151 is 
bound by the Dicer complex, but cleavage and release of mature miRNA is 
prevented (Kawahara et al., 2007). Although ADARs are mainly localised to the 
nucleus some isoforms can shuttle between the cytoplasm and the nucleus. 
(Kawahara et al., 2007). ADARs are able to interfere with cytoplasmic pre-miRNA 
and edit the “seed” sequence resulting in inhibition of completely different 
mRNA targets as proven for miR-376 (Kawahara et al., 2007). Although ADAR 
editing is widespread amongst miRNA transcripts and its regulatory effects on 
miRNAs seem apparent, the biological significance of ADAR editing for a majority 
of miRNAs is not known.  
 
It has recently been reported that 3’ adenylation and uridylation of precursor 
and mature miRNAs, result in post-transcriptional enhancement or deregulation 
of the miRNA. MicroRNA-122 is stabilised by adenylation of its mature transcript 
by GLD-2, while uridylation by TUTase4 destabilises miR-let-7 at the precursor 
stage (Katoh et al 2009; Heo et al 2009). It is possible that adenylation and 
uridylation mechanisms compete for activation or degradation of the same 
miRNA transcript (Yu and Chen, 2010). Sequencing results have identified that 3’ 
modifications are common amongst precursor and mature miRNAs implying that 
this may be a general mechanism for regulation of miRNAs (Newman et al., 
2011). 
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Recently a large post-transcriptional regulatory network of conserved 
pseudogenes has been discovered, containing 3’UTRs with conserved miRNA 
binding sites (Sumazin et al., 2011, Treiber et al., 2012). These pseudogenes are 
actively transcribed and function as “sponges” to sequester mature miRNAs, 
preventing binding of genuine targets (e.g. PTEN and pseudogene PTENP1) 
(Sumazin et al., 2011, Treiber et al., 2012). In addition a smaller number of genes 
were discovered that affect miRNA-mRNA interactions through indirect 
sequestration of specific miRNAs, known as “non-sponge” regulators (Sumazin et 
al., 2011, Treiber et al., 2012). 
 
The increasing number of publications on post-transcriptional regulation of 
miRNAs over the past decade emphasises the significance of understanding 
miRNA biogenesis. Despite this, there have been few reports of miRNAs 
regulated post-transcriptionally in human ESCs and ESC differentiation, the most 
well-known example being Lin28 regulation of the let-7 miRNA family.  
 
1.2.7 MicroRNAs in stem cells and disease 
Human embryonic stem cells (ESCs) are isolated from the inner cell mass of a 
blastocyst. The hallmark characteristic of ESCs, is their ability to remain 
indefinitely in an undifferentiated state of self-renewal, whilst simultaneously 
having the capacity to differentiate into all cell types (pluripotency) (Friel et al., 
2005). Consequently, ESCs have the exciting potential for the treatment of 
disease through regenerative medicine and can also provide valuable model 
systems for drug development. ESCs’ unique characteristics are under spatial-
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temporal control regulated by cell signalling, epigenetic, transcriptional and 
post-transcriptional factors (Gangaraju and Lin, 2009). The switch from 
pluripotency to differentiation of stem cells requires reduced cell proliferation 
and transcriptional activation of cell lineage genes (Berardi et al., 2012). 
 
In order to understand ESCs’ great therapeutic potential for disease, we must 
expand our understanding of the mechanisms behind self-renewal and 
pluripotency. Consequently much focus has been placed on the generation of 
induced pluripotent stem cells (iPSCs) (Thorrez and Sampaolesi, 2011). A novel 
approach by Takahashi and Yamanaka to generate these cells involved the use of 
four defined transcription factors, Oct4, Sox2, Nanog, and Lin28 to generate 
iPSCs in mice and human fibroblast cells (Takahashi and Yamanaka, 2006, 
Takahashi et al., 2007). These pluripotency transcription factors and others e.g. 
Klf4, c-Myc and Esrrb have been discovered to be regulated by miRNAs at a post-
transcriptional level (Takahashi and Yamanaka, 2006, Takahashi et al., 2007, 
Feng et al., 2009).  
 
Neural differentiation of human ESCs in vitro occurs in three stages where more 
than 90% of the cell population becomes neural progenitor stem cells (NPSCs) 
after 3 weeks of differentiation (Gerrard et al., 2005). This was achieved by 
growing ESCs in neurobasal media supplemented with N-2, B-27 and mouse 
recombinant noggin which ensured differentiation into NPSCs by blocking the 
bone morphogenetic protein pathway (Gerrard et al., 2005). Cells at each of the 4 
stages of neural differentiation have specific characteristics including differences 
in appearance (see Figure 1.4) and cell surface antigen expression. In 
44 
 
collaboration with Dr Wei Cui, our laboratory has made miRNA libraries from 
ESCs before and after differentiation into stage N3 NPSCs. Solexa sequencing of 
these libraries in Dr Nick Dibb’s group by Dr Elcie Chan has identified a number 
of miRNAs that are preferentially expressed in ESCs or NSPCs (figure 1.5, and see 
the rest  in supplementary table S1). 
 
Figure 1.4 Phase-contrast images of ESCs and neural differentiation 
stages N1, N2 and N3 (courtesy of Dr Wei Cui (Gerrard et al., 2005). 
Figure 1.5 Northern blot and Sequencing data validating 
expression of miRNA specific to ESCs and NPSCs (Chan et 
al 2009 unpublished) 
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Dr Elcie Chan’s sequencing data corroborates recent publications showing a 
distinct miRNA expression profile in stem cells, suggesting a miRNA-specific 
influence in maintaining pluripotency and influencing differentiation 
(Lakshmipathy et al., 2007, Laurent et al., 2008, Wilson et al., 2009). The 
preferential expression pattern of specific miRNA families in ESCs and the 
reduction of others is largely conserved in mice (Leonardo et al., 2012).  
 
Since miRNAs are known to regulate over 50% of mammalian protein coding 
genes it is not surprising to learn of miRNA involvement in maintaining 
pluripotency and influencing differentiation (Chekulaeva and Filipowicz, 2009, 
Gangaraju and Lin, 2009). During development and disease miRNAs regulate 
cells by influencing self-renewal, differentiation, survival and apoptosis in 
addition to controlling cell response to external stimuli (Vidigal and Ventura, 
2012).  
 
Knockout of the microprocessor machinery (Drosha and/or DGCR8) in mice 
results in embryonic lethality proving miRNAs to be essential for development 
(Bernstein et al., 2003, Wang et al., 2007). Recently reports show that in vitro 
expression of ESC-specific miRNAs can greatly enhance the efficiency of somatic 
reprogramming to an ESC-like state as well as sustain pluripotency in ESCs (Li 
and He, 2012, Liao et al., 2011, Kuo and Ying, 2013).  This verifies the role of 
highly expressed miRNAs in maintaining pluripotency in ESCs. 
 
The miR-302 cluster was identified in Elcie’s sequencing data and many others 
as being highly expressed in ESCs. Key transcriptional regulators Oct4 and Sox2 
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are required for the transcriptional regulation of the miR-302 family, and the 
miR-302 cluster is a known regulator of Oct4 and Sox2 forming an intricate 
feedback mechanism regulating ESC pluripotency (Marson et al., 2008, Card et al., 
2008, Lin et al., 2008, Subramanyam et al., 2011, Liao et al., 2011, Judson et al., 
2009). In 2008, Lin et al showed that by retroviral transduction of the miR-302 
cluster in human skin cancer cells, they were able to recapitulate the gene 
expression profile of ESCs and iPSCs, however typical ESC morphology could not 
be visualised (Lin et al., 2008).  Following this, it was discovered that the miR-
302 cluster in humans, and a number of other miRNA clusters in mice, were able 
to enhance iPSC reprogramming of mouse and human fibroblasts, when used in 
conjunction with Oct4, Sox2 and Klf4 reprogramming factors (Lin et al., 2008, 
Subramanyam et al., 2011, Liao et al., 2011, Judson et al., 2009).  
 
Recent reports claim that when performing lentiviral transduction, the miRNA-
302 cluster alone can achieve full reprogramming of mouse and human somatic 
cells, with up to two times more efficiency than the transcription-factor based 
method (Anokye-Danso et al., 2011, Miyoshi et al., 2011). In addition to the 
reprogramming ability of the miR-302 cluster, it has been suggested that relative 
expression of miR-302b could serve as a biomarker for the developmental stage 
of ESCs and iPSCs, as miR-302b is strictly spatially and temporally regulated in 
ESCs (Berardi et al., 2012).  
 
MYC also binds and up-regulates the ESC-specific miR-17 cluster, (Suh et al., 
2004) and acts to repress the expression of miR-34 and miR-29, suggesting that 
ESC-specific transcription factors and miRNAs act mutually (Leonardo et al., 
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2012). ESCs have a very short cell cycle which is essential to their pluripotency; 
their lack of G1/S checkpoint means a short G1 phase resulting in highly 
proliferative cells (Becker et al., 2006). Many ESC-specific miRNAs have mRNA 
targets involved in the cell-cycle pathway e.g. cyclin D1 and retinoblastoma-like 
1 (Card et al., 2008, Leonardo et al., 2012, Subramanyam et al., 2011), and the 
majority of highly expressed miRNAs in ESC contribute to cell-cycle regulation by 
accelerating the G1 to S transition (Leonardo et al., 2012).  
 
MicroRNA-let-7 was the first miRNA shown to play vital roles in development 
across a range of species (Bagga et al., 2005, Thornton and Gregory, 2012). 
Unlike miR-302, miR-let-7 is depleted in ESCs and upregulation of the miR-let-7 
family promotes differentiation of ESCs by repressing “stemness factors” Lin28 
and c-Myc (Thornton and Gregory, 2012). Careful regulation of miR-let-7 is 
evident by the extensive regulatory feedback mechanism with Lin28 (discussed 
in Ch 1.2.5). This suggests that fine tuning of miRNA biogenesis is important in 
the maintenance and differentiation of the ESC state. These studies demonstrate 
the importance of miRNAs in ESC differentiation as well as somatic cell 
reprogramming. 
 
Comprehensive miRNA profiling of ESCs has produced distinctive expression 
patterns specific to ESCs. ESC-specific miRNAs are more likely to be arranged in 
genomic clusters, they have higher oncogenic miRNA gene expression, and highly 
expressed miRNAs share a consensus seed sequence indicating mutual 
regulation of specific target-mRNAs (Laurent et al., 2008).  Although there is 
currently limited literature about post-transcriptional regulation, specifically in 
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human ESCs, it has been reported that expression of many primary miRNA 
transcripts during early mouse development is blocked post-transcriptionally at 
the Microprocessor stage (Thomson et al., 2006).  
 
Given the significant impact of miRNAs in biological processes it is not surprising 
to learn that miRNAs are under significant control and are highly regulated. 
Despite this, misregulated miRNA processing does occur resulting in down-
regulation of miRNAs in many cancers and other diseases highlighting the 
importance of research into regulation of miRNA (Thomson et al., 2006, Garzon 
et al., 2009).  
 
My aim is to use the deep sequencing database generated by Dr Elcie Chan in 
conjunction with other available sequencing databases, to investigate miRNAs 
that are highly or lowly expressed in ESCs and differentiated NPSCs. Some of 
these specific miRNAs are known to play a clear role in maintaining pluripotency 
and promoting neural differentiation however, the regulatory mechanism 
responsible for the expression of the majority of miRNAs is not yet known. 
Currently, the methods of post-transcriptional regulation of only a few miRNAs 
are known. Consequently there is a severe lack of understanding about how the 
majority of miRNAs expressed in ESCs get downregulated upon differentiation. 
Likewise, the mechanism by which miRNAs that promote differentiation get 
upregulated is not completely understood. Therefore I intend to uncover any 
miRNA regulation patterns that are distinct to either ESCs or NPSCs in an 
attempt to uncover the mechanism behind miRNA-mediated ESC differentiation.    
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1.3 SPLICING AND THE SPLICEOSOME  
1.3.1 RNA splicing and the spliceosome 
In 1977 it was discovered that many eukaryotic genes contain non-coding 
intervening sequences (introns), that interrupted protein-coding sequences 
(exons) (Alberts, 2002). The entire gene undergoes transcription into precursor 
mRNA, requiring further processing into mature mRNA (Alberts, 2002). 
Precursor mRNA splicing can take place co-transcriptionally whilst the RNA is 
still bound to DNA by RNA polymerase II (Brody and Shav-Tal, 2011, Listerman 
et al., 2006). The spliceosome machinery is tightly regulated with an excision 
time in vivo of less than 3 minutes after transcription by RNA polymerase II 
(Beyer and Osheim, 1988). Pre-mRNA processing therefore takes place in the 
nucleus as do further distinct processing steps including 5’ capping, 3’ end 
processing and 3’ polyadenylation (Alberts, 2002). Following the processing of 
pre-mRNA, the mature mRNA is exported into the cytoplasm where translation 
takes place (Alberts, 2002).  
 
The spliceosome is an evolutionarily conserved multi-megadalton, 
macromolecular complex, that catalyzes the splicing reaction of pre-mRNA 
(Wahl et al., 2009, Rino and Carmo-Fonseca, 2009, Galej et al., 2013). A major 
and a minor form of the spliceosome have been characterised, designated to 
target U2- or U12-type introns (Will and Luhrmann, 2005). The U2-dependent 
spliceosome is the main form found in all eukaryotes and catalyses the excision 
of the most commonly found U2-class of introns. This spliceosome is composed 
of five small nuclear ribonucleoproteins (snRNPs) (U1, U2, U4/U6 and U5), each 
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of which are composed of specific small nuclear RNAs (snRNAs) and associated 
proteins. In addition to snRNPs, the splicing machinery interacts with over 200 
distinct proteins including RNA binding proteins and enzymes (Wahl et al., 2009, 
Rino and Carmo-Fonseca, 2009, Bonnal et al., 2012, Cooper et al., 2009).  
 
Typically the splicing machinery recognises pre-mRNA substrates by “strength” 
(i.e. binding complementarity) of the 5’ and 3’ splice site consensus sequences, 
(A/C)AG/GUAAGU and (C/U)N<10(C/T)AG/G respectively, situated at the ends of 
each intron (Buvoli et al., 2007, Roybal and Jurica, 2010, Kaida et al., 2007).  
Along with the splice site sequences, the branch site consensus sequence 
(UAUAAC) and other silencer and enhancer signals are required to regulate 
splicing. The branch site is located upstream of the 3’ splice site flanking a 
specific adenosine base which is involved in catalyzing the two-step enzymatic 
pre-mRNA splicing reaction (Wahl et al., 2009, Alberts, 2002). Recognition of the 
5’ splice site by the U1 snRNP initiates gradual spliceosomal assembly on pre-
mRNA transcripts. This is followed by the recognition of the branch site by U2 
snRNP and subsequent binding at the polypyrimidine tract resulting in the 
recruitment of preassembled U5/U4/U6 snRNP (Wahl et al., 2009, Rino and 
Carmo-Fonseca, 2009). Subsequently catalytic activation of the spliceosome is 
achieved by conformational and compositional rearrangement resulting in the 
formation of a structured RNA network between the branch sequence of the pre-
mRNA and U2, U5 and U6 snRNPs (Wahl et al., 2009). This initiates two 
transesterifcation reactions; initially the hydroxyl group of the adenosine 
flanking the branch site attacks the phosphodiester bond at the 5’ splice site 
generating a free 5’ exon and an intron lariat 3’ exon (Wahl et al., 2009). 
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Consequently, the 5’ exon hydroxyl group attacks the phosphodiester bond at the 
3’ splice site causing exon ligation and excision of the lariat intron (Wahl et al., 
2009) (see figure 1.6). Following the 2nd catalytic reaction the spliceosome 
dissociates from the mRNA (and associated proteins) as well as releasing U2, U5 
and U6 snRNPs to be reused in future splicing reactions (Wahl et al., 2009). This 
model of stepwise spliceosomal assembly on pre-mRNA substrates is conserved 
and has been derived from multiple in vitro and in vivo biochemical studies in 
yeast and mammalian systems (Rino and Carmo-Fonseca, 2009). It is possible 
that another model for spliceosome assembly exists based on evidence that the 
five snRNPs can associate and remain assembled in the absence of pre-mRNAs 
(Wahl et al., 2009, Rino and Carmo-Fonseca, 2009).  
Figure 1.6 Schematic of pre-mRNA splicing by the spliceosome: Pre-mRNA is 
represented by two exons (blue boxes) separated by an intron (grey line) and the 
5’splice site, branch site and 3’ splice site are labelled. The sequence of the snRNP and 
pre-mRNA associations resulting in the removal of the intron from the pre-mRNA and 
the release of the mRNA with associated protein is displayed, adapted from (Wahl et 
al., 2009). 
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The less abundant U12-dependent spliceosome catalyses the removal of U12-
type introns which are present in less than 1% of all human mRNAs and other 
species contain them including plants and animals (Will and Luhrmann, 2005, 
Koonin, 2006). Although both U2- and U12-dependent spliceosomes co-exist in 
cells and act upon pre-mRNAs with both intron types, the target branch sites and 
splice sites have different consensus sequences. The sequences for the U12-type 
5’ splice site (A/GUAUCCUUU) and the branch site (UCCUUAACU) are closer 
together in distance; longer in sequence and more highly constrained than U2-
type sites. In addition contrary to the U2-type, the sequence of U12-type 3’ splice 
site can be variable. The minor U12-dependent spliceosomes assembles and 
removes U12-type introns in an identical mechanism to the major U2-dependent 
spliceosome and parallel snRNPs are involved. Other than differences in splice 
site recognition and snRNP composition mechanistic variations are limited and 
the U12-dependent spliceosome remains relatively uncharacterized compared to 
the U2-type spliceosome (Will and Luhrmann, 2005).  
 
1.3.2 Splice site selection and alternative splicing 
The conformation and the composition of the spliceosome is highly dynamic, 
making the machinery accurate and flexible. The choice of 5’ and 3’ splice sites by 
the spliceosome, plays a major role in the resultant mature mRNA and 
subsequent protein expression. Splice site selection is regulated by a number of 
factors and the relative binding affinity of the splice site for U1 and/or U2 snRNP 
plays a significant part however, this alone is not capable of directing 
spliceosome assembly (Wahl et al., 2009).  
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As previously mentioned, the cis-acting flanking pre-mRNA enhancer and 
silencer sequences play a huge role in determining splice site usage by binding 
trans-acting factors that either recruit snRNPs to the splice site or prevent snRNP 
binding (Singh and Valcarcel, 2005). Serine/Arginine rich (SR) proteins and 
heterogeneous nuclear ribonucleoproteins (hnRNPs) are trans-acting factors 
that exhibit exonic splicing enhancing (ESEs) or exonic splicing silencing (ESSs) 
properties respectively (see figure 1.7). Furthermore some regulatory factors 
can regulate both ways depending on the sequence and position of target pre-
mRNA (Zhu et al., 2001, Caceres et al., 1994, Kornblihtt et al., 2013).  
Figure 1.7 Splice site recognition. Splice site recognition is determined by cis-acting 
sequences in the pre-mRNA. Ser/Arg-rich protein (SRs) and heterogeneous nuclear 
ribonucleoproteins (hnRNPs) bind to 5’ and 3’ splice site regions flanking the exon and 
target components of the spliceosome (shown in green). This can cause activation or 
inhibition on the recognition and use of the specific splice sites by the spliceosome. 
(exonic splicing enhancers (ESEs), exonic splicing silencers (ESSs),intronic splicing 
enhancers (ISEs) and intronic splicing silencers (ISSs)) Adapted from (Kornblihtt et 
al., 2013) 
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These RNA binding proteins act together in an opposing manner, exerting both 
silencing and enhancing effects that collectively directs splice site recognition by 
the spliceosome (Wahl et al., 2009) (see figure 1.7). This external regulatory 
feature of pre-mRNA splicing is not present in yeast genomes, where the 5’splice 
site and branch site consensus sequences bind with perfect complementarity to 
U1 and U2 snRNPs. In mammalian genomes perfect complementary binding of 
the branch sites and splice sites to the spliceosome components is not necessary 
for recognition allowing flexible selection of splice sites, forming the basis for 
alternative splicing.  
 
Alternative splicing is an important and evolutionarily advantageous mechanism, 
responsible for the proteomic complexity of higher organisms allowing the 
human genome to create a huge variety of distinct mRNA transcripts from only 
20,000 genes (Kornblihtt et al., 2013). Messenger RNA selection by the use of 
alternative splice sites, is a process that is often subject to tissue-specific or 
developmental control (Mayeda and Krainer, 1992). Alternative splicing is the 
primary mechanism for generating mRNA diversity although other mechanisms 
exist such as alternative transcription start sites, alternative polyadenylation and 
RNA editing (Nilsen and Graveley, 2010, Licatalosi and Darnell, 2010).  
Production of variable forms of mRNA from a single pre-mRNA transcript, by 
alternative splicing, is predicted to generate proteins with differing and 
sometimes even opposing functionality (Nilsen and Graveley, 2010, Licatalosi 
and Darnell, 2010). Furthermore alternative splicing is able to regulate specific 
mRNA downregulation, by introducing premature termination codons, resulting 
in nonsense mediated decay or regulation of cis-acting elements (Nilsen and 
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Graveley, 2010, Licatalosi and Darnell, 2010). Results of genome-wide RNA 
sequencing show that alternative splicing occurs in nearly 95% of human genes, 
with utilization of the varying splice sites dependent on physiological 
development and external stimuli, potentially impacting all aspects of biology 
(Wang et al., 2008, Kalsotra and Cooper, 2011, Kornblihtt et al., 2013, Mironov et 
al., 1999) 
 
Alternative splicing patterns may change in response to external stimuli, 
implying functional significance. Yet alternative splicing may not always result in 
development modifications, rather it may cause a shift in ratios of mRNA 
isoforms, allowing “fine-tuning” of protein expression.  Consequently the extent 
of functional impact of alternative splicing is not entirely understood, and the 
diverse mRNA profile includes thousands of low abundance transcripts that are 
not conserved. This indicates that a large number of alternative splicing events 
are potentially stochastic and unregulated (Pickrell et al., 2010).  
 
Database analysis and deep RNA sequencing have verified that alternative 
splicing is widespread and that there is evidence for a large class of low level 
intraexonic splicing, and alternative 5’ and 3’ splicing, that uses non-canonical 
splice sites, which do not necessarily conform to the GT-AG splice site consensus 
of most introns (Ng et al., 2004, Pickrell et al., 2010). It is not clear whether non-
canonical splicing is catalysed by the splicing machinery and for this reason the 
extent of non-canonical splicing remains uncharacterised. The splicing 
machinery is highly conserved and known to be present and functional in a 
variety of yeast species whose genomes contain very few introns. This suggests  
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extended functionality of the spliceosome beyond just splicing and corroborating 
evidence supports that the macromolecular complex is involved in gene 
transcription, mRNA biogenesis and nonsense mediated decay (Roy and Gilbert, 
2006, Le Hir et al., 2000, Pleiss et al., 2007).    
 
1.3.3 Roles of splicing in disease 
Splicing is essential to understanding gene expression and is also of medical 
relevance. Translation of erroneously spliced pre-mRNA leads to aberrant 
proteins, which forms the basis of many diseases (Will and Luhrmann, 2011, 
Nilsen and Graveley, 2010). Splicing is regulated by many factors including 
numerous sequencing codes, several snRNPs and RNA binding proteins. It is this 
complex set of interactions which cause increased chance of exposure to 
mutations that can cause mRNA misregulation.  
 
Aberrant pre-mRNA splicing is one of the most common mechanisms underlying 
human genetic disease and cancer disorders (Haj Khelil et al., 2008, Cooper et al., 
2009). A large number of diseases can be caused by missense, nonsense and 
frame-shift mutations in exons of protein coding genes, as well as mutations in 
mRNA UTRs that affect translation and mRNA stability (Cooper et al., 2009). It is 
predicted that more than a third of disease-causing SNPs are able to disrupt 
splicing (Singh and Cooper, 2012) and for some genes, up to 50% of point 
mutations that cause disease lie within splicing consensus sequences (Cooper et 
al., 2009).  
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To identify putative disease causing pre-mRNA splicing mutations, available 
bioinformatic tools provide estimates on potential disruption of 5’ and 3’ splice 
sites, branch sites, enhancer and silencer sites and other features such as protein 
binding sites and RNA secondary structure. The dbass database 
(http://www.dbass.org.uk/) contains a detailed list of splicing-associated 
diseases with 577 5’ splice site mutations and 307 3’ splice site mutations 
recorded to date. Mutations that target 5’ or 3’ splice sites, the polypyrimidine 
tract, branch sites, enhancers and/or silencers most frequently result in exon 
skipping however intron retention can also occur (Singh and Cooper, 2012). 
Additional splicing abnormalities can occur where 5’, 3’ or both splice sites can 
undergo mutation, weakening the canonical splice sites, resulting in the specific 
activation of alternative dormant splice sites known as cryptic splice sites or 
induce splicing of intronic sequences known as pseudoexons (Singh and Cooper, 
2012). Both events lead to inclusion of additional sequence in the spliced mRNA, 
that may act in preference to existing splicing enhancer or silencer sequences, or 
disrupt the mRNA reading frame producing defective proteins (Singh and Cooper, 
2012).  
 
Trans-acting splicing factor genes responsible for regulating alternative splicing 
are also exposed to mutations which can affect a large set of genes, rather than 
singular mRNA targets by mutations in cis-regulatory elements (Singh and 
Cooper, 2012). Genome-wide approaches have linked changes in alternative 
splicing profiles to tumorgenesis, with alteration of approximately half of all 
alternative splicing events in ovarian and breast cancer tissue (Venables et al., 
2009). Alternative splicing contributes to cancer progression with roles in cell 
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proliferation, cell death and angiogenesis (Bonnal et al., 2012). An example of 
alternative splicing regulation during angiogenesis is the choice between 
alternative 3’ splice sites of vascular endothelial growth factor (VEGF) isoforms 
which assist or impede blood vessel formation essential for tumour growth and 
spreading (Harper and Bates, 2008). 
 
Misregulation of RNA splicing due to disease-causing mutations is generating an 
array of new therapeutics targeting the splicing factors and the spliceosome. An 
abundance of data has highlighted the role of splicing components as targets of 
novel therapeutics in a variety of diseases (Bonnal et al., 2012). Efforts are 
underway to target abnormal pre-mRNA splicing. This includes nucleic acid 
based therapy, such as antisense oligonucleotides, that bind competitively to 
splicing enhancers to prevent recognition (Hua et al., 2010, Bonnal et al., 2012). 
This method is being developed for the treatment of spinal muscular atrophy 
(SMA) which is caused by the disruption of SMN1 (survival of motor neuron 1) 
(Hua et al., 2010, Bonnal et al., 2012). The human genome makes an almost 
identical gene, SMN2, except for a nucleotide change that causes skipping of exon 
7 (Hua et al., 2010, Bonnal et al., 2012).  The modified antisense oligos base pairs 
with intronic splicing silencer sequences that inhibit the binding of splicing 
repressors preventing skipping of exon 7 and restoring the expression of SMN1 
mRNA (Hua et al., 2010, Bonnal et al., 2012). The splicing defect can be corrected 
in SMA mouse models and in cell-free splicing assays in cultured human cells 
(Kornblihtt et al., 2013, Hua et al., 2010, Bonnal et al., 2012). 
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1.3.4 Splicing inhibitors  
Recently an abundance of novel inhibitors of splicing have been identified and 
purified from the bacterial species Pseudomonas and Streptomyces as well as 
other sources (Bonnal et al., 2012).  
Spliceostatin A (SSA) is a synthetic analogue of FR901463 FR901464 and 
FR901465 originating from a fermentation broth of Pseudomonas spp (Kaida et 
al., 2007). SSA displays cytotoxic effects in multiple tumour cell lines resulting in 
arrest in the G1 and G2/M phases of cell cycle (Kaida et al., 2007). SSA is proven 
to have improved activity, stability and solubility in vitro compared with its 
naturally occurring counterparts (Kaida et al., 2007). Using biotinylated SSA, it 
was discovered that splicing factor 3B (SF3b), a sub complex of the spliceosomal 
U2 snRNP, most tightly bound to streptavidin beads linked to SSA (Kaida et al., 
2007). In addition knockdown of SF3b1 expression, mimics many of the drug 
induced effects, confirming SSA inhibition of the SF3B complex (Kaida et al., 
2007). SF3b is a 5-polypeptide complex and the exact binding location has not 
yet been determined and remains to be fully elucidated. (Bonnal et al., 2012). 
Although SF3b3 is the most highly enriched component bound to SSA in a 
complex, the SF3b1 displays the tightest binding to SSA in competition 
experiments (Bonnal et al., 2012).  With this in mind it is possible that the 
binding pockets of SSA involve an interface between the two SF3B subunits 
(Kaida et al., 2007, Bonnal et al., 2012). SSA association with the SF3b subunit 
blocks binding to pre-mRNA, resulting in a conformational change that 
compromises RNA binding efficiency and disables the proofreading mechanism 
(Kaida et al., 2007, Bonnal et al., 2012). This results in destabilisation of the U2 
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snRNP and their complexes with pre-mRNA preventing subsequent spliceosomal 
assembly (Kaida et al., 2007).  
 
Despite targeting basic steps in splice site recognition, SSA appears to have a 
cytostatic (not cytotoxic) effect on cells with an enhanced effect in cancer cells 
(Kaida et al., 2007).  This could be due to a number of factors including cellular 
permeability; splicing demand and lack of effect on U12-dependent splicing 
(Bonnal et al., 2012). 
 
Another more characterised splicing inhibitor, TG003, is a benzothiazole 
inhibitor of the serine/arginine rich (SR) protein kinases CLK1 and CLK4. During 
splicing, SR proteins are highly phosphorylated and by this method are able to 
catalyse splicing reactions and spliceosome formation. TG003 inhibits the CLK-
mediated phosphorylation of SR proteins and consequently inhibits the SR 
protein regulation of pre-mRNA splicing (Muraki et al., 2004, Hagiwara, 2005).  
 
Pre-mRNA splicing inhibitors are leading the field in therapies against disease 
caused by deregulation of splicing. For example TG003 is of potential relevance 
for the treatment of Duchenne muscular dystrophy, as it is able to promote 
skipping of a mutant exon in the dystrophin gene, but not of the wild-type exon 
(Bonnal et al., 2012). SSA and related compounds display anti-tumoural 
properties with some, e.g. cisplatin, that are currently used in chemotherapy 
(Bonnal et al., 2012). Thus SSA may potentially be used not only as a powerful 
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tool for analysing pre-mRNA splicing but also for developing new therapeutics 
(Kaida et al., 2007).  
 
Kaida et al 2007 report that SSA effectively inhibits the U2 component SF3b from 
binding to pre-mRNA thereby inhibiting splicing completely. However Kaida et al 
2010 and Younis et al 2010 report that although SSA was able to inhibit splicing 
fully in vitro, the observed inhibitory action of SSA in vivo appeared to be partial 
even at high concentration (Kaida et al., 2010, Younis et al., 2010). The focus of 
my research is to establish a working assay for SSA in vivo in order to further 
investigate the properties of the novel inhibitor and its effects on RNA and the 
spliceosome. 
 
1.3.5 Splicing and microRNAs 
Recent evidence suggests an evolutionary connection between the RNA splicing 
machinery and miRNA mediated gene silencing (Dumesic et al., 2013, Tabach et 
al., 2013). Splicing proteins and miRNAs co-localize to P bodies and Cajal bodies, 
supporting the idea of functional cross-talk between splicing and miRNA gene 
silencing (Tabach et al., 2013).   
 
Tabach et al 2013 suggest that a large number of proteins involved in intron 
removal are also required for miRNA interference, and they claim that genomes 
with few introns do not need miRNA regulation either. In addition there is a 
strong correlation between the presence of Ago proteins (and other miRNA 
components) and the number of introns a species has (Tabach et al., 2013). 
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Tabach et al 2013 suggests that miRNA pathway components such as Argonaute, 
can engage with pre-mRNA to provide another layer of splicing surveillance. 
Without cross-talk between Ago proteins and pre-mRNA the selective advantage 
of introns could fade too (Tabach et al., 2013).  
 
Dumesic et al 2013 reveals that stalled spliceosomes promote the expression of 
small silencing RNAs in Cryptococcus neoformans, reinforcing the concept of 
functional cross-talk between the spliceosome and RNAi machinery (Dumesic et 
al., 2013). Mutations of the pre-mRNA 3’ splice site resulted in increased 
production of siRNA however mutation of the 5’ splice site did not affect siRNA 
production indicating that spliceosome initiation was the major player in siRNA 
generation.  Inefficient splicing of pre-mRNAs means a greater dwell time on 
spliceosomes which provides the substrate for siRNA synthesis (Dumesic et al., 
2013). MicroRNA regulation together with splicing mechanisms form part of a 
mRNA surveillance pathway consisting of synonymous components that act as 
quality control of mRNA splicing. 
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1.4 PROJECT AIMS 
1.4.1 MicroRNA regulation in ESCs  
To investigate the regulatory mechanisms, which are responsible for the 
observed differences in microRNA expression, between ESCs and differentiated 
NPSCs.  
 
1.4.2 Alternative polyadenylation of miRNA genes 
Whilst investigating miRNA regulation, I discovered an extensive use of 
alternative polyadenylation sites in miRNA genes. This generated a second aim, 
to uncover the extent of alternative polyadenylation within miRNA genes, and to 
establish if this mechanism is a potential method for post-transcriptional 
regulation of miRNAs. 
 
1.4.3 Establishing a working assay for novel splicing inhibitor, Spliceostatin 
A 
To establish a better assay of the effect of splicing inhibitors, in vivo, in order to 
establish the global effects of spliceosome inhibition upon splicing in human cells 
and to facilitate the development of splicing inhibitors for therapeutic purposes.   
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CHAPTER 2 - MATERIALS AND METHODS 
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2.1 Cell Culture 
2.1.1 Cell culture of HEK293, HT1080 and HeLa cells 
Cells were cultured in D10 media which contains Dulbecco’s modified eagle’s 
medium (DMEM) with 10% (v/v) heat inactivated fetal bovine serum (FBS), 
supplemented with 2 mM L-glutamine, 50 U/ml penicillin and 50 μg/ml 
streptomycin, at 37oC in 10% CO2 (Invitrogen, Gibco). Generally, cells were 
passaged twice a week or once they reached ~80% confluency by washing in 
PBS and then incubating with 0.25% trypsin (Invitrogen, Gibco) for ~5 minutes 
at 37oC in 10% CO2. The cells were then re-suspended in D10 media and 
centrifuged at 1200 rpm for 5 mins. The cell pellet was resuspended in D10 and 
plated to the required density.  
 
2.1.2 Human embryonic stem cells and neuroprogenitor stem cells 
Human embryonic stem cell (ESCs) lines designated H7 and H1 and their 
differentiated neuroprogenitor stem cells (NPSCs) were kindly given to me by Dr 
Wei Cui (Imperial College London),  
 
NPSCs were grown on poly-L lysine (Sigma) and laminin (Invitrogen) coated 
plates. 6-well plates were coated with 1 ml of 16.7 µg/ml of poly-L lysine in PBS 
for 1 hr at RT. The poly-L lysine solution was aspirated and 1 ml of 20 µg/ml of 
laminin in PBS was added to each well and incubated at 4oC overnight. The 
laminin solution was aspirated before the cells were seeded. NPSCs were grown 
in N2B27 medium containing 1:1 of DMEM and neurobasal medium 
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supplemented with 1% B27, 0.5% N2 and 1% L-glutamine (Invitrogen). The 
medium was replaced every 2 days and 20 ng/ml of EGF and 20 ng/ml of bFGF 
were added fresh with every passage. To passage the NPSCs, TrypLE express 
(Invitrogen) was used to separate NPSCs into single cells. 
 
The H1 and H7 designated ES cells were cultured in conditioned mouse 
embryonic fibroblasts (MEFs) and SR medium (knockout DMEM and knockout 
serum replacement) with 8 ng/ml bFGF, 50 U/ml penicillin/streptomycin 
(Invitrogen, Gibco) and 200 µM glutamine (Invitrogen, Gibco) on matrigel-coated 
plates (Invitrogen, Gibco). The medium was changed daily and cells were 
maintained in ES cell colonies at confluence. 
 
2.1.3 Freezing cell lines 
Adherent cells were washed with PBS and then incubated with 1 ml of 0.25% 
trypsin. The trypsin was inactivated with 9 mls of D10 media and then the cells 
were centrifuged at 1000 rpm for 5 minutes. The pellet was re-suspended in D10 
media with 10% dimethyl sulfoxide (DMSO) and instantly aliquoted into 1 ml 
cryotubes. The cells were frozen in a cryo-freezing container containing 
isopropyl alcohol at -80C for at least 48 hrs and then stored in the -80oC freezer 
or in liquid nitrogen.  
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2.2 GENERAL RNA AND DNA PROTOCOLS 
 
2.2.1 Total RNA extraction 
Trizol was used as per manufacturer’s instructions (Invitrogen) to lyse cells and 
extract total RNA. 6 x 35 mm diameter dishes of confluent cells could generate 20 
µg - 100 µg of total RNA depending on the cell type. 1 ml of trizol reagent was 
used per 35mm well, and then 200 µl chloroform was added to isolate total RNA. 
The isolated total RNA was then precipitated with isopropanol and washed with 
80% ethanol before being resuspended in 30 µl of nuclease-free water. 1 μl of the 
sample was removed for quality check of 28S and 18S RNA on a 1% agarose gel. 
1 μl of the sample was measured in a UV spectrophotometer. All RNA samples 
were stored at –80oC. The quality of RNA samples was checked on a 1% TBE 
agarose gel containing 0.1 µg/ml of Ethidium Bromide (Sigma). The samples 
were run at 100 V for 1 hr and the quality of the 28S and 18S rRNA bands were 
checked under UV light.  
 
2.2.2 Small RNA enrichment 
Approximately 100 µg of total RNA was enriched for small RNAs using the 
miRVana kit (Ambion) according to the manufacturer’s instructions. Small RNAs 
were precipitated with an equal volume of 100% isopropanol and 3 µl of 
glycogen (Ambion glycoblue) and incubated at –80oC for 30 minutes. The RNAs 
were centrifuged at max speed in a microcentrifuge at 4oC.  The pellet was 
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washed with 80% ethanol and after air drying the RNA, the pellet was dissolved 
in a total of 10 µl of nuclease-free water (Ambion).  
2.2.3 cDNA synthesis  
20-100 ng of RNA was used for the reverse transcription reaction into cDNA. The 
sample of RNA, 0.5 µg of random hexamers and 1 µl of 10 mM dNTPs were 
combined with water to make a total of 35µl and the solution was denatured at 
65oC for 5 mins. 1 µl of 100 mM DTT, 2 µl of 5 x first strand buffer, 1 µl of 
RNAseOUT (40 U/μL), and finally 1 μl of SuperScript™ III RT enzyme (200U/μL) 
(Invitrogen) were added, making the solution a total of 40µl. The sample was 
incubated at 42oC for 30 mins, then 50oC for 30 mins and stored at -20oC.  
 
2.2.4 Polymerase Chain Reaction (PCR) 
1 µl of the RT sample (see chapter 2.2.3) was added to 1 µl of each of the gene 
specific forward and reverse primers (10 uM), 1 µl of 10 mM dNTPs, 2 µl of 10 x 
buffer and 1 µl of Taq polymerase (New England Biolabs) and made up to 20 µl 
with water. The PCR reaction was set at 94oC for 2 mins, followed by 35 cycles of 
94oC for 30 sec, 55oC for 30 sec, 72oC for 30 sec, and terminated at 72oC for 10 
mins (extension time is based on a rate of extension of 1 kb/min).  
 
PCR products were run on TBE agarose gels or 5% PAGE to check the product 
sizes. 1-2% (w/v) agarose, depending on product size, was dissolved in 1x TBE 
and cooled before adding 0.1 µg/ml ethidium bromide (Sigma-Aldritch). To make 
the 5% PAGE gels 2.5 ml 10 x TBE, and 6.75 ml of 40% (w/v) 19:1 
acrylamide:bis-crylamide was combined and adjusted to 50 ml with water.  Then 
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350 μl of 10% (w/v) ammonium persulphate (APS) and 17.5 μl of TEMED were 
added and the gel solution was mixed and poured into cassettes (Invitrogen). 
Samples were mixed with 6 x loading dye containing bromophenol blue and then 
loaded into the wells of the gel along with a 1kb ladder (New England Biolabs), 
100bp ladder (New England Biolabs) or a 50 bp ladder (New England Biolabs). 
Gels were run at 100V for ~1 hour and then visualised for bands on a UV light 
box.   
 
2.3 DNA EXTRACTION AND SEQUENCING 
 
2.3.1 DNA gel elution 
The DNA band of expected size was excised from the gel and eluted with 3 x 
volume of DNA elution buffer (0.5 M ammonium acetate, 10 mM magnesium 
acetate, 1 mM EDTA, 0.1% w/v SDS), at 16oC under agitation overnight or 37 oC 
for >2hr. The solution was filtered using spin-x centrifuge filter tubes with a 0.22 
µm pore and the remaining gel removed. The solution was precipitated with 3 x 
volume of -20oC ethanol, plus 0.1 x volume of 3 M sodium acetate and 1 µl of 
glycogen, overnight at -20oC. The DNA pellet was resuspended in 10 µl of water.  
 
2.3.2 Vector cloning 
The DNA eluted from the gel was cloned into pGEM-T Easy vector (Promega – 
see vector map below) by mixing 3.5 µl of the DNA with 0.5 µl of pGEM-T Easy 
vector, 5 µl of 2 x rapid ligation buffer and 1µl of T4 DNA ligase. The ligation 
reaction was incubated at room temperature for 2 hrs, and added to 50 µl of 
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Dh5α competent cells and incubated on ice for 1 hour. The cells were subjected 
to heat shock for 30 sec at 42oC, and then placed immediately on ice. 200 µl of YT 
medium was added to the cells and incubated at 37oC, agitating at 250 rpm for 
30 minutes. LB plates supplemented with ampicillin were pre-warmed to 37oC, 
and 100 – 200 µl of the cells were spread evenly onto the plate and incubated at 
37oC overnight.  
 
 
 
 
 
 
 
2.3.3 Colony PCR  
The PCR mix per sample consisted of 2 µl of 10 x Taq polymerase buffer, 0.4 µl of 
10 mM dNTPs, 0.2 µl of both the M13 forward and reverse primers (100 µM), 
0.73 µl of 1% w/v W-1 detergent (Sigma Brig-35P) and 0.2 µl of Taq polymerase 
enzyme was mixed together and made up to 20 µl with water. A p10 pipette tip 
was used to swipe single colonies on the plate and placed inside a PCR tube 
containing the 20 µl PCR mix. The solution was pipetted repeatedly to ensure 
sufficient mixing of the solution in each PCR tube and the tube was spun briefly. 
Vector used for DNA sequencing: pGEM-T easy vector were used in 
the cloning of RT-PCR products (taken from Promega manual).  
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The PCR reaction was set at 94oC for 2 mins, followed by 35 cycles of 94oC for 30 
sec, 55oC for 30 sec, 72oC for 30 sec, and terminated at 72oC for 10 mins. A 
sample of 10 µl of each of the PCR products was then checked on a 1.5% TBE 
agarose gel for amplification.  
Shrimp alkaline phosphatase (SAP) and exonuclease I (Exo I) reaction mix was 
set up by mixing 2 µl of SAP (1 U/µl) with 0.2 µl of Exo I (20 U/µl) and 12.8 µl 
water. This was then added to which was added to the 10 µl PCR mix. The 
samples were then incubated at 37oC for 30 mins, and inactivated at 80oC for 10 
mins.  
 
2.3.4 Sequencing 
The pre-sequencing PCR was prepared by mixing 4 µl of each sample with 1 µl of 
M13 forward primer (3.2 pmol/µl) and 2 µl of Big Dye Terminator (BDT) 3 µl 
water. The PCR thermocycler was set at 94oC for 2 mins, followed by 35 cycles of 
94oC for 30 sec, 50oC for 30 sec, 72oC for 30 sec, and terminated at 72oC for 10 
mins. 
 
8 mls of Big Dye precipitations solution was made with 6.25 mls of 100% ethanol, 
0.3 mls of 3 M sodium acetate and 1.45 mls of water. 40 µl of the precipitation 
solution was added to each of the pre-sequencing PCR products and left at room 
temperature for 20 mins. The samples were centrifuged at 4000 rpm for 40 mins, 
and the supernatant was discarded. The invisible pellet was washed with 50 µl of 
70% ethanol and centrifuged at 4000 rpm for 5 mins. The supernatant was 
discarded and the samples were left to dry at 37oC for 30 mins. Samples were 
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submitted for in-house sequencing with ABI Prism Big Dye Terminator cycle 
sequencing reaction kit. 
2.4 RACE 
 
2.4.1 5’rapid amplification of cDNA ends (5’RACE) 
The 5’RACE assay was carried out using the Ambion FirstChoice RLM-RACE kit 
(Invitrogen AM17000) as per manufacturer’s instructions and using reagents 
provided in the kit unless otherwise specified. Primers used were either 
provided in the kit or uniquely designed to be gene-specific, they can be found 
listed in section 2.10.5 under 5’RACE primers.  
 
10 µg of total RNA was treated with Calf Intestinal Phosphatase (CIP) for 1hr at 
37oC, and the reaction was stopped by adding ammonium acetate. The solution 
was then subject to acid phenol-chloroform extraction and the aqueous phase 
containing RNA was precipitated with equal volume of isopropanol for 10 mins 
at RT. This solution was then centrifuged at max speed for 20 mins at 4oC. The 
precipitated pellet was washed in 80% ethanol; air dried and resuspended in 10 
µl RNAse-free water. The sample was then treated with Tobacco Acid 
Pyrophosphatase (TAP) for 1 hr at 37oC. The RNA was then ligated to the 5’RACE 
adapter with T4 RNA ligase for 1 hr at 37 oC and half of the sample was reverse 
transcribed with M-MLV Reverse Transcriptase and random decamers for 1 hr at 
42oC. This sample was then ready to undergo nested PCR, first with the 5’RACE 
gene-specific outer primer followed by the 5’RACE gene-specific inner primer. 
Both PCR cycles followed with an initial denaturing step at 94oC for 3 mins, then 
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35 cycles of 94oC for 30 sec, 60oC for 30 sec, 72oC for 30 sec, and a final extension 
of 72oC for 7 mins. 5’RACE PCR products were visualised on a 5% PAGE gel 
stained with ethidium bromide and all bands were excised for sequencing in 
accordance with the sequencing protocol (Ch 2.3.4). See Figure 2.1 for an 
overview of the 5’RACE procedure and the position of primers used in the 
5’RACE PCR.  
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2 3’rapid amplification of cDNA ends (3’RACE) 
The 3’RACE assay was carried out using the Ambion FirstChoice RLM-RACE kit 
(Invitrogen AM17000) as per manufacturer’s instructions and using reagents 
provided in the kit unless otherwise specified. Primers used were either 
provided in the kit or uniquely designed to be gene-specific, they can be found 
listed in section 2.10.4 under 3’RACE primers.  
Figure 2.1 Overview of the 5’RACE protocol and 5’RACE 
amplification of transcripts. A) Diagram of the overview 
of 5’RACE procedure described in ch 2.4 B) Diagram of 
primer positions for 5’RACE, white arrows denote the 
position of primers supplied by the kit and the black 
arrows represent the position of gene-specific 
transcripts (Taken from the Ambion FirstChoice RLM-
RACE protocol manual) 
A 
B 
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1 µg of total RNA was used in a reverse transcription reaction which involved the 
binding of an anchored oligo(dT) 3’RACE primer to poly(A) containing RNA 
transcripts. Anchored oligo(dT) primers require the annealing of the oligo(dT) to 
the Poly(A) tail and the anchored nucleotide (“NV” see fig 2.2) to the 5’end of the 
3’poly(A) tail. MLV-Reverse Transcriptase was used for this reaction which took 
place at 42oC for 1hr. The sample was then ready to undergo nested PCR, first 
with the 3’RACE gene-specific outer primer followed by the 3’RACE gene-specific 
inner primer. Both PCR cycles followed with an initial denaturing step at 94oC 
for 3 mins, then 35 repeats of 94oC for 30 sec, 60oC for 30 sec, 72oC for 30 sec, 
and a final extension of 72oC for 7 mins. 3’RACE PCR products were visualised 
on a 5% PAGE gel stained with ethidium bromide and all bands were excised for 
sequencing in accordance with the sequencing protocol (Ch 2.3.4). See Figure 2.2 
for an overview of the 3’RACE procedure and the position of primers used in the 
3’RACE PCR.  
 
 Figure 2.2 Overview of the 3’RACE protocol and 
3’RACE amplification of transcripts. A) Diagram of the 
overview of 3’RACE procedure described in ch 2.4 B) 
Diagram of primer positions for 3’RACE, white arrows 
denote the position of primers supplied by the kit 
and the black arrows represent the position of gene-
specific transcripts (Adapted from the Ambion 
FirstChoice RLM-RACE protocol manual) 
 
A 
B 
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2.5 NORTHERN HYBRIDISATION 
 
2.5.1 Labelling of DNA probes32P γATP 
DNA oligonucleotide probes were designed to be complementary to the target 
miRNAs. 50 µM of oligonucleotide probe was labelled by mixing with 1 µl of 
polynucleotide kinase (PNK) buffer, 1 µl of PNK enzyme, 1 µl of 32P γATP and 6.5 
µl of water. The sample was incubated at 37oC for 1 hr. To remove excess32P 
γATP the samples were precipitated with ethanol by adding 70 µl of Tris-EDTA 
pH 8.0 (TE) buffer, 20 µl of ammonium acetate (10 M) and 1 µl of glycogen to the 
sample. The sample was mixed and then 250 µl of -20oC ethanol was added and 
the sample was left on ice for 1 hr. The sample was centrifuged at max speed at 
4oC for 20 mins. The supernatant was removed and the sample was left to air dry 
briefly before being resuspended in 50 µl TE. The radioactivity of the sample was 
checked and compared with the supernatant with a Geiger counter, and stored at 
-80oC. 
 
2.5.2 Northern blot gel 
10 – 30 µg of total RNA was denatured at 95oC for 5 mins and separated on a 
15% polyacrylamide denaturing gel with 7M Urea in 0.5 x TBE buffer at 100- 
250V. The gel was washed in 0.5 x TBE to remove excess urea. 6 pieces of 
Whatman filter paper, and 1 piece of Hybond N+ nylon membrane was cut to the 
same size as the gel and soaked in 0.5 x TBE. 3 of the pieces of filter paper were 
then placed on the semi-dry blot apparatus and the membrane was layered on 
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top. The gel was positioned on top of the membrane before the remaining 3 
pieces of filter paper were layered on the gel. Bubbles within the “gel sandwich” 
were removed by rolling a long pipette over the top, and any excess liquid 
surrounding the sandwich was wiped away. The semi-dry apparatus was run at 
3.3 mA/cm2 of the gel size for 35 mins (~5 V). The membrane was washed in 0.5 
x TBE for 5 mins, and then placed on top of a piece of filter paper and UV cross-
linked at 1200 µJoules, twice.  
 
2.5.3 Hybridisation 
The membrane was washed with 2 x SSC + 0.1% SDS for 5 mins at room 
temperature. Hybridisation buffer consisting of 3 ml of 20 x SSC, 1 ml of 50 x 
Denhardt’s solution, 0.25 ml of 10% SDS, and 5.75 ml water, was pre-warmed to 
42oC. The membrane was placed inside a 15 ml falcon tube with the transferred 
RNA side facing upwards, and pre-hybridised with 3 mls of the hybridisation 
buffer, rotating at 42oC for 30 mins. The solution was removed and fresh 
hybridisation buffer was added to the tube along with 100 μl of the 32P γATP 
labelled oligonucleotide probe. The probe was hybridised to the membrane for at 
least 12 hrs at 42oC, and then washed twice in 2 x SSC + 0.1% SDS at room 
temperature. The membrane was exposed at -80oC with an intensifying screen 
for a minimum of 3 days.  
 
2.5.4 Northern blots with double-DIG labelled LNA probes 
Pre-designed miRCURY LNA microRNA Detection Probes made by Exiqon with 3’ 
and 5’ Digoxigenin (DIG) labels were used instead of the radioactive DNA probes. 
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The denaturing PAGE and semi-dry blot follows the same procedure however the 
hybridisation, washing and detection steps differ. 
 
2.5.5 Hybridisation with LNA probes 
Hybridisation buffer consisting of 9 ml of 20 x SSC, 3 ml of 50 x Denhardt’s 
solution, 0.75 ml of 10% SDS, and made up to 30 ml with water, was pre-warmed 
to 42oC. The membrane was placed inside a 250 ml cylindrical container with the 
transferred RNA side facing upwards, and pre-hybridised with 15 mls of the 
hybridisation buffer, rotating at 42oC for 30 mins. The solution was removed and 
fresh hybridisation buffer was added to the tube along with 2 nM of denatured 
mercury double-DIG labelled LNA microRNA Detection Probes. The probe was 
hybridised to the membrane for at least 12 hrs at 42oC.  
 
2.5.6 Washing and detection 
The membrane was washed twice with a low stringent buffer (2 x SSC and 0.1% 
SDS in water) at 50oC and then twice with a high stringent buffer (0.1 x SSC and 
0.1% SDS in water) 50oC. It was then briefly rinsed twice in 1 x washing buffer 
(Roche) at 50oC. The membrane was incubated for 3hrs at room temperature in 
blocking buffer containing maleic acid buffer and 1% BSA (Roche). The blocking 
buffer is replaced for 30 minutes with DIG antibody solution which is a dilution 
of the DIG antibody 1 in 10000 in blocking buffer (Roche). The membrane is 
rinsed again in 1x washing buffer (Roche) four times after which, the membrane 
is incubated for 5 minutes in 1x detection buffer (Roche). The substrate solution 
containing a 1 in 100 dilution of CSPD (Roche) in detection buffer is then added 
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to cover the membrane. This is left to incubate at room temp for 5 minutes 
before the membrane is sealed and incubated in the dark at 37oC for 15 minutes. 
The membrane is then exposed at -80oC for 5 mins. The exposure time can be 
adjusted according the strength of the signal and the substrate last for up to 48 
hrs.  
 
2.5.7 Northern blotting of primary miRNAs by agarose-formaldehyde gel 
Prior to making the gel the 10 x running buffer was prepared with the following 
materials; 0.2 M MOPS pH 7, 20 mM Sodium acetate, 10 mM EDTA (pH 8) and 
RNAse free DEPC-treated water. Following this the 1% agarose formaldehyde gel 
was cast by melting 1 g agarose in 72 ml RNAse free water. In the fume hood, 10 
mls of 10 x running buffer and 18 ml of 37% formaldehyde was added and mixed. 
Subsequently the horizontal gel cast and comb was assembled and the molten 
1% agarose-formadehyde gel was poured and left to set.  
 
Sample preparation 
0.1 μg/ml of ethidium bromide was added to 30 µg of RNA and 1:1 denaturing 
dye (10 ml deionized formamide, 200 μl 0.5 M EDTA pH 8.0, 1 mg xylene cyanol 
FF, 1 mg bromophenol blue) which was then denatured at 65 oC for 10 minutes. 
The sample was then loaded into the 1% agarose-formaldehyde gel in 1 x 
running buffer for 2-3 hours at 100 Vs. The gel is then visualised by UV to check 
the integrity of the RNA.  
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Capillary transfer arrangement  
Before transferring, the gel is washed DEPC-water 2 x 5mins and 10 x SSC for 2 x 
5 mins. During this time 4 x Whatman filter paper, and 1 piece of Hybond N+ 
nylon membrane is soaked in 10 x SSC and arranged as described in figure 2.3. 
The transfer takes place overnight (or two nights) and is topped up with 10x SSC 
transfer buffer as necessary. After transfer the membrane is washed in DEPC-
water and UV crosslinked to fix the RNA.  
 
 
 
 
 
 
 
 
 
Probe labeling with radioactive dCTP 
The probe was generated by RT-PCR of genomic DNA using gene specific primers 
to generate a complementary probe of ~200bs. Probe labelling is performed 
with radioactively labelled dCTP (Perkin Elemer BLU013H100UC) and the 
Fermentas DecaLabel kit (K0622) following manufacturer’s instructions. Briefly, 
25 ng of PCR product is combined with 10 µl buffer and 40 µl water which is then 
heated in boiling water for 10 mins and snap cooled on ice to denature the DNA. 
Following radioactive guidelines the sample is then combined with 3 µl MixC 
(dNTPs without dCTP), 5 µl radioactively labelled dCTP and 1 µl Klenow enzyme. 
Figure 2.3 Capillary transfer arrangement. From bottom to top: Within a deep dish filled with 10x 
SSC transfer buffer rests within a platform with 2x whatman filter paper soaked in 10x SSC. On 
top of this lies the gel with the edges covered in saran wrap to prevent any contact with the 
buffer disrupting the current. Then Hybond N+ nylon membrane is placed directly onto the gel 
followed by 2 x whatman filter paper (soaked in 10 x SSC), a stack of paper towels and a 500g 
weight(picture taken from Molecular Cloning, Maniatis).  
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After incubation for 5 mins at 37oC the labelled probe is precipitated, washed 
with 80% ethanol and resuspended in 50 µl water. The radioactivity of the 
sample was checked with a Geiger counter, and the probe was used straight 
away or stored at -80oC. 
Hybridisation 
Hybridisation buffer consisting of 15 mls of 20 x SSC, 5 mls of 50 x Denhardt’s 
solution, 2.5 mls of 10% SDS, and made up to 50 ml with water, was pre-warmed 
to 42oC and then 10 mls was used for pre-hybridisation of the membrane 
rotating at 42oC for 30 mins. The pre-hybridisation buffer is discarded and 
replaced with the hybridisation buffer containing 50 µl of probe and left to 
hybridise at 42oC overnight. The membrane was then washed 4 x SSC + 0.1% SDS 
at 42oC. The membranes were incubated with x-ray film and exposed at -80oC 
with an intensifying screen for a minimum of 5 days.  
 
2.6 ISOLATING NASCENT RNA TRANSCRIPTS 
 
2.6.1 Thiouridine labelling 
HepG2 cells and mouse NIH 3T3 fibroblasts were cultured in 10cm cell culture 
dishes (Corning) until 80% confluent. Final concentrations of 200 µM 
Thiouridine (4sU) (Sigma T4509) was added to cells for 2-3 hours to achieve 
labelling of nascent RNAs.  
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2.6.2 Total RNA extraction  
To end 4sU labelling, the cell culture medium was removed from cells and 5 mls 
of Trizol was added immediately to cells. This was incubated at room 
temperature for 5 minutes to allow nucleoprotein complexes to dissolve and 
then the lysate was transferred into 15 ml falcons. 1 ml of chloroform was added 
to 5 mls of trizol and shaken vigorously for 30 secs. After incubation at RT for 5 
minutes the falcons were then centrifuged at 13,000 g for 15 mins at 4oC. The 
aqueous upper phase was transferred to a new 15ml falcon tube with half the 
reaction volume of isopropanol. After mixing and incubating at RT for 10 mins 
the falcon tubes were centrifuged at 13,000 g for 10 mins at 4oC. The supernatant 
was removed immediately and an equal volume of 80% ethanol was added and 
shaken to detach the pellet. Following this the falcon was centrifuged at 13,000 g 
for 10 mins at 4oC. Again the supernatant was discarded and to ensure all 
remaining ethanol was removed the falcon was centrifuged again and remaining 
ethanol was removed by pipetting using a 200 µl and a 20 µl pipette. The RNA 
pellet is then resuspended in 100 µl of 1x TE (10 mM Tris and 1 mM EDTA) and 
dissolved on ice. The RNA was measured on the nanodrop and run on a 1% 
agarose gel to visualise the integrity of the RNA.      
 
2.6.3 Biotinylation of 4sU labelled RNA transcripts 
In 2 ml eppendorfs, 100 ug of 4sU labeled total RNA (from chapter 2.6.4) was 
added to 200 µg of Biotin-HPDP dissolved in Dimethylformamide (DMF) (Pierce, 
EZ-Link Biotin-HPDP) (final concentration 100 ng/ul); 100 µl of 10x 
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Biotinylation buffer (100 mM Tris pH 7.4 and 10 mM EDTA) and 700 µl of DEPC-
treated water. This was incubated at RT for 1.5 h with rotation.  
 
To isolate the biotinylated RNA an equal volume of Chloroform was added, mixed 
vigorously and incubated for 5 minutes at RT until the phases begin to separate. 
This was then centrifuged at full speed for 5 minutes. The upper phase was 
carefully transferred to phase lock gel heavy tubes (Eppendorf) (these tubes help 
avoid loss of material) and the chloroform step was repeated to ensure removal 
of unincorporated biotin-HPDP. The RNA was then precipitated in 1/10 of 
volume of 5 M NaCl and an equal volume of isopropanol. This was centrifuged at 
max speed for 20 mins at 4oC, the supernatant was then removed and the pellet 
was washed with 80% ethanol and precipitated again at max speed for 10 mins 
at 4oC. After removal of ethanol as described in chapter 2.6.2 the biotinylated 
RNA was resuspended in 100 µl (1 x TE). 
 
Analysis of biotinylated RNA was performed by dot blot, this involved placing 1 
µl drops of biotinylated RNA dilutions (5 10-fold dilutions were used 1 µg – 1 ng) 
and a positive (biotinylated oligo) and negative (unlabelled RNA) control on 
Hybond N+ nylon membrane. The RNA was then UV cross-linked to the 
membrane. The membrane was incubated in 40 ml blocking solution (20 ml 20% 
SDS, 20 ml 1 x PBS and 1 mM EDTA) with shaking. The blocking solution was 
replaced with streptavidin-horseradish peroxidase solution (10 ml 1 x PBS, 10 
ml 20% SDS and 20 µl Streptavidin-HRP (Millipore Cat 18-152) and incubated 
with shaking for 15 mins. The solution was then removed and the membrane 
was washed 2 x 10 mins with 40 mls 1:1 PBS and 20% SDS followed by 2 x 10 
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mins with 40 mls 1% SDS in PBS and finally 2 x 10 mins with 40 mls 0.1% SDS in 
PBS. The membrane was then dried lightly and covered with 2-5 mls ECL reagent 
for 2 minutes. The membrane was encased in a clear plastic wallet and excess 
ECL was removed. The membrane was exposed to an x-ray film for 1 – 5 mins.  
 
2.6.4 Biotin affinity purification of 4sU labelled RNA (nascent RNA) 
100 µg of biotinylated RNA was captured using 100 µl of µMACS streptavidin 
beads and columns (MIltenyi). The RNA-bead mixture was incubated at RT with 
rotation and then the beads were transferred and magnetically fixed to columns. 
The column was washed three times with 900 µl 65oC washing buffer (100 nM 
Tri-HCL, pH 7.4, 10 mM EDTA, 1 M NaCl and 0.1% Tween20) followed by three 
washes with RT washing buffer. The use of the columns eliminated the risk of 
purifying unlabelled RNA. Labelled RNA was eluted by adding 100 µl of freshly 
prepared 100mM dithiothreitol (DTT) followed by another elution with DTT 5 
minutes later. Recovery of nascent RNAs was achieved using the RNAeasy 
MinElute Cleanup Protocol following the manufacturer’s instructions (Qiagen).   
 
2.7 IMMUNOCYTOCHEMISTRY OF NASCENT RNAS 
Equal densities of HepG2 cells (and ESCs) were plated onto 13 mm2 glass 
coverslips (VWR) placed in a 24-well plate and left to adhere overnight. The 
following day cells were left untreated or pre-treated with 1 μM actinomycin D, 
200 ng/ml SSA or 2 ng/ml TG003 for 1 hour at 37 oC in the dark. Subsequently, 
cells (where indicated) were treated with 1mM 5-fluorouridine (5-F) for 1 hour 
at 37 oC in the dark. After treatment, cell staining was performed in low light 
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levels and at RT. Initially the cells were fixed with 10% formalin (w/v) for 15 
minutes and then washed in PBS supplemented with 0.1% BSA and 0.2% 
Tween20 (PBS-BT). Then the cells were permeabilised with 0.1 Triton-X/PBS for 
5 minutes. Cells were washed again with PBS-BT and then 10% FCS in PBS was 
used for blocking for 30 minutes. The block was then removed and replaced with 
1:500 anti-BrdU antibody (in 10% FCS) for 30 minutes. After washing cells three 
times with PBS-BT, cells were incubated with 1:100 anti-mouse alexa fluor (in 
10% FCS) conjugated antibody for 1 hour. Lastly cells were washed twice in PBS-
BT and once in distilled water and mounted on glass slides using Prolong 
antifade with DAPI (Invitrogen). Photographs were taken on an SP5 confocal 
microscope and LAS AF Lite, Adobe Photoshop and Image J software was used to 
analyse the data.  
 
2.8 ISOLATION OF NUCLEAR AND CYTOPLASMIC RNAS 
Cells were grown in a 6 well plate, at 80% confluency cells were trypsinised in 1 
ml, washed with PBS and pelleted. The cell pellet was resuspended in 120 µl LB 
buffer  (10 mM NaCl, 2 mM MgCl, 10 mM Tris-HCL pH 7.8, 5 mM DTT, 0.5% 
Nonidet-P40) for cell lysis, placed on ice for 5 minutes and centrifuged for 5 mins, 
8000 rpm at 4oC . The supernatant containing the cytoplasmic RNA was 
transferred to a new eppendorf with 120 µl Proteinase K buffer (0.2 M Tris pH 
7.5, 25 mM EDTA, 0.3 M NaCl, 2% SDS). The remaining nuclear RNA pellet was 
resuspended in 120 µl LB buffer and 120 µl Proteinase K buffer was added. The 
following treatments were performed on both the cytoplasmic and nuclear RNA 
fractions. The samples were then incubated at 37oC for 20 mins.  The RNA was 
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then extracted with 700 µl Trizol and 140 µl Chloroform followed by vigorous 
shaking and centrifugation for 5 mins at 13,000 g. The supernatant was 
transferred to a new eppendorf with 15 µg glycogen and 1 ml 100% ethanol. 
After thorough mixing, the sample was centrifuged for 20 mins at 13,000 g at RT. 
The ethanol was removed thoroughly and the pellet was dried before 
resuspending in 400 µl DEPC-water. The RNA sample was precipitated again 
with 1/10 vol sodium acetate and 1 ml 100% ethanol. The pellet was washed 
with 80% ethanol, dried thoroughly and resuspended in 20 µl DEPC-water. 
 
2.9 LENTIVIRUS PRODUCTION AND INFECTION 
One million HepG2 cells were seeded into a 10 cm plate the day before 
transfection. The next day, a plasmid DNA mix of 15 μg lentivector (figure 2.4), 
10 μg pCMVΔ8.91 packaging construct and 5 μg VSV-g envelope construct, in the  
ratio of 3:2:1 (Lentivector: Packaging: Envelope), sterile water and 50µl calcium 
phosphate were combined  to a total volume of 500 μl. This mix was added drop-
wise to 500 μl of 2x HBS while mixing rigorously then the solution was incubated 
at room temperature for 30 minutes. Fresh media was supplied to the HepG2 
cells with 25 μM chloroquine (Sigma) and then the plasmid / calcium phosphate 
mix was added drop-wise. The cells were incubated overnight at 37oC with 5% 
CO2. 18 hours post-transfection, the cells were washed twice with D10 and 
replaced with 8 mls fresh media. The media containing lentivirus was harvested 
continuously for 2 days, concentrated and stored at -80oC.  
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50,000 cells were seeded in a 24-well plate one day prior to infection. The next 
day, 4 μg/ml polybrene (Sigma) was added to the media followed by 10-20 μl of 
lentiviral particle. The cells were incubated overnight and replaced with fresh 
media the following day. Total RNA extraction using Trizol was performed after 
48 or 72 hours.  
 
Figure 2.4 pTRIPz inducible lentiviral vector used in the cloning of the three miR-let-
7a/miR-let-7f transcripts (see figure 4.2.4) expression vector. pTRIPz inducible 
lentiviral vector was used in the cloning for construction of let 7a and let 7f expression 
vector (vector map reproduced from Thermo Scientific Open Biosystems technical 
manual). 
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2.10 REAGENTS AND PRIMERS 
 
2.10.1 PCR, Northern blotting and Cloning reagents 
15% denaturing PAGE: 21 g urea, 2.5 ml 10 x TBE, 18.75 ml of 40% (w/v) 19:1 
acrylamide:bis-acrylamide, Adjust volume to 50 ml with 
water. Add 350 μl of 10% (w/v) ammonium persulphate 
(APS) and 17.5 μl of TEMED 
5% non-denaturing PAGE: 2.5 ml 10 x TBE, 6.75 ml of 40% (w/v) 19:1 
acrylamide:bis-acrylamide, Adjust volume to 50 ml 
with water. Add 350 μl of 10% (w/v) ammonium 
persulphate (APS) and 17.5 μl of TEMED 
1% Agarose gel:  1 g Agarose, 10 ml 10 x TBE, 90 ml water. Add 0.1 μg/ml of 
ethidium bromide. 
Denaturing loading dye: 10 ml deionized formamide, 200 μl 0.5 M EDTA 
    pH 8.0, 1 mg xylene cyanol FF, 1 mg bromophenol 
    blue, 
Non-denaturing loading dye:  0.02% w/v 1 M EDTA pH 8.0, 0.25% w/v xylene 
cyanol FF, 0.25% w/v bromophenol blue, 15% Ficoll 
in water. 
2.10.2 Other commonly used reagents 
10 x PBS:  0.5 M NaH2P04 (30 g/500 ml), 0.5 M Na2HP04 (35.5 g/500 
ml) 
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pH 7.2 for stock solution. 200 ml of stock, add 8.76 g NaCl 
and make up to 1 litre with distilled water. 
10 x TBE:   432 g Tris, 220 g Boric acid, 37.2 g EDTA, Water to 4 litres 
20 x SSC  175.3 g NaCl, 88.2 g Sodium citrate, water to 1 litre pH 7 
TE Buffer:   10 mM Tris-HCL pH 7.4, 1 mM EDTA 
50x DEN buffer:  2ml 50% Dextran (10 g Dextran and 15.4 ml distilled 
water), 5 ml formamide, 1 ml 10% SDS, 2 ml 5M NaCl 
DNA elution buffer: 0.5 M ammonium acetate, 10 mM magnesium acetate, 1 mM 
EDTA, 0.1% w/v SDS 
YT medium:   16 g Tryptone, 10 g Bacto-yeast extract 5 g NaCl, Water to 1
   litre 
 
2.10.3 Conditions for commonly used chemicals and drugs 
Abbreviations: Dimethylsulfoxide (DMSO), Dimethylformamide (DMF), 
Phosphate buffer saline (PBS)  
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2.10.4 MicroRNA PCR primers 
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2.10.5 3’RACE primers  
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2.10.6 5’RACE primers 
Adapter Outer: GCTGATGGCGATGAATGAACACTG 
Adapter Inner: CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG 
miR-302 Cluster Outer: TTTGTTATTTTAATGTATCAGCTC 
miR-302 Cluster Inner: TACAGATCTTCCTGAACTAGTTCCCAAA 
 
2.10.7 Northern blotting probes  
Primer for N.blot probe L7af fwd:  CCAGGCGGTCTGATAGAAAG 
Primer for N.blot probe L7af rev:  GGGTAAAATCACTACCCCACAA 
miR-let 7a LNA probe:  AACTATACAACCTACTACCTCA 
 
 
2.10.8 Primers used for checking lentivirus transfection miR-let 7a and 
miR-let 7f 
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2.10.9 Primers used in Chapter 5 
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2.11 BIOINFORMATICS PROGRAMS  
miRBase: http://microrna.sanger.ac.uk/sequences/  
UCSC Genome Browser: http://genome.cse.ucsc.edu/cgi-bin/hgBlat  
Ensembl Genome Browser: http://www.ensembl.org/index.html  
NCBI: http://www.ncbi.nlm.nih.gov/ 
Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/ 
Primer3:  http://frodo.wi.mit.edu/  
NEB cutter V2.0: http://tools.neb.com/NEBcutter2/  
OligoAnalyzer 3.1: 
http://eu.idtdna.com/analyzer/applications/oligoanalyzer/default.aspx  
Alternative splicing database: http://t.caspur.it/ASPicDB/simple_search.php 
Sequence editor: http://www.fr33.net/seqedit.php 
Database of new exon boundaries: http://www.dbass.soton.ac.uk/dbass5/ 
Multiple sequence alignment: http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
Poly(A) mining data tool: https://github.com/coggy/signals_in_sequence 
Finnzymes multiple primer analyser: 
https://www.finnzymes.fi/java_applets/multiple_primer_analyzer.html 
miRGator v3.0:  http://mirgator.kobic.re.kr/ 
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CHAPTER 3 - EXTENSIVE POST-TRANSCRIPTIONAL 
REGULATION OF MICRORNAS IN ESCS 
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3.1 INTRODUCTION 
3.1.1 MicroRNA signature in human stem cells 
In collaboration with Dr Wei Cui, our laboratory made miRNA libraries from 
ESCs before and after differentiation into NPSCs. Solexa sequencing of these 
libraries identified miRNAs that were exclusively or preferentially expressed in 
ESCs or NPSCs (table 3.1.1). Figure 3.1.1 compares the expression of miRNAs in 
ESCs and their neural derivatives, NPSCs, by sequencing and northern blotting.  
For example, mir-302a was sequenced 2370 times in ESCs but not once in NPSCs 
and this result is supported by the northern blot results (figure 3.1.1). The three 
visible bands for miR-182 in ESCs represent isomers that differ in size by one or 
two nucleotides (figure 3.1.1). Our sequencing data and others show a distinct 
miRNA expression profile in stem cells signifying specific miRNA influence in 
maintaining pluripotency and influencing differentiation. Dicer-null and DGCR8 
knock out ESCs do not fully downregulate pluripotency markers and show 
defects in differentiation demonstrating the significance of miRNA expression in 
ESCs (see Introduction).  
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Table 3.1.1 MicroRNA expression data taken from in ESC and 
NPSC sequencing libraries (100ug total RNA). Table shows 
sequencing reads of miRNAs that are highly and preferentially 
expressed in ESCs or NPSCs and not detected in the other cell 
type (n=0) (Dr Elcie Chan) 
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3.1.2 Post-transcriptional regulation of microRNAs 
During early mouse development the expression of many miRNA transcripts are 
inhibited post-transcriptionally at the Drosha stage (Thomson et al., 2006). Given 
the conserved nature of miRNA transcripts across a number of species it is 
possible that a similar mode of miRNA regulation is present in human ESCs. 
Extensive regulation of miRNAs in human ESCs is to be expected given the 
significant impact of miRNAs in pluripotency (Thomson et al., 2006, Garzon et al., 
2009).  
 
Differential expression of miRNAs can be seen across different cell and tissue 
types as well as different developmental stages.  Whether regulation occurs by 
RNA binding proteins, RNA editing, 3’ modification or other miRNAs themselves, 
Figure 3.1.1 Northern blot and Sequencing reads for 
miRNAs specific to ESCs and NPSCs (Chan et al 2009 
unpublished) 
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post-transcriptional regulation is known to occur at any stage of biogenesis 
(figure 3.1.2) and there is reasonable evidence to suggest an abundance of post-
transcriptional regulation (Siomi and Siomi, 2010, Ryazansky et al., 2011, Davis 
and Hata, 2009, Newman and Hammond, 2010, Thomson et al., 2006, 
Obernosterer et al., 2006). Differential expression of miRNAs within 
polycistronic clusters, discrepancy in expression of the miRNA strands and 
different miRNA isomer expression can be post-transcriptionally dictated by 
developmental timing and external conditions (Zhang et al., 2009).  
 
Despite recognition of post-transcriptional mechanisms in miRNA regulation 
there have only been reports of a few miRNAs regulated post-transcriptionally in 
human ESCs and ESC differentiation, the most well-known example being Lin28 
regulation of the let-7 miRNA family. My aim is to classify the method of 
regulation of miRNAs highly expressed in ESCs in an attempt to understand the 
mechanisms involved in regulating ECS differentiation via miRNAs.  
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Figure 3.1.2 Many stages of miRNA biogenesis are open to post-transcriptional regulation A) 
Schematic diagram of the miRNA biogenesis (He and Hannon, 2004) B) Phases of miRNA 
biogenesis that could be subject to post-transcriptional regulation (taken from Sumazin, P 
http://www.genome.gov/Multimedia/Slides/TCGA1/TCGA1_Sumazin.pdf) 
. 
 
 
A B 
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3.2 RESULTS  
3.2.1 RT-PCR methods cannot control for detection of confounding 
transcripts that overlap miRNAs of interest 
I performed RT-PCR using primers that I initially thought were specific to 
miRNAs of interest; these experiments resulted in the consistent detection of a 
large number of transcripts in both ESCs and NPSCs despite the differential 
expression of mature miRNAs and precursor miRNAs (Fig 3.2.1A-B, Fig 3.2.2). 
The implied abundance of post-transcriptional regulation of miRNAs in ESCs and 
NPSCs that we detected seemed unusual and did not correlate with current 
reports. Because the majority of human miRNAs are located within intronic 
regions of transcribed genes, it seemed possible that our RT-PCR approach was 
detecting overlapping transcripts of the miRNA genes. (figure 3.2.1C). This was 
confirmed in figure 3.2.1E where the overlapping gene, LARP7, can be detected 
in both cell lines indicating that the primer pairs for 302a also amplify the LARP7 
transcript (figure 3.2.1D).  
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Figure 3.2.1 RT-PCR of miRNA is confounded by overlapping transcripts A) RT-PCR of total ESC and 
NPSC RNA show that miRNAs expression can be detected in both cell types despite one of the cell 
types not producing the mature miRNA. B) The table shows sequencing data illustrating the 
mature miRNA expression in each cell type. C) The primers, denoted by the arrows, can amplify 
the primary miRNA, precursor miRNA and the overlapping genes in total RNA samples D) 
Organisation of LARP7 overlapping miR-302, the genomic position of the primers used in RT-PCR 
reaction shown in fig 3.2.1E is highlighted by the red star (LARP7) and black star (302a) (See 
materials and methods for primer sequences) E) Shows the detection by RT-PCR of miR-302a and 
its overlapping gene LARP7 in both cell lines, using specific primers for these transcripts the 
position of which is highlighted by the red and black stars in fig3.2.1D, each star represents a pair 
of RT-PCR primers. 
ESC NPSC 
C 
A B 
 
 
E D 
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3.2.2 Problems with RT-PCR analysis of miRNA expression are confirmed 
when investigating precursor miRNAs  
As previously mentioned RT-PCR analysis of miRNAs can lead to inadvertent 
detection of other gene transcripts that are not the miRNA of interest. To avoid 
this problem I analysed precursor miRNAs only. This was achieved by isolating 
small RNAs of less than 200 bases by using the mirVANA protocol. This resulted 
in the exclusion of overlapping genes and also primary miRNA transcripts 
because of their large size, so that only precursor miRNAs could be analysed 
(figure 3.2.2). RT-PCR of small RNA showed that pre-miRNAs could only be 
detected in the cells which expressed the mature miRNA (figure 3.2.2B) these 
bands were sequenced to confirm their miRNA identity.       
 
Although the analysis of small RNA removed the problem of overlapping 
transcripts, there was a limitation with this technique in that we were also 
unable to analyse large primary miRNA transcripts.  This is important because it 
is known that let-7 precursor miRNAs are expressed in ESCs, even though 
mature miRNA is not made (Bagga et al., 2005, Newman et al., 2008, Heo et al., 
2008). However, our analysis of small RNA from ESCs gave no indication of miR-
let-7 expression (Fig 3.2.2B).        
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Figure 3.2.2 RT-PCR analysis of precursor microRNAs A) Small RNA extraction of ESC and NPSC 
RNA. Small RNAs less than 200 nucleotides in length were isolated from total ESC and NPSC RNA 
using the Ambion mirVana kit. Evidence of isolation can be seen by the appearance of low 
molecular weight RNA and the disappearance of the rRNAs on a 1% agarose gel. B) RT-PCR of 
cDNA generated from total RNA and small RNA from ESC and NPSCs. Total RNA and small 
extracted RNA below 200 bases were used for the reaction. Primers used for “Total RNA” and 
“Small RNA” were the same for each miRNA (see fig 3.2.1c).   
A B 
Total RNA Small RNA 
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3.2.3 3’RACE successfully overcomes detection of confounding overlapping 
transcripts allowing the identification of primary miRNAs regulated by 
transcription and post-transcriptionally 
 
In order to avoid the detection of transcripts that overlap miRNAs, yet still be 
able to analyse primary miRNA expression, we decided to use 3’ Rapid 
amplification of cDNA ends (3’RACE) for our analysis of miRNA expression. 
3’RACE involves the binding of an anchored oligo(dT) primer sequence to the 
poly-A tail of RNA transcripts, subsequent cDNA synthesis and then PCR with a 3’ 
primer specific to the oligo(dT) adapter and a 5’ primer specifically binding the 
desired miRNA transcript. The theory behind using this method is that the 
overlapping transcript and the miRNA have different 3’ends and paired with the 
5’ primer specific to the miRNA, the two transcripts that could be potentially 
generated by RT-PCR would be clearly distinguishable by size. In many cases 
overlapping transcripts are transcribed antisense to the miRNA therefore there 
is no possibility of detecting the overlapping transcript using the 5’ miRNA 
specific primer. Consequently this technique allowed successful distinction of the 
primary miRNAs from the overlapping transcript. In addition the technique only 
amplified transcripts with poly (A) tails therefore distinguishing pri-miRNAs 
from pre-miRNAs.   
 
Using this technique we were able to show that 18 out of 29 primary miRNA 
transcripts are regulated by transcription (fig 3.2.3). This is evident by the 
preferential expression of the primary transcript in the cell type that expresses 
the mature miRNA (fig 3.2.3). This indicates that transcription is one of the main 
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mechanisms of controlling cell-specific miRNA expression. In figure 3.2.3 where 
more than one band can be seen, the sequencing results indicate that the 
different bands represent alternate forms of primary miRNA transcripts; this is 
discussed at greater length in chapter 4. In miR-99a, miR-let-7g and miR-182 the 
bands in the cell lines that do not express mature miRNAs were sequenced and 
found to be non-specific.  
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Figure 3.2.3 Transcriptional regulation of miRNAs 
specific to ES and NPS cells. A) 3’RACE PCR and RT-PCR 
detects miRNA primary transcripts that are differentially 
expressed in either ESCs or NPSCS where the mature 
miRNA is expressed. This is indicative of transcriptional 
regulation. The U6 gene is used as a control. In miR-99a, 
miR-let 7g and miR-182 the bands in the non-expressing 
cell line were sequenced, confirming their non-
specificity. B) All miRNAs that were sequenced and 
preferentially expressed in either ESCs or NPSCs and not 
detected (n=0) in the other cell type are listed with their 
sequencing reads.  
A 
B 
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Figure 3.2.4 Post-transcriptional regulation of miRNAs in ESCs. A) 3’RACE PCR of miRNA primary 
transcripts that are expressed in ESCs and NPSCs despite low expression of the mature miRNAs. This is 
indicative of post-transcriptional regulation. B) The sequencing data showing the proportion of mature 
miRNAs in ESCs and NPSCs.  
A 
B 
3.2.4 Many miRNAs in ESCs are regulated post-transcriptionally  
Post-transcriptional regulation of miRNAs was inferred for 11 out of 29 miRNAs 
investigated (Fig 3.2.4). A pattern emerged showing a prevalence of post-
transcriptionally regulated miRNA in ESCs. MiR-let-7a and miR-let-7f are known 
to be regulated post-transcriptionally by ESC-specific RNA binding protein Lin28. 
MiR-7 and miR-21 are known to be post-transcriptionally regulated in other cell 
types however it is not yet known how miR-125b-1, miR-542, miR-450b, miR-
29a and miR-29c are regulated.  
 
A B 
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3.2.5 Post-transcriptionally regulated miRNA are actively transcribed and 
turned over 
The validity of post-transcriptionally regulated primary miRNA was uncertain as 
it was not yet known if the primary miRNAs were being actively expressed and 
turned over as they would be in cells making the mature miRNA. Consequently 
the active transcription of some of these primary miRNAs was tested by 
inhibition of transcription with actinomycin D (Act-D). The efficacy of 
actinomycin D at inhibiting RNA synthesis was demonstrated by its blocking of 
5-fluorouridine (5-FU) incorporation into nascent RNA (fig 3.2.5 A-C).  The 
inhibition of primary miRNA expression post treatment with Act-D indicated that 
the transcripts were actively transcribed and turned over in ESCs despite the 
lack of mature miRNA expression (fig 3.2.5 D). 
 
 
 
C 
B 
A 
B 
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Fig 3.2.5 RNA turnover of primary miRNA specific to ESCs and NSCs indicates that post-
transcriptionally regulated miRNA are consistently being processed. A) 3’RACE PCR and RT-PCR 
of total ESC RNA treated with DMSO (Control) and 1μM Actinomycin D (Act-D) for 4 hours, 
indicates that transcripts in both ESCs and NPSCs are turned-over after 4 hours of inhibiting 
transcription with Actinomycin D. MiR-302b and miR-302a are transcriptionally regulated so 
transcription and turnover is only detected in ESCs.  
 
A B C 
Fig 3.2.5 RNA turnover of primary miRNA indicates that post-transcriptionally regulated miRNA 
are consistently being processed. A-C) Actinomycin D inhibits transcription in ESCs A) ESCs were 
not subjected to treatment B) ESCs treated with 1mM 5-Fluorouridine (5-F) incorporation into 
nascent RNA C) or pre-treated with 1 μM Actinomycin D for 30 minutes and then treated with 
1mM 5-Fluorouridine. Cells were then stained by immunocytochemistry using either anti-BrdU 
antibody or DAPI. Photographs were taken on an SP5 confocal.D) 3’RACE PCR and RT-PCR of 
total ESC RNA treated with DMSO (Control) and 1μM Actinomycin D (Act-D) for 4 hours, 
indicates that transcripts in both ESCs and NPSCs are turned-over after 4 hours of inhibiting 
transcription with Actinomycin D. MiR-302b and miR-302a are transcriptionally regulated so 
transcription and turnover is only detected in ESCs. E) The table shows sequencing data 
illustrating the mature miRNA expression in each cell type.    
 
D 
E 
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To further verify the expression of primary transcripts, nascent ESC RNAs were 
biotin affinity purified to omit stable RNAs. This was achieved by incorporating a 
uridine base analogue, thiouridine (4sU), into growing cells. Subsequent 
biotinylation of newly synthesised RNAs allowed the biotin affinity purification 
of the nascent RNAs with streptavidin beads. Figure 3.2.6a1 shows that ESC and 
NPSCs samples were run on a 1% agarose gel after biotinylation to ensure RNA 
integrity, following this biotinylated samples underwent a dot blot assay to 
ensure that only samples with 4sU were labelled (fig 3.2.6a2) and finally, after 
biotin affinity purification, samples were run on a 1% agarose gel to show that in 
samples without 4sU (-), RNA was absent and samples that had incorporated 4sU 
were purified and had not degraded (obvious by the presence of the 28S and 18S 
rRNAs) (fig 3.2.6a3) (refer to chapter 5 for further details about this technique). 
3’RACE of these samples show that post-transcriptionally regulated primary 
miRNAs are expressed in newly transcribed RNA confirming that miRNA genes 
are actively transcribed in ESCs although they are not processed into mature 
miRNAs (fig 3.2.6b).  
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Fig 3.2.6 Detection of miRNAs in nascent RNA samples from ESCs and NPSCs indicates that post-
transcriptionally regulated miRNAs are continuously being transcribed. A) Detection and integrity analysis 
of 4sU incorporated RNA. 1) 1% agarose gel of total RNA after biotinylation of ESC RNA with no 4sU (“-“) 
and “4sU ESC” and “4sU NPSC” representing the RNA of ESCs and NPSCs treated with 200 μM 4sU 2) Dot 
blot assay showing the thiol-specific biotinylation of RNA. 10 fold dilutions of RNA was blotted down the 
membrane. 3) 1% agarose of RNA after biotin affinity purification, the “+” control was total ESC RNA. The “-
“ control was ESCs RNA with no 4sU showing that only 4sU incorporated RNA could be purified. +: Total ESC 
RNA; -: ESC RNA with no 4sU incorporation; 4sU ESC: ESCs treated with 200 μM 4sU; 4sU NPSC; NPSCs 200 
μM 4sU. In C) +: 5’-biotinylated DNA oligo. B) 3’RACE PCR and RT-PCR of nascent ESC and NPSC RNA show 
that post-transcriptionally regulated miRNA are continuously being made. C) The table shows sequencing 
data illustrating the mature miRNA expression in each cell type.    
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3.2.6 Over-active expression of primary miRNAs in ESCs suggest a 
prevalence of post-transcriptional regulation of miRNAs 
In order to estimate the number of miRNAs that are regulated at a post-
transcriptional level in human ESCS, I analysed all of the miRNA genes on 
chromosome 1 and 2 (miRGator v3.0: http://mirgator.kobic.re.kr/) that are 
poorly expressed in ESCs but strongly expressed in differentiated cell types.   
 
Initially I investigated 37 miRNAs on chromosome 1 and 2 that are highly 
expressed in mature human cells but not ESCs. Out of these, 18 primary miRNAs 
were expressed in ESCs (Figure 3.2.7). Figure 3.2.7 shows that four miRNA genes 
(miR-34a, miR-101-1, miR29c and miR-200a) were analysed by RT-PCR and the 
remaining miRNAs were analysed by 3’RACE as their transcripts overlap with 
other genes. Treatment with actinomycin D revealed that 16/17 of these miRNAs 
were actively transcribed and turned over in ESCs despite the lack of mature 
miRNA expression (Fig 3.2.7). MicroRNA 200a is expressed in ESCs however it is 
not turned over; this could be an example of a dead-end product that is not 
actively transcribed. MicroRNA 101-1 was used as a positive control as this 
miRNA is expressed in ESCs and turned over. The remaining twenty of the 37 
microRNAs did not show evidence of primary miRNA expression in ESCs. We 
have confirmed that many of these miRNAs are regulated by transcription in 
ESCs as primary miRNA expression is evident in expressing cell types using the 
same primers.  
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Figure 3.2.7 Over-expression of primary miRNAs in ESCs implies that the processing of 
many miRNAs is blocked. 3’RACE PCR and RT-PCR of total ESC RNA treated with DMSO 
(Control) and 1μM Actinomycin D (Act-D) for 4 hours, indicates that the majority of 
primary transcripts expressed in ESCs are turned-over after 4 hours of inhibiting 
transcription with Actinomycin D. There are no sequencing results available for these 
miRNAs in ESCs indicating that these mature miRNAs are not expressed.  
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3.3 DISCUSSION  
 
3.3.1 Transcriptional regulation of miRNAs 
A great of deal of evidence suggests that like most other protein coding and non-
coding RNAs, transcription is a major regulator of miRNA biogenesis (Wang et al., 
2011, Marson et al., 2008). 18 of the 29 miRNAs investigated were regulated by 
transcriptional mechanisms (figure 3.2.3). Evidence of transcriptional regulation 
in ESCs can be seen clearly in the relationship between miR-302 and 
pluripotency factors such as Oct4 and Sox2, which are known to bind the 
promoter of the miR-302 gene cluster in order to regulate its transcription 
(Marson et al., 2008). In parallel, the miR-302 cluster is known to regulate Oct4 
and Sox2 resulting in a feedback mechanism that is able to fine tune gene 
expression to achieve cell determination (Liao et al., 2011). Epigenetic regulation 
of miRNAs is a key factor in transcriptional control (Suzuki et al., 2011). In 
mouse ESCs, miR-9 is under epigenetic regulation resulting in silencing in ESCs 
and expression in NPSCs. The miR-9 promoter contains bivalent domains, so its 
expression is dependent on two histone marks, when H3K4me3 is lost and 
H3K27me3 is retained the genes are transcribed, however when the opposite 
occurs expression is silenced (Suzuki et al., 2012, Marson et al., 2008). 
Regulation of miRNAs by transcription factors and epigenetic markers operate in 
a feedback loop mechanism whereby upregulation or downregulation of miRNAs 
influence signalling cascades which can cause reversible fine tuning of gene 
expression within a cell (Babiarz and Blelloch, 2008). Regulation of miR-9 and 
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miR-302 demonstrates the importance of reversible transcriptional regulation 
indicating that feedback mechanisms are in place to promote cell fate. 
 
3.3.2 Post-transcriptional regulation of microRNAs is prevalent in ESCs 
There is growing evidence for regulation of miRNA biogenesis which could occur 
at any of the steps in the processing pathway including Drosha cleavage, nuclear-
cytoplasmic export, Dicer cleavage and RISC loading and silencing (Heo et al., 
2008, Davis and Hata, 2009, Kedde et al., 2007, Michlewski et al., 2008) (fig 3.1.3). 
 
Deep sequencing of miRNAs demonstrates a huge difference in miRNA 
expression between ESCs and NPSCs (supplementary table S1), suggesting 
important functions for those miRNAs in maintaining pluripotency and 
promoting differentiation. Analysis of differentially expressed miRNA genes 
indicates that the majority of miRNAs were regulated transcriptionally. The 11 
out of 29 miRNAs that were regulated by post-transcriptional mechanisms were 
regulated in this manner in ESCs only. Prevalence of post-transcriptional miRNA 
regulation in ESCs is a phenomenon also observed in mouse embryonic 
development (Thomson et al., 2006). Thomson et al., 2006 describes extensive 
post-transcriptional regulation at the Drosha processing stage resulting in 
downregulation of several miRNAs in mouse ESCs and primary tumours. Our 
data presents a lack of correlation between primary, precursor and mature 
miRNA expression levels in ESCs while differentiated NPSCs appeared to show 
more consistent expression between the different miRNA stages; these 
observations were previously made in mouse ESCs (Thomson et al., 2006). This 
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infers that Drosha regulation is necessary to regulate miRNA expression in early 
developmental stages which could otherwise be detrimental (Thomson et al., 
2006). 
 
As expected, the post-transcriptionally regulated miRNAs I identified included 
miR-let 7a-1, miR-let 7a-2 and miR-let 7f-1 for which the mechanism of post-
transcriptional activity is well known (Heo et al., 2008). Interestingly miR-let 7f-
2 was identified to be regulated transcriptionally which implies that the two 
independent sources of mature miR-let-7f are controlled by a complex 
transcriptional/post-transcriptional system. Evidence suggests that miR-542, 
miR-450b, miR-29a, miR-29c, miR-125b-1, miR-21 and miR-7 are also regulated 
post-transcriptionally in ESCs. Expression of these miRNAs have known 
implications in stem cell development and several cancers (Bray et al., 2011, 
Gebeshuber et al., 2009, Lui et al., 2007, Sengupta et al., 2008, Shalom-Feuerstein 
et al., 2012) and miR-125b and miR-21 have even been proposed to be suitable 
biomarkers for specific types of cancers (Cho, 2010, Chen et al., 2008). 
 
In many types of cells, miR-21 is post transcriptionally regulated at the Drosha 
step by Smad proteins (Davis and Hata 2009). The Smads are signalling proteins 
of the TGF-β family signalling cascade and can be co-precipitated in a complex 
with Drosha on the pri-miR-21 hairpin upon miRNA stimulation with TGF-β 
(Davis and Hata 2009). Furthermore, factors upregulating or downregulating 
mature and precursor miR-21 did not alter the expression of primary miR-21 
again indicating post-transcriptional regulation at the Drosha processing step 
(Davis and Hata, 2009). Davis and Hata, 2009 detail many miRNAs that are post-
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transcriptionally regulated by Smads implying a crucial role of rapid alteration of 
miRNA expression in cytokine signalling. 
 
It is possible that this mechanism of post-transcriptional regulation also occurs 
in ESCs however it has not been possible to perform loss-of-function assays in 
ESCs. ESCs are notoriously difficult to transfect because of their characteristic 
clonal growth pattern consequently it has not yet been possible to identify if 
Smad proteins are responsible for post-transcriptional regulation of miR-21.  
 
MicroRNA 7 is described as a tumour suppressor in glioblastoma cells (Kefas et 
al., 2008). In ESCs miR-7 was revealed to be post-transcriptionally regulated, this 
is corroborated by data from glioblastoma tumour cells indicating that primary 
miR-7 is constantly expressed despite radical reduction of precursor and mature 
miR-7 expression (fig 3.2.4-6).  Post-transcriptional regulation of miR-7 in 
glioblastoma tumours seemed specific to the miR-7 however the mechanism 
remains unknown (Kefas et al., 2008).  In this case, miRNA expression and 
regulation in ESCs appear to match miRNA expression data in different cancer 
cell lines.   
 
The literature remains elusive with regard to regulation of miR-125b-1, miR-
450b, miR-542, miR-29a and miR-29c despite their significant biological 
relevance in controlling pluripotency, immune responses and roles in several 
cancers (Boldrup et al., 2012, Bray et al., 2011, Ma et al., 2011, Sengupta et al., 
2008, Sun et al., 2013, Wang and Gu, 2012, Cui et al., 2012a, Cui et al., 2012b). 
Our data is the first to indicate that these miRNAs are regulated post 
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transcriptionally in ESCs. These miRNAs may also be post-transcriptionally 
regulated in cancer cells because of the similar properties shared with ESCs and 
the extreme differences in expression of these miRNAs in cancer (Bray et al., 
2011, Sengupta et al., 2008, Sun et al., 2013, Wang and Gu, 2012). The 
mechanism behind post-transcriptional regulation of these miRNAs is yet to be 
confirmed. RNA editing and 3’ modifications cannot be detected in the 
sequencing data of these miRNAs therefore it is likely that RNA binding proteins 
play a role in their regulation.  
 
In order to further investigate the potential of ESCs to over-actively transcribe 
primary miRNAs, we systematically analysed microRNAs located on 
chromosome 1 and 2. The miRNAs investigated are highly expressed in 
differentiated cell types and poorly expressed in ESCs (figure 3.2.7). These 
results show that 16/37 primary microRNAs were actively expressed in ESCs 
despite a lack of mature miRNA expression in ESCs. Twenty out of 37 primary 
microRNAs showed no evidence of expression in ESCs thus indicating 
transcriptional regulation of these miRNAs. Nevertheless, preliminary analysis 
has shown that 43% of primary microRNAs from chromosome 1 and 2 are 
actively expressed in ESCs. This supports our evidence and others (Thompson et 
al 2006) that post-transcriptional regulation of primary miRNAs is widespread in 
ESCs.   
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3.3.3 The role of post-transcriptional regulation of miRNAs 
Post-transcriptional mechanisms controlling miRNA expression in ESCs allows 
for rapid, tissue-specific and stringent fine tuning of miRNA expression. During 
differentiation of ESCs it is necessary to tightly control the expression of genes 
which promote cell determination. Consequently it is likely that miRNAs which 
regulate mRNAs involved in ESC differentiation are consistently transcribed and 
ready to be processed upon physiological stimulus. In differentiated lineages like 
NPSCs, they are defined in cell type and do not have the ability to differentiate 
therefore constant transcription of miRNA genes with no immediate function 
may not be necessary. As a result, ESCs ability to differentiate remains the 
rationale behind the extensive post-transcriptional regulation of miRNAs. The 
extensive post-transcriptional regulation of miRNA biogenesis that we observe 
in ESCs has been reported in different cell types and linked to human diseases, 
including cancer (Thomson et al., 2006, Siomi and Siomi, 2010).  
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CHAPTER 4 - EXTENSIVE ALTERNATIVE 
POLYADENYLATION OF MICRORNAS 
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4.1. INTRODUCTION 
 
Solexa deep sequencing of ESCs and NPSCs gave rise to an abundance of 
anomalous miRNA expression data that did not match the predicted 
transcriptional models. For example the expression levels of mature miRNAs 
within clusters (e.g. the miR-302 cluster) differed greatly despite being regulated 
by the same promoter (Table 4.1.1). When using 3’RACE to investigate miRNA 
regulation we observed extensive use of potential alternative polyadenylation 
sites in miRNA genes expressed in ESCs and NPSCs. Alternative polyadenylation 
may provide an explanation for differential expression of miRNAs within clusters 
and between cell types.  
 
 
Table 4.1.1 Sequencing reads of miRNAs within clusters. MicroRNAs 
are grouped into clusters according to their genomic location and the 
relative sequencing numbers represent their expression in ESCs and 
NPSCs (Solexa sequencing by Dr Elcie Chan) 
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4.1.1 Alternative polyadenylation 
Polyadenylation and 3’ processing play a crucial part in eukaryotic mRNA 
synthesis which consists of co-transcriptional endonucleolytic cleavage followed 
by the addition of repeated adenosine bases by a poly(A) polymerase (PAP) 
enzyme. The structure and location of the 3’UTR and poly(A) tail is thought to 
influence all areas of mRNA processing including mRNA stability, translational 
efficiency and nuclear-cytoplasmic export (Colgan and Manley, 1997). 3’ end 
positioning is dictated by a number of factors including the poly(A) signal (PAS), 
usually defined by multiple cis-elements e.g. an AAUAAA hexamer, a U- or GU- 
rich downstream element (DSE) and other sequences (Shi, 2012). PAS 
recognition is dependent on the cleavage and polyadenylation specificity factor 
(CPSF) complex which recognises the AAUAAA sequence (or alternative A-rich 
hexamer), while the cleavage stimulation factor (CstF) and the cleavage factor Im 
(CFIm) complexes bind auxiliary motifs such as the U- or GU- rich DSE (Fig 4.1.1) 
(Colgan and Manley, 1997). 
 
Figure 4.1.1 Polyadenylation of pre-
mRNA. Diagram of the steps in 
eukaryotic polyadenylation and the 
factors involved. Initially proteins bind 
to the polyadenylation signal (PAS) 
AAUAAA and the downstream GU rich 
region. Shortly after, the 3’ GU rich 
region is cleaved and the Poly(A) 
polymerase (PAP) catalyzes the 
addition of a string of adenosine bases 
to the 3’end of the mRNA. 
Abbreviations: CPSF: Cleavage and 
polyadenylation specificity factor, CstF: 
Cleavage stimulation factor, CFIm: 
Cleavage factor Im. 
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Alternative polyadenylation (APA) has been documented for some time however 
the mechanism has only recently been recognised as a major regulator of RNA 
expression (Boutet et al., 2012, Lutz, 2008, Mueller et al., 2013).  
 
Upon completion of various global sequencing projects including the human 
genome project it was realised that over half of all mammalian genes are 
alternatively polyadenylated with many evolutionarily conserved alternative 
polyadenylation signals (Lutz, 2008, Mueller et al., 2013). The discovery of such 
extensive and widespread APA came as a surprise and furthermore over 70% of 
genes were found to be alternatively polyadenylated in human and yeast which 
implies that APA is far more ancient a mechanism than first imagined (Lutz, 2008, 
Mueller et al., 2013).  
 
Lutz (2008) describes two types of alternative polyadenylation (fig 4.1.2); type I 
polyadenylation refers to genes that have two or more PASs in the 3’UTR 
(normally located with the canonical PAS) and type II polyadenylated genes have 
a PAS signal located anywhere on the gene producing a truncated protein coding 
transcript (fig 4.1.2). Type I APA can influence regulation of the transcript 
whereas Type II APA can result in the production of aberrant truncated protein 
isoforms.  
 
Changes in 3’UTR length of mRNA (type I APA) can have a huge effect on 
abundance through a variety of mechanisms. Shortening of 3’UTRs can result in a 
decrease in miRNA targeting of transcripts and removal of NMD motifs affecting 
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turnover of transcripts and affecting transcript localization and translational 
efficiency (Mueller et al., 2013).  
Many factors can determine APA activity including activity of core 
polyadenylation factors e.g. CstF and CFIm, tissue specific RNA binding proteins, 
and mutations of canonical PASs (Gruber et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2 Alternative polyadenylation and stem cells 
Tissue specific APA has been investigated bioinformatically revealing a pattern 
of APA bias, where a particular PAS is in significantly higher use than another in 
certain tissue and cell types (Shi, 2012, Winter et al., 2007, Licatalosi and Darnell, 
2010, Ji and Tian, 2009). This is likely to be a consequence of the cellular choice 
of a promoter which may dictate the PAS that defines the 3’end of the mRNA, 
however no mechanism for this is known (Mueller et al., 2013, Ji and Tian, 2009). 
Figure 4.1.2 Types of alternative polyadenylation. For type I alternative polyadenylation 
there is more than one polyadenylation signal in the 3′UTR. Type II alternative 
polyadenylation involves alternative splicing coupled with alternative polyadenylation 
(Lutz, 2008). 
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An example of tissue specific APA is seen in the expression of Opitz syndrome 
gene MID1 where the cellular choice of an alternative transcriptional start site 
(TSS) and promoter dictates the use of a particular PAS (Winter et al., 2007).  
 
Recent microarray and RNA sequencing analyses have indicated that APA is 
important in regulating stem cell pluripotency and differentiation (Mueller et al., 
2013). Global mRNA analyses in a variety of species have led to the discovery of 
the dynamic nature of APA in proliferating cells such as ESCs (Mueller et al., 
2013). Proximal PASs generates mRNAs with shorter 3’ends in ESCs whereas in 
differentiated cells distal PASs generate mRNAs with long 3’UTRs. Furthermore, 
microarray data for cells at different stages of reprogramming of iPSCs displayed 
shorter 3’UTR lengths compared to the somatic cells from which they were 
derived (Ji and Tian, 2009). Ji et al 2009 show 3’UTR lengthening during mouse 
embryonic development again showing that proliferating cells like ESCs have 
mRNA with shorter 3’UTRs than differentiated cell types (Mukhopadhyay et al., 
2009). Mueller et al., 2013 theorise that global changes in 3’UTR length seen in 
ESCs could contribute to general miRNA availability and activity.  
 
APA is functionally significant to the regulation of the mRNA by miRNA and is 
particularly prevalent in cancer cells which have high expression of short 3’UTR 
mRNA isoforms that evade miRNA regulation (Clancy et al., 2011, Mayr and 
Bartel, 2009). APA also has the potential to serve as a biomarker in cancer as 
there is a precise APA molecular signature that is distinguishable between 
similar tumour subtypes (Di Giammartino et al., 2011). 
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A bioinformatic study revealed that based on EST information, alternative 
mRNAs lacking target sequences for specific miRNAs were preferentially 
expressed in cell lines where the targeting miRNAs were also expressed 
(Legendre et al., 2006). This implies that the alternative transcripts would be 
able escape regulation by miRNAs but the canonical transcript with the long 
3’UTR could not (Legendre et al., 2006). This has been experimentally verified 
with Pax3, a myogenic regulator expressed in two cell subtypes, satellite cells 
(SCs) and quiescent satellite cells (QSCs). Both cell types express Pax3 and miR-
206 which is a negative regulator of Pax3; however QSCs produce an 
alternatively polyadenylated Pax3 transcript with a shorter 3’UTR escaping miR-
206 regulation resulting in higher protein expression in these cells (Boutet et al., 
2012).  
 
An abundance of mRNA contributes to reducing the effects of miRNAs and 
siRNAs by behaving like miRNA sponges. The availability of miRNAs which act on 
multiple transcripts is directly affected by the abundance of any one of the 
targeted mRNAs. Therefore mRNAs with long 3’UTRs can act as sponges, so a 
global reduction of 3’UTR length as seen in ESCs and cancer cell types can result 
in an overall increase in free miRNAs (Mueller et al., 2013).  
 
4.1.3 Regulation of microRNA biogenesis by alternative polyadenylation  
 The number of novel miRNAs has been rapidly growing due to advancements of 
sequencing technologies, with a current estimate of over 2578 miRNAs in the 
human genome. Despite these advances the primary miRNAs which encode them 
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remain largely uncharacterized. Consequently there are few published examples 
of alternative polyadenylation regulating primary miRNA expression (Ribas et al., 
2012).   
 
A single primary miRNA, miR-21 is reported to have two sources of origin which 
I confirm in ESCs and NPSCs (supplementary figure S1). One transcript has an 
independent promoter within the VMP1 gene intron just a couple of hundred 
bases away from the precursor making a primary transcript separate from the 
VMP1 gene. The other uses the promoter of VMP1 and alternative 
polyadenylation to make a hybrid VMP1-miR-21 transcript that is processed by 
the microprocessor machinery and made into mature miR-21 (Ribas et al., 2012). 
This shows that alternatively polyadenylated miRNA transcripts can be 
functional and processed in the same way as canonical primary miRNAs. In 
addition it could allude to the importance of promoter choice in miRNA 
regulation.  
 
More and more evidence points towards cross-talk between transcription and 
primary miRNA processing. It has been reported that exogenous primary 
miRNAs without poly(A) tails cannot be processed into mature forms and are 
retained at the transcription site (Pawlicki and Steitz, 2010). Furthermore the 
choice of promoter is likely to play a part in primary miRNA production. It has 
been shown that expression of a primary miRNA from a miRNA promoter in vitro 
results in higher expression of Drosha protein and increased processing of the 
primary miRNA compared to different promoters e.g. cytomegalovirus (CMV) 
driving the same primary miRNA (Ballarino et al., 2009). It can be concluded that 
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many intricate features could play a role in primary miRNA processing and 
alternative 5’ and 3’ processing may play a large part despite remaining 
relatively unknown as a post-transcriptional method of regulating miRNAs.  
 
The alternative polyadenylation of clustered miRNAs may promote distinct 
miRNA expression. From our deep sequencing data and others published it is 
obvious that miRNAs within clusters, sharing the same promoter, can have very 
different expression profiles and the method of post-transcriptional regulation 
for miRNAs within a cluster has not yet been identified (Thomson et al., 2006, 
Tang and Maxwell, 2008). 
  
4.2 RESULTS 
4.2.1 Annotation of the miR-302 cluster with evidence of extensive 
alternative polyadenylation  
3’ Rapid amplification of cDNA ends (3’RACE) allows amplification of a specific 
gene with an unknown 3’end. The method involves binding of an anchored 
oligo(dT) primer adapter to the poly(A) tail of the RNA and then amplifying the 
transcript with primers against the oligo(dT) adapter and a gene-specific 
sequence.  
 
This method identified several putative 3’ ends of each miRNA within the miR-
302 cluster; this is evident by the multiple bands seen in the ESC lanes in figure 
4.2.1a. These bands were sequenced and the genomic positioning of the primary 
miRNAs were mapped and can be visualised in figure 4.2.1b, note that the 5’ends 
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are artificially determined by the gene specific primer. Figure 4.2.1b displays the 
numerous putative primary transcripts produced by alternative polyadenylation 
matched against the canonical annotation of primary miR-302 (Barroso-delJesus 
et al., 2008).  
 
Detection of alternative polyadenylation sites using anchored oligo(dT)s 
increase validity of the alternative primary transcripts generated by 3’RACE. 
This is because anchored oligo(dT)s have been proved to bind to genuine 3’ 
poly(A) tails even in competition with internal poly(A) sites that are up to 14 
adenine nucleotides long (Nam et al., 2002). Anchored oligo(dT) primers consist 
of a string of 20 deoxythymidylic acid (dT) residues followed by two additional 
nucleotides that act as an anchor allowing the primer to anneal only at the 5’end 
of the poly(A) tail of RNA, providing more efficient cDNA synthesis for 3’RACE 
(see chapter 2). In agreement with this, we found that the majority of the 3’ ends 
of our 3’RACE transcripts did not coincide with internal polyA sites.  
 
To help verify the authenticity of the APA sites, potential polyadenylation signals 
were mined using a web-based tool (created by Mr T. Coggrave) which annotated 
the 12 known poly(A) motif variants in a given sequence (Kalkatawi et al., 2012) 
(supplementary table S2) (Polyadenylation mining web tool: 
https://github.com/coggy/signals_in_sequence). The data mining tool found 17 
potential polyadenylation signals between the genomic positions 
chr4:113,568,706-113,569,780. Polyadenylation signals are reported to be found 
~10-30nts upstream from the poly(A) tail, in this case putative polyadenylation 
signals could be predicted upstream from a few of the novel 3’ends of the miR-
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302 cluster denoted by the “*”  next to the miRNA transcripts in figure 4.2.1b 
(supplementary figure S2 shows the sequence in full with annotated PASs and 
3’ends aligned with the mouse sequence to show conservation of the PASs). As 
there are many additional factors involved in APA recognition we cannot dismiss 
the other transcripts discovered but further evidence is required to prove that 
the transcripts are genuine.  
 
Different alternative 3’ends could promote or reduce expression of individual 
miRNAs from the miR-302 cluster. In addition, there also seem to be splicing 
mechanisms in place to isolate miR-302b and miR-302b* from the remaining 
miRNAs of the miR-302 cluster. Figure 4.2.1c shows that the splicing would 
disrupt miR-302b and remove the remaining miRNAs.  It is possible that miRNAs 
302c, 302a, 302d and 367 could still be made from the spliced lariat but not miR-
302b as it would be unable to form a stem region (fig 4.2.1c). 
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Figure 4.2.1 The 302 microRNA cluster has many 3’ ends potentially allowing differential expression of 
miRNAs within the cluster A) 5% PAGE of 3' RACE PCR products of primary miR-302 in ESCs and NPSCs 
B) A Schematic diagram of the sequencing results from the 3’ RACE PCR products. The sequences are 
aligned to the LARP7 gene intron where the miRNA cluster resides. The black arrows represent 
sequences identified as the primary miRNA for the cluster by Barroso-del Jesus et al., 2008. The arrows 
are colour coordinated to represent the different 3’RACE bands of the different miRNA. The arrows 
which are starred (*) represent transcripts whose 3’end is verified by a nearby PAS. The dotted line 
signifies alternative splicing of the transcript. C) Illustration of 3’RACE showing two different splicing 
variations of the miR-302 cluster. The primary transcript produced only includes the miR-302b*. With 
only half a precursor miRNA it would not be possible to form the stem loop that is recognised by the 
microprocesser machinery therefore degradation of this transcript is likely.  
 
 
B 
A 
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4.2.2 Annotation of the transcription start site of the microRNA 302 cluster 
 
5’RACE of the miR-302 cluster corroborates existing data annotating the TSS 153 
nts upstream of precursor miR-302b (Barroso-delJesus et al., 2008) (Fig 4.2.2). 
The outcome of individual miRNA expression within the miR-302 cluster could 
also be dependent on the use of alternative 5’ TSS. However unlike miR-21 
whose alternative 3’ polyadenylation is accompanied by alternative 5’ TSS, 
multiple 5’ RACE experiments of transcripts downstream of the annotated 5’ TSS 
indicated there were no other TSSs in the miR-302 cluster (data not shown). 
 
Figure 4.2.2 Identification of miR-302 transcription start site corroborating existing data from 
Barroso-del Jesus et al 2008. A) The band in the ESC line represents the transcript identified as 
the TSS displayed in the schematic diagram. The TSS was identified using 5’RACE which involves 
ligating an adapter to the 5’end of the RNA and using primers specific to the gene and adapter to 
perform nested PCRS. As expected a TSS could not be detected in NPSCs. B) Sequencing of the 
5’RACE product, 5’RACE adapter is highlighted in blue lettering, the 3’ gene specific primer (GS 
primer) is highlighted in grey. The transcription start site is annotated with the (+1) arrow, 
indicating the position that 5’adapter annealed to.  
 
 
A 
B 
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4.2.3 Alternative polyadenylation of a singular miR-99a 
 
Another example of alternative polyadenylation occurs in miR-99a, a conserved 
intronic miRNA located on chromosome 21 next to miR-let-7c and miR-125b-2 
however it is unknown if the three miRNAs are polycistronic. Interestingly the 
sequencing data indicates that the expressions of the three mature miRNAs are 
different in NPSCs (fig 4.2.3c, Table 4.1.1).  
 
Figure 4.2.3a shows that there are three alternative 3’UTRs in NPSCs and the 
single band in the ESC line proved to be non-specific after sequencing. Figure 
4..2.3d shows the conserved sequence alignment of human and mouse miR-99a. 
The highlighted yellow sequence shows putative PASs (using PAS mining tool: 
https://github.com/coggy/signals_in_sequence) and the red sequence indicates 
the position of the three novel 3’ends established by DNA sequencing of the 
bands from figure 4.2.3a.  
 
As illustrated the multiple 3’ends of pri-miR-99a are supported by potential 
conserved PASs within 30 nt upstream of the poly(A)tails. MicroRNA 99a 
expression is heavily downregulated in several types of cancers and studies 
show that RNA in cancer cells are highly alternatively polyadenylated, with a 
tendency towards shorter 3’UTRs which can be subject to less post-
transcriptional regulation.  If miR-99a is transcribed together with nearby 
miRNAs, miR-let-7c and miR-125b-2, the function of multiple 3’ends could be to 
differentiate expression of the miRNAs within the cluster as well as between cell 
types and allow fine tuning of expression under different conditions.  
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Figure 4.2.3 miR 99a shows extensive alternative polyadenylation A) 5% PAGE of 3'RACE PCR 
products representing primary miR-99a in ESCs and NPSCs B) A Schematic diagram of the 
sequencing results from the 3’RACE PCR products. The sequences show 3 different 3’end 
termini. The different length arrows represent the different sized 3’RACE bands (Fig 5A). C) A 
schematic of the genomic situations of miR-99a, miR-let 7c and miR-125b-2 (adapted from 
Roush and Slack 2008). D) Conservation of 99a sequence between human and mouse species. 
Matching sequences are labelled with a “*” below the nucleotides. Underlined sequence 
represents the pre-miR-99a, the sequences in yellow represents potential PASs and the red 
sequence annotates the multiple 3’ ends established by 3’RACE and ABI 3730xl DNA 
sequencing. 
miR-99a miR-let 7c miR-125b-2 
D 
C 
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4.2.4 MicroRNA let 7a/f cluster forms different primary transcripts in ESCs 
and NPSCs.  
The microRNA let 7 family is well known to be post-transcriptionally regulated 
in ESCs, and our deep sequencing data confirms the absence of mature miR-let-7 
expression in ESCs (table 4.1). 3’RACE of the miR-let-7a/f cluster revealed 
differential alternative polyadenylation of the primary miRNA between ESCs and 
NPSCs (fig 4.2.4a).  
 
The gel in figure 4.2.4a representing miR-let-7a shows a larger band in the ESC 
sample. After sequencing of all the bands we were able to determine that three 
alternatively polyadenylated primary miR-let-7a/f transcripts were being made. 
Again, in these samples the 5’ end was artificially determined by the gene specific 
primer.  
 
In NPSCs individual primary transcripts for the two miRNAs were potentially 
made whereas in ESCs a large primary transcript incorporating both miR-let-7a 
and miR-let-7f was expressed (fig 4.2.4b). It is possible that NPSCs also make the 
large primary transcript incorporating both miRNAs; however limitations of 
3’RACE means that the technique preferentially amplifies shorter transcripts 
implying that expression of longer transcripts may not be detected (fig 4.2.4b). 
As mentioned previously, let-7 miRNAs are specific to NPSCs and known to be 
post-transcriptionally regulated in ESCs (Heo et al 2008); meaning that the 
primary or precursor form is present in ESCs but the mature transcript is not 
processed. With this is mind, the difference in polyadenylation of the transcripts 
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between the two cell lines could play a role in how the transcript is inhibited in 
ESCs but processed in NPSCs.  
 
The miR-let-7 family is most characterised for their mechanism of post-
transcriptional regulation in ESCs. Van Wynsberghe et al., 2011 report that Lin28 
binds to primary miR-let-7 co-transcriptionally, since polyadenylation also 
occurs co-transcriptionally it is possible that it plays a role in Lin28 silencing of 
miR-let-7. The novel 3’ends of miR-let-7a/f can be found downstream from a 
putative conserved PAS however the genomic distance appears to be further 
than 30 nts (fig 4.2.4c).  
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miR-let-7a-1 
miR-let-7f-1 
C 
Figure 4.2.4 Primary miR-let-7a and miR-let-7f are differentially 
polyadenylated in ESCs and NPSCs. A) 5% PAGE of 3' RACE PCR 
products representing primary miR-let 7 in ESCs and NPSCs B) A 
schematic diagram of the sequencing results from the 3’ RACE 
PCR products. The sequences are aligned to the genomic 
position of the precursor miR-let-7a-1 and miR-let-7f-1. The 
black arrow represents the sequence of the 3' RACE PCR of miR-
let-7a-1 in ESCs. The orange arrow represents the 3' RACE PCR of 
miR-let-7a-1 in NPSCs. The pink arrow represents the 3' RACE 
PCR of miR-let-7f-1 in NPSCs. C) Conservation of let7a and let7f 
sequence between human and mouse species. Underlined 
sequence represents the precursor miRNAs, the sequence in 
yellow represents potential PASs and the red sequence 
annotates the multiple 3’ ends established by 3’RACE and ABI 
3730xl DNA sequencing. 
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4.2.5 Each alternatively polyadenylated let 7a/f primary transcript found 
in ESCs and NPSCs can be processed into precursor miRNAs in HepG2s.  
 
To further investigate the nature of the three primary transcripts, each of the 
sequences plus ~100 bases extra upstream and downstream of the sequences 
annotated in figure 4.2.5a-c were cloned into pTRIPz inducible lentiviral vector 
and packaged with pCMV∆8.91 packaging construct and VSV-g envelop construct. 
 
Figure 4.2.5d is a northern blot of total RNA from HepG2 cells infected with the 
three different pri-miRNA sequences and probed with a double-DIG labelled LNA 
that binds to the mature miR-let-7a and miR-let-7f sequence. Figure 4.2.5d 
shows that even uninfected HepG2 cells express mature miR-let-7a and miR-let-
7f, however the precursor cannot be detected. In the control sample (PTE) 
infected with an empty vector the same can be seen. However in the samples 
infected with primary miR-let-7a and primary miR-let-7f (as separate 
transcripts) precursor miRNA expression is visible. The difference in size of 7 nts 
between the precursor miRNAs verifies the sizes reported on miRBase. The cells 
infected with the long precursor (miR-let-7af) incorporating both precursor 
transcripts (specific to ESCs) is also able to make both the precursor transcripts 
of miR-let-7a and miR-let-7f. Unfortunately due to the expression of mature miR-
let-7a and miR-let-7f in control samples it was not possible to establish whether 
the infected transcripts could be processed into mature miRNAs. MicroRNAs let-
7a and let-7f are ubiquitously expressed in most cell types and their sequence is 
conserved amongst many species, therefore it proved difficult to find a cell type 
that did not express miR-let-7a or miR-let-7f. As a result I was not able to 
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establish if the lentivirally expressed primary transcripts were made into mature 
miRNAs even though precursor production was obvious.  
 
Expression of specific miR-let-7a, miR-let-7f or miR-let-7af pTRIPz transcripts 
was confirmed by RT-PCR of the sequence specific to the pTRIPz vector and the 
miRNA transcript (fig 4.2.5e and supplementary figures S3, S4 and S5). This 
ensured that the infected cell lines did make the miRNA expressed by the 
lentiviral vector and that this is the precursor transcript detected by northern 
blot. 
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Figure 4.2.5 Lentivirus infection of HepG2 cells with primary miR-let-7a and miR-let-7f of different 
sequence lengths indicates that alternative polyadenylation alone cannot inhibit precursor miRNA 
production A-C) Displays UCSC BLAT results of the sequencing of the DNA inserts used to make 
miR-let-7a, miR-let-7f and miR-let-7af expressing lentiviral vectors. D) Northern blot of HepG2 cell 
infected with the 3 different lentiviral vectors expressing the various miRNAs in the cells expressing 
both miR-let-7a and miR-let-7f, two precursor transcripts can be seen indicting that all transcripts 
are capable of making precursor miRNAs. E) RT-PCR confirms the expression of the DNA insert-
vector sequence in the infected cell lines.  
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4.3 DISCUSSION  
 
4.3.1 MicroRNA gene clusters 
 
Despite the discovery of over 2578 miRNAs in the human genome alone, very 
few miRNA genes have been annotated; miRNA promoters, transcriptional start 
sites and 3’ends remain elusive. Lack of knowledge about miRNA gene structure 
and miRNA biogenesis presents a problem as the increasing importance of 
miRNAs in biological processes and disease becomes known.  
 
MicroRNA gene clusters are composed of two or more miRNA genes within 
proximal distance on a chromosome. They can be located in a polycistron and co-
expressed to coordinate the regulation of multiple processes such as embryonic 
development and cell differentiation. MicroRNA gene clusters are predicted to be 
formed by insertion of tandem repeats and many clusters are evolutionarily 
conserved across several species (Zhang et al., 2009). Genomic studies have 
found that miRNA genes across species have a tendency to be found in clusters 
rather than being scattered across the genome (Lagos-Quintana et al., 2001, Lai, 
2002). The discovery of more and more miRNAs in the human genome has 
revealed that about 40% of human miRNAs are located less than 3 kb from 
adjacent miRNAs (Kim et al., 2008, Altuvia et al., 2005).  
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4.3.2 Alternative polyadenylation in miRNA clusters 
MicroRNAs investigated in this study were chosen because of their differential 
expression in ESCs and NPSCs regardless of their genomic location in relation to 
other miRNAs. Therefore the high occurrence of alternative polyadenylation in 
clustered miRNAs is likely to be widespread and is possibly a regulatory feature 
for individual expression of miRNAs.  
 
Table 4.1.1 shows the vast differences in mature miRNA expression between 
individual miRNAs found in clusters e.g. miR-let-7a expression value is 3631 
whereas the expression value for miR-let-7d is only 183. However the miRNA 
sequencing data refers to mature miRNA expression which includes miRNAs 
generated from different miRNA genes therefore their expression levels may not 
represent the exact expression from the primary miRNA cluster of interest. For 
example miR-let-7a-1 is located in a cluster with miR-let-7f-1 and miR-let-7a-2 is 
clustered with miR-125b-1 therefore the proportion of mature miR-let-7a made 
from each genomic location cannot be determined. This demonstrates the need 
for primary and precursor miRNA sequencing data in ESCs and differentiated cell 
types. Due to the varying degrees of sensitivity of sequencing techniques and the 
transient nature of precursor miRNA expression, this sequencing data in ESCs is 
not widely available and that which exists is inconclusive. 
 
The miRNA-302 cluster is polycistronic, located on chromosome 4 and produces 
5 mature miRNAs 302a/b/c/d and miR-367 (and their star counterparts) in a 
single transcription unit. The cluster is exclusively expressed in pluripotent cells 
and is evolutionarily conserved over a variety of species. The miRNA-302 cluster 
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is one of the few whose miRNA gene structure has been identified and the 
promoter characterised and functionally validated (Barroso-delJesus et al., 2008). 
Experimental evidence shows that each miRNA within the miR-302 cluster 
undergoes alternative polyadenylation which, in theory, could allow the 
expression of several different putative primary transcripts. It is possible that 
the miR-302 cluster could express separate primary transcripts for each 
individual miRNA or even a primary transcript incorporating a few but not all of 
the miRNAs could be preferentially expressed. MicroRNAs in the miR-302 cluster 
can only be generated from the locus on chromosome 4 and no other methods of 
post-transcriptional regulation of the miR-302 cluster have been identified. As 
polyadenylation tends to stabilise RNA transcripts it is likely that these 
alternative primary transcripts are expressed in order to be processed rather 
than to be degraded. Consequently it is possible that the differential expression 
seen in the deep sequencing data between the mature miRNAs could be 
influenced by alternative polyadenylation (fig 4.3.1).   
 
The use of alternative polyadenylation will result in the generation of alternative 
primary miRNAs that do not incorporate all miRNAs within a cluster and 
therefore individual loop regions of the precursor miRNAs may be missing.  The 
loop regions of miRNAs are important because they are known to be targets for 
RNA binding proteins (Thornton and Gregory, 2012, Viswanathan et al., 2008, 
Chakraborty et al., 2012) (see Introduction). Consequently alternative 
polyadenylation might be expected to alter both the miRNA and the RNA binding 
proteins known to associate with the primary miRNAs. To support this theory, 
tertiary RNA structure and interaction of stem-loops within a primary miRNA 
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cluster have been shown to play a huge role in processing (Chaulk et al., 2011, 
Chakraborty et al., 2012). Alterations of tertiary RNA structure can potentially 
sequester RNA binding sites to either promote or impede processing of miRNAs. 
Within the miR-17-92 cluster, the tertiary structure actually limits the 
accessibility of miR-92a resulting in decreased expression compared with other 
miRNAs in the cluster. In addition it has been shown in mice that altering the 3’ 
end of pri-miR-17~19 disrupts the tertiary RNA structure resulting in increased 
miRNA expression (He et al., 2005, Chaulk et al., 2011). Therefore it is possible 
that APA could alter tertiary structure of primary miRNA resulting in altered 
binding of associated proteins thereby influencing miRNA expression levels.   
 
The 3’RACE of miR-302 also suggests that alternative splicing is active within the 
cluster however it is not yet clear what influence alternative splicing has upon 
miRNA production. 
 
The miR-99a, miR-let-7c and miR-125b-2 cluster is located on chromosome 21 in 
the human genome and occurs in almost all species that express miR-let-7, 
however the order of the miRNAs and the spacing between them on the 
chromosome differ between species (Roush and Slack, 2008). In Drosophila the 
miR-99a cluster is polysistronic therefore transcribed as one primary miRNA. 
However in humans it is not yet known if this cluster is polycistronic or if it is 
further processed into individual primary miRNAs before processing by Drosha 
(Roush and Slack, 2008). As miR-99a and flanking sequences are conserved in 
Drosophila it is likely that human miR-99a is part of a cluster with miR-let-7c and 
miR-125b-2. 3’RACE of miR-99a identified three alternate 3’ends which may 
145 
 
Fig 4.3.1 Maps of the 5’ end of primary miR-let-7a-1/let-7f-1 cluster reproduced from Wang et al 
2011 (A) and Zhao et al 2011 (B). In both publications the transcription start site detected by 5’ 
RACE is indicated by labelled arrows.  
A B 
function to regulate the expression of the individual miRNAs within the miR-99a 
cluster. 
 
In the human genome the conserved miR-let-7a/f (also found with miR-let-7d) 
gene cluster found on chromosome 9, has been annotated with identification of 
four alternate 5’TSS and one 3’end, with all three miRNAs included in each of the 
alternative transcripts (Wang et al., 2011 and Zhao et al., 2011). 
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The miR-let-7a/f cluster is regulated by MYC which binds directly to the 
promoter causing downregulation of the miR-let-7a/f cluster promoting 
tumorigenesis (Roush and Slack, 2008). The let-7a/f cluster is known to be post-
transcriptionally regulated almost entirely by the Lin28 RNA binding protein in 
ESCs at the primary and precursor miRNA stage. Our results show that the miR-
let-7a/f cluster is alternatively polyadenylated in NPSCs, utilizing a PAS between 
miR-let-7a and miR-let-7f resulting in separate primary transcripts. Alternative 
polyadenylation could be a novel mechanism for regulation of miR-let-7a/f 
specific to ESCs and is likely to play a role in the expression of precursor and 
mature miRNAs. Further experiments show that expression of separate primary 
transcripts for miR-let-7a-1 and miR-let-7f-1, identical to the alternatively 
polyadenylated transcripts, can be processed into precursor miRNAs in HepG2 
cells which do not express Lin28. It is also possible that in ESCs the block in 
Drosha processing of the pri-miR-let-7 due to Lin28 binding could result in the 
inhibition of polyadenylation between pre-miR-let-7a and pre-miR-let-7f. 
Further investigation into the connection between alternative polyadenylation of 
miR-let-7 transcripts and Lin28 silencing of let-7 miRNAs could help to further 
unravel the mechanism behind post-transcriptional regulation of miR-let-7 in 
human ESCs. Unfortunately this has been difficult to investigate in ESCs as loss-
of-function assays have not yet been possible to achieve due to the characteristic 
clonal growth pattern of ESCs making them resistant to transfection.  
 
We have discovered extensive putative alternative polyadenylation of primary 
miRNAs, a phenomenon that has only recently been reported in miRNAs and 
could be an important novel factor in regulating miRNA biogenesis. We show 
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that alternative polyadenylation occurs in primary miRNA processing within and 
between cell types; potentially playing a role in regulating the miR-302 cluster 
and miR-let-7a/f as well as other miRNAs (miR-99a and miR-21 – see 
supplementary figure S1) confirming existing literature (Ribas et al., 2012). 
Alternative polyadenylation has the potential to play a regulatory role in miRNA 
synthesis, regardless of whether the miRNA is under transcriptional or post-
transcriptional control. 
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CHAPTER 5 - DEVELOPING A WORKING 
ASSAY FOR THE NOVEL ANTI-TUMOUR DRUG 
SPLICEOSTATIN A 
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5.1 INTRODUCTION 
 
5.1.1 Spliceostatin A and TG003  
Spliceostatin A (SSA) is a specific inhibitor of splicing that possesses potent anti-
proliferative and anti-tumour characteristics by causing arrest in the G1 and 
G2/M phases of the cell cycle. SSA is one of six synthetic inhibitors derived from 
the fermentation broth of Pseudomonas spp however SSA has the most enhanced 
stability and inhibitory activity (Kaida et al., 2007) (figure 5.1.1). 
Figure 5.1.1 Natural splicing inhibitors and 
their synthetic derivatives originating from 
Pseudomonas spp. Natural compounds 
FR901463, FR901464, FR901465 (left) can 
be chemically modified to generate six 
synthetic analogues, SSA, Meayamycin, 
Meayamycin B, Sudemycin C1, Sudemycin 
E and Sudemycin F (adapted from Bonnal 
et al., 2012). 
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Following U1 snRNP recognition and association of the pre-mRNA 5’ splice site, 
the 3’ splice site (and polypyrimidine tract) is initially primed by the branch-
point binding protein and U2 snRNP auxillary factors (Corrionero et al., 2011). 
These interactions result in an RNA secondary structure that activates further 
pre-mRNA spliceosomal processing (Kent et al., 2003). Subsequently the 17S U2 
snRNP complex is enlisted, composed of 2 protein subcomplexes (SF3a and 
SF3b) and a number of polypeptides. SF3b is the larger of the two subcomplexes 
and is composed of at least eight subunits. U2 snRNP forms a pre-spliceosomal 
complex with the pre-mRNA by base-pairing to the branch site causing the 
branch site adenosine to bulge thus facilitating the initial catalytic splicing 
reaction. The largest and most conserved subunit SF3b-155 binds in a sequence-
independent manner to the 5’ and 3’ end of the branch sequence holding the U2 
snRNP to the location of the branch site (Kent et al., 2003).  
 
Kaida et al 2007 initially showed that SSA can be immunoprecipitated with SF3b. 
It was then proven that SSA association with SF3b caused inhibition of the 
binding of SF3b to pre-mRNA branch site (Kaida et al., 2007). This initiates a 
conformational change that reduces RNA binding efficiency and disables a 
proofreading mechanism (Bonnal et al., 2012). Roybal and Jurica 2010 also 
reports that SSA prevents spliceosome assembly prior to U2 snRNP addition 
destabilising U2 snRNP and their pre-mRNA complexes which prevents 
subsequent spliceosomal assembly. These results are supported by the finding 
that knockdown of SF3b1 expression mimics the drug induced effects. (Kaida et 
al., 2007, Roybal and Jurica, 2010).  Further studies show that SSA specifically 
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prevents the association of a 155-kDa subunit of SF3b (SF3b-155) with the pre-
mRNA resulting in a lack of interaction of the U2 snRNP with the branch site 
(Corrionero et al., 2011). Furthermore SSA inhibition of SF3b can cause nuclear 
retention of pre-mRNA (Kaida et al., 2007). 
 
Microarray analysis demonstrates that SSA does not globally inhibit splicing 
(Corrionero et al., 2011). Corrionero et al 2011 show that individual pre-mRNAs 
are diversely affected by SSA treatment. Some pre-mRNA 3’splice sites show 
different sensitivity to SSA treatment which can vary according to the base-
pairing potential of the branch site with U2 snRNA (Corrionero et al., 2011). This 
signifies a role of SSA in influencing alternative splicing in addition to inhibiting 
general splicing (Corrionero et al., 2011). SSA induced alternative splicing results 
in the decline of cell cycle gene expression including cyclin A2 which could 
explain the mechanism behind the anti-proliferative effect of SSA (Corrionero et 
al., 2011).  
 
Despite targeting basic steps in splice site recognition, SSA appears to have a 
cytostatic (not cytotoxic) effect on cells, especially in cancer cells (Bonnal et al., 
2012). This could be due to a number of factors including cellular permeability, 
splicing demand and drug concentrations (Bonnal et al., 2012). In addition, SSA 
has been shown to affect only a subset of genes in vivo (Kaida et al., 2010, Younis 
et al., 2010). 
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The other inhibitor used in this study is TG003, a benzothiazole inhibitor of the 
SR protein kinases CLK1 and CLK4. Phosphorylated SR proteins CLK1 and CLK4 
assist splicing reactions and spliceosome formation. Therefore TG003-induced 
inhibition of CLK1 and CLK4 can inhibit pre-mRNA splicing (Muraki et al., 2004, 
Hagiwara, 2005).  
 
The focus of my research is to investigate the effects of the novel anti-tumour 
splicing inhibitor SSA on RNA transcripts in vivo and TG003 is used as a control 
to verify and compare its effects. 
 
5.1.2 The importance of splicing inhibitors in disease 
Currently there are only a few identified splicing inhibitors known to target the 
splicing pathway (Bonnal et al., 2012). Pre-mRNA splicing inhibitors promise to 
reveal original insights into the spliceosome and splicing pathways (Bonnal et al., 
2012). 
 
Abnormal splicing plays a major role in the production of aberrant proteins. This 
highlights the importance of pre-mRNA splicing inhibitors in the field of disease 
therapy (Bonnal et al., 2012). Targeting modulators of alternative splicing of 
mRNA transcripts is a potential treatment for diseases such as muscular 
dystrophies and neurodegenerative disorders (Bonnal et al., 2012).  For example 
TG003 is of potential relevance for the treatment of Duchenne muscular 
dystrophy and SSA displays anti-tumoural properties (Bonnal et al., 2012). Thus 
SSA may be used not only as a powerful tool for analysing pre-mRNA splicing but 
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also for developing new therapeutics (Kaida et al., 2007). Since the discovery of 
SSA much has been revealed about the mechanism of splicing inhibition however 
its effect on RNAs in vivo and the mechanism behind its anti-tumour capabilities 
remain elusive. 
 
5.1.3 Aims 
Kaida et al., 2010 and Younis et al., 2010 observed only partial inhibitory action 
of SSA in RT-PCR assays despite SSAs complete inhibition of splicing in vitro and 
they also show that even at high SSA concentration, splicing inhibition in vivo 
appeared to be restricted (Kaida et al., 2010, Younis et al., 2010). After 
preliminary RT-PCR experiments, I confirmed these observations showing that 
<25% of genes investigated appeared to be affected by SSA (figure 5.2.1). Many 
reports have been published about the effects of SSA on splicing suggesting that 
it is unlikely that the lack of effect on the mRNAs I assayed is due to the efficiency 
of SSA. Therefore we wondered if the effect of SSA on RNA splicing is masked by 
the presence of RNAs with long half-lives, which obscure RT-PCR analysis.  
 
With this in mind, I intend to establish if the effect of Spliceostatin A in vivo can 
be better observed on newly generated RNA. SSA treated cells will be subjected 
to treatment with Interferon α in order to induce gene expression and then 
isolated nascent RNAs will be analysed to attempt to observe the total effect of 
SSA on RNA.  This will help establish a working assay for potentially important 
therapeutic anti-cancer treatments and provide insight into the function of 
splicing components and their effects on RNA synthesis.  
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5.2 RESULTS  
 
5.2.1 The effect of Spliceostatin A is obscured by existing stable RNAs 
We obtained small amounts of SSA in collaboration with Professor Minoru 
Yoshida and the concentration of SSA used (200 ng/ml) was based upon a 
previous titration and current literature (Kaida et al., 2007, Roybal and Jurica, 
2010, Corrionero et al., 2011). Microarray analysis shows that SSA did not have 
an effect on a large subset of genes in vivo (Kaida et al., 2010). I verified this 
observation, noting that <25% of genes investigated appeared to be affected by 
SSA (figure 5.2.1). 
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Figure 5.2.1 SSA shows little visible effect on RNA by RT-PCR analysis. A) PCR of 
expressed genes in HT1080 cells (control) and SSA-treated HT1080 cells. The gel shows 
that gene expression does not change with the addition of SSA in total RNA samples. B) 
Table of genes which have been investigated by RT-PCR for effects of treatment with SSA 
(the cell lines used to investigate the different genes are stated in superscript). 
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To establish if the effects of SSA were masked by existing RNAs in vivo, RT-PCR 
reactions were performed on newly synthesised RNA transcripts. To induce the 
synthesis of RNA transcripts, cells were treated with Interferon α (IFNα).  IFNα is 
a cytokine that specifically induces the expression of a large number of genes 
(Der et al., 1998)  (supplementary table S3). The primers for RT-PCR were 
designed in two adjacent exons under the hypothesis that the addition of SSA 
would increase the unspliced intron-containing transcripts. All RT-PCR reactions 
have been repeated and sequenced to verify the correct transcript.   
 
Figure 5.2.2 illustrates a number of RT-PCR reactions performed on cDNA 
generated from HT1080 cells treated with a combination of IFNα, SSA and 
Cycloheximide. Cycloheximide inhibits nonsense-mediated mRNA decay (NMD), 
which is a method of post-transcriptional regulation of irregular mRNA. NMD 
inhibitors such as Cycloheximide may allow detection of mRNA splicing that has 
been inhibited but whose transcript could not be detected because of premature 
degradation due to NMD. Figure 5.2.2 shows that 7/8 of the gene transcripts 
analysed following treatment with IFNα showed some response to SSA. Figure 
5.2.2 shows three examples; RING4, TRIM21 and P48 where IFNα has induced 
increased expression of the spliced mRNA transcript. Upon the addition of SSA, 
(figure 5.2.2, lanes C-E) the levels of the spliced transcripts (lower band) are 
reduced and the levels of unspliced mRNA transcripts are increased (higher 
band). Only the RT-PCR of RING4 illustrates the value of the addition of 
Cycloheximide, where the unspliced transcript can be seen clearly in the 
Cycloheximide treated sample (fig 5.2.2E) indicating that NMD has been 
inhibited, preventing degradation of the transcript. RT-PCR of TRIM21 shows 
Figure 2 
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that the expression of the spliced transcript is reduced with the addition of SSA, 
whereas the RT-PCR of P48 shows that the amount of spliced transcript was 
nearly negligible. Furthermore SSA showed a negative effect on the expression of 
4/8 of the genes induced by IFNα (MxA, ISGI5, 6-16 and OAS1) (fig 5.2.2). The 9-
27 gene (fig 5.2.2) displayed a reduced response to SSA compared to the other 
genes tested; however a reduced response to IFNα could also be seen. 
 
Figure 5.2.3 shows that the inhibition of MxA, 6-16 and OAS1 expression is due 
to splicing inhibition. When observing different exon/intron boundaries of these 
genes it becomes clear that SSA also inhibited their splicing. Presumably 
unspliced transcripts are difficult to detect by RT-PCR due to NMD which may 
not be efficiently inhibited by Cycloheximide (fig 5.2.3). 
 
The effects of SSA and inhibiting splicing on RNA transcripts induced by IFNα 
could be reproduced with a different splicing inhibitor, TG003 (fig 5.2.4), 
confirming that the results were due to splicing inhibition (fig 5.2.4).  
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Figure 5.2.2 Spliceostatin A has a visible effect on genes induced by IFNα. cDNA 
synthesis and RT-PCR of genes known to be induced by IFNα in human HT1080 cells 
under varied conditions A) no treatment B) treated with IFNα (2 μg/ml) for 2 hours 
C) treated with SSA (2 ng/ml) for 2.5 hours D) pre-treated with SSA (2 ng/ml) for 
30mins and then incubated with IFNα (2 μg/ml) for 2 hours E) pre-treated with SSA 
(2 ng/ml) for 30mins and then incubated with IFNα (2 μg/ml) and cyclohexamide (1 
μg/ml) for 2 hours. 
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Figure 5.2.3 Detection of splicing inhibition for MxA, OAS1 and 6-16 genes. 
See Fig 5.2.2 A) no treatment B) treated with IFNα (2 μg/ml) for 2 hours C) 
treated with SSA (2 ng/ml) for 2.5 hours D) pre-treated with SSA (2 ng/ml) for 
30mins and then incubated with IFNα (2 μg/ml) for 2 hours E) pre-treated 
with SSA (2 ng/ml) for 30mins and then incubated with IFNα (2 μg/ml) and 
cyclohexamide (1 μg/ml) for 2 hours. MxA In 7 – refers to RT-PCR of exons 
flanking the 7th intron from the 5’ UTR. 
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Figure 5.2.4 Alternative splicing inhibitor TG003 has a similar effect on RNA splicing 
as Spliceostatin A. RT-PCR of genes known to be induced by IFNα in human HT1080 
cells under varied conditions A) no treatment B) treated with IFNα (2 μg/ml) for 2 
hours C) treated with TG003 (2 ng/ml) for 2.5 hours D) pre-treated with TG003 (2 
ng/ml) for 30mins and then incubated with IFNα (2 μg/ml) for 2 hours E) pre-treated 
with TG003 (2 ng/ml) for 30mins and then incubated with IFNα (2 μg/ml) and 
cyclohexamide (1 μg/ml) for 2 hours 
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5.2.2 Effects of Spliceostatin A on nascent RNAs 
Although IFNα is able to induce the expression of a variety of genes, this 
technique did not allow us to have a global view of the effect of SSA on all RNA 
transcripts. Consequently we decided to establish a method for isolating and 
analysing newly synthesised (nascent) mRNA. 
 
Nascent RNA was isolated by labelling and selectively enriching nascent mRNA in 
vivo by incorporation of exogenous 4-thiouridine (4sU). 4sU is a naturally 
occurring uridine derivative which allows isolation of nascent RNA transcripts 
with minimal interference to cell growth and gene expression (Windhager et al., 
2012, Dolken et al., 2008, Kenzelmann et al., 2007). Following 4sU-labelling, total 
cellular RNA undergoes thiol-specific biotinylation which can then be separated 
into “tagged” (nascent transcripts) and “untagged” (pre-existing) RNAs using 
μMACs streptavidin-coated magnetic beads and columns (as described in Dolken 
et al., 2008). In order to ensure that RNA integrity was maintained throughout 
the protocol, 1% agarose gels were run after biotinylation and biotin affinity 
purification (figure 5.2.5a and 5.2.5c). Figure 5.2.6a shows that after 
biotinylation, samples were run on a gel to check that RNA had not degraded; 
this can be established by the presence of distinct 28S and 18S rRNA bands.  To 
check that biotinylation of samples was thiol-specific, I performed a dot blot 
assay (fig 5.2.5b). This assay required blotting 10 fold dilutions of RNA in order 
to detect biotin incorporation by using streptavidin-horseradish peroxidase 
solution followed by x-ray exposure with ECL reagent. Figure 5.2.5b shows that 
biotin can only be detected in the positive control and 4sU incorporated samples. 
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The small amount of exposure seen in the negative control is background signal 
and is common when performing this type of dot blot (Lars Dölken, University of 
Cambridge, personal communication). The gel run after biotin affinity 
purification verifies that only samples with incorporated 4sU were pulled down 
and the integrity of the RNA is maintained (obvious by the 28S and 18S rRNA) 
(fig 5.2.5c). The nascent RNA was then recovered and analysed for effects of SSA 
on splicing via RT-PCR (Figure 5.2.6). 
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Figure 5.2.5 Detection and integrity analysis of biotinylated and biotin affinity purified RNA. A) 
1% agarose of total RNA after biotinylation of RNA with no 4sU (“-“) and “4sU” RNA treated with 
200 μM 4sU; “4sU SSA”; RNA treated with SSA (2 ng/ml) and 200 μM 4sU. B) Dot blot assay 
showing the thiol-specific biotinylation of RNA. 10 fold dilutions of RNA were blotted down the 
membrane. C) 1% agarose of RNA after biotin affinity purification, the “+” control was total RNA. 
The “-“control was RNA with no 4sU showing that only 4sU incorporated RNA could be purified.     
+: Total HepG2 RNA; -: HepG2 RNA with no 4sU incorporation; 4sU: RNA treated with 200 μM 
4sU; 4sU SSA; RNA treated with SSA (2 ng/ml) and 200 μM 4sU. In C) +: 5’-biotinylated DNA 
oligo. RNA used in this experiment was derived from HepG2 cells and NIH 3T3 fibroblasts (NIH) 
 
18s 
28s 
18s 
28s 
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Pre-treatment with SSA resulted in a visible effect on 12/14 genes. 8 out of 14 of 
these genes clearly showed an appearance of the unspliced transcript in some 
cases accompanied by the loss of the spliced transcript (fig 5.2.6). 4/14 genes 
(ki67, cytokeratin 8, N-cadherin and caspase 3) showed a complete loss of the 
spliced transcript upon the addition of SSA (fig 5.2.6). Again this result is likely to 
be due to NMD rather than an effect on transcription. Lastly 2/14 genes (RPL19 
and G6PD) showed no visible effect of SSA by the RT-PCR method (fig 5.2.6). An 
effect on G6PD can be seen when splicing is inhibited by TG003 therefore it is 
possible that G6PD may be less sensitive to SSA treatment. In addition, RPL19 is 
an abundant transcript in cells therefore some bias may be occurring in favour of 
isolating non-nascent transcripts which could mask the effects of SSA on RPL19.  
 
Overall these results show that analysing the effect of SSA on nascent RNA 
provided an enhanced view of the effects of the drug on global RNA and it has 
revealed differential effects of SSA on distinct RNA transcripts.  
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Figure 5.2.6 Spliceostatin A has a visible effect on newly synthesised RNAs in mouse NIH 3T3 
fibroblasts (A) and human HepG2 (B). cDNA synthesis and RT-PCR of nascent RNAs in human 
HepG2 cells under varied conditions  A) no treatment B & C) treated with 200 μM thiouridine 
(4sU) base analogue for 2 hours D & F) pre-treated with SSA (200 ng/ml) for 30mins and then 
incubated with 200 μM 4sU for 2 hours. E) Treated with 200 μM thiouridine (4sU) base analogue 
for 2 hours F) pre-treated with TG003 (2 µg/ml) for 30 mins and then incubated with 200 μM 
4sU for 2 hours. All samples were then biotinylated and biotin affinity purified with streptavadin 
beads so that nascent RNA could be isolated (as described in Dolken et al., 2008). 
 
 
A 
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5.2.3 Inhibition of the spliceosome causes retention of RNA in the nucleus 
I then investigated the effects of SSA on RNA localisation and export in cells. 
Immunocytochemistry analysis shows that upon treatment with SSA, newly 
synthesised RNA labelled with 5’Flurouridine can be seen to localise largely in 
the nucleus (Figure 5.2.7). Both SSA and TG003 cause nuclear retention of RNAs 
to different degrees, with SSA being more potent and causing enhanced nuclear 
retention of RNAs (Figure 5.2.7 and figure 5.2.8). Samples treated with SSA show 
56% colocalisation of nascent RNAs with the nucleus; TG003-treated samples 
show less nuclear retention with 36% and control samples show only 12% 
nuclear colocalisation (figure 5.2.8). This result can be seen upon titration of the 
drugs, proving that the difference between the effects of inhibitors is not due to 
differences in concentration of the drugs (figure 5.2.9). RNA retention in the 
nucleus could be assumed to be largely ribosomal RNAs (rRNAs) as they form 
~80% of all RNA transcripts in a cell. Curiously, a majority of rRNAs are 
intronless therefore the effect of inhibiting the splicing machinery on these 
transcripts could be unprecedented. However it is possible that inhibiting the 
spliceosome may result in knock-on effects on other cell processes thereby 
having an indirect effect on intronless genes (Maniatis and Reed, 2002, 
Grzybowska, 2012).  
 
Kaida et al., 2007 suggests that the SF3b subunit of the U2 snRNP, which is a 
target of SSA, plays a key role in nuclear retention of RNA. SF3b is known to 
interact with the retention and splicing (RES) complex implicating that without 
functional SF3b, pre-mRNAs leakage occurs. Figure 5.2.7 c & f show some leakage 
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of RNA from the nucleus however retention of RNA in the nucleus is much more 
prevalent. 
 
 
 
 
 
Figure 5.2.7 Spliceostatin A and TG003 splicing inhibitors cause retention of RNAs in the nucleus. 
A-F) Immunocytochemistry analysis of HepG2 cells A & D) No treatment B & E) Treatment with 1 
mM 5-Flurouridine for 2 hours C) Pre-treatment with 200 ng/ml SSA for 30 mins and then 1 mM 5-
Flurouridine for 2 hours F) Pre-treatment with 2 µg/mlTG003 for 30 mins and then 1 mM 5-
Flurouridine for 2 hours. Cells were then stained by immunocytochemistry using either anti-BrdU 
and Alexa Fluor 555 antibody or DAPI. Photographs were taken on an SP5 confocal.  
 
No Treatment 
No Treatment 
5-Flurouridine (5-F) 
5-Flurouridine (5-F) 
SSA & 5-F 
TG003 & 5-F 
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Figure 5.2.8 Quantification of immunocytochemistry analysis of HepG2 cells (figure 5.2.7). Values 
represent percentage of colocalisation of nuclear stain DAPI with nascent RNA (5’F anti-BrdU 
staining). “Control” represents samples treated with 1mM 5-Flurouridine for 2 hours. “SSA” 
represents SSA pre-treated samples and then 1 mM 5-Flurouridine for 2 hours. TG003 represents 
TG003 pre-treated samples and then 1 mM 5-Flurouridine for 2 hours. Fiji image j and JACoP 
software was used to obtain colocalisation values from confocal images generated in four 
independent experiments – error bars represent standard error of the mean.   
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Figure 5.2.9 Titration of Spliceostatin A and TG003 concentration. Immunocytochemistry analysis 
of HepG2 cells, treatments of each sample is described above the picture. Varying concentration 
of SSA and TG003 were added to cells 30 minutes before the addition of 1 mM 5-Flurouridine for 2 
hours. Cells were then stained by immunocytochemistry using either anti-BrdU and Alexa Fluor 
555 antibody or DAPI. Photographs were taken on an SP5 confocal.  
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5.2.4 More pre-mRNA can be detected in the nucleus of SSA treated samples 
compared to the cytoplasm indicating possible nuclear retention of RNA  
 
In order to elucidate the effect of SSA on nuclear RNA retention, nascent RNAs 
from the nucleus and the cytoplasm were isolated. Subsequently RT-PCRs of 
genes found commonly in HepG2 cells and rRNAs were performed (fig 5.2.10). 
The RT-PCR of the βactin, HMBS and RPS3A genes verified the 
immunocytochemistry analysis, showing a build-up and retention of RNAs in the 
nucleus of SSA-treated cells. Figure 5.2.10 shows that upon the addition of SSA 
there is a visible increase in pre-mRNA (unspliced transcripts) in the nucleus. In 
addition this is confirmed by a build-up of pre-mRNA also seen in the nucleus of 
cells treated with TG003; again confirming the immunocytochemistry it can be 
seen to a lesser extent than with SSA treatment (fig 5.2.10 C-F). Contrary to our 
initial hypothesis RT-PCR of 18S and 5.8S rRNAs indicated that neither SSA nor 
TG003 affected their nuclear export; therefore rRNAs may not be the major 
component of RNAs retained in the nucleus upon SSA treatment.  
Figure _ Spliceostatin A and TG003 splicing inhibitors cause retention of RNA in 
the nucleus. A-F) Immunocytochemistry of HepG2 cells. A & D) No treatment. B & 
E) Treatment with 1mM 5-Flurouridine for 2 hours C) Pre-Treatment with 
200ng/ml SSA for 30 mins and then 1mM 5-Flurouridine for 2 hours . F) 
Pretreatment with 2ng/mlTG003 for 30 mins and then 1mM 5-Flurouridine for 2 
hours. Cells were then stained by immunocytochemistry using either anti-BrdU 
and Alexa Fluor 555 antibody or DAPI. Photographs were taken on an SP5 
confocal.  
Figure _ Spliceostatin A and TG003 splicing inhibitors cause retention of RNA in 
the nucleus. A-F) Immunocytochemistry of HepG2 cells. A & D) No treatment. B & 
E) Treatment with 1mM 5-Flurouridine for 2 hours C) Pre-Treatment with 
200ng/ml SSA for 30 mins and then 1mM 5-Flurouridine for 2 hours . F) 
Pretreatment with 2ng/mlTG003 for 30 mins and then 1mM 5-Flurouridine for 2 
hours. Cells were then stained by immunocytochemistry using either anti-BrdU 
and Alexa Fluor 555 antibody or DAPI. Photographs were taken on an SP5 
confocal.  
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Figure 5.2.10 Spliceostatin A causes a build-up of nascent pre-mRNA in the nucleus. cDNA 
synthesis and RT-PCR of nascent RNA taken from cytoplasmic and nuclear portions of 
human HepG2 cells under varied conditions  A) Cytoplasmic RNA treated with 200 μM 
thiouridine (4sU) base analogue for 2 hours. B) Nuclear RNA treated with 200 μM 
thiouridine (4sU) base analogue for 2 hours C) Cytoplasmic RNA pre-treated with SSA (200 
ng/ml) for 30 mins and then incubated with 200 μM 4sU for 2 hours D) Nuclear RNA pre-
treated with SSA (200 ng/ml) for 30mins and then incubated with 200 μM 4sU for 2 hours 
E) Cytoplasmic RNA pre-treated with TG003 (2 µg/ml) for 30mins and then incubated with 
200 μM 4sU for 2 hours F) Nuclear RNA pre-treated with TG003 (2 µg/ml) for 30 mins and 
then incubated with 200 μM 4sU for 2 hours. Primers that span only an exon, so mature 
mRNA can be detected, are used as a control (HPRT1 gene). In all other samples the 
primers bind to adjacent exons flanking an intron.  
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5.3 DISCUSSION 
 
5.3.1 The effects of splicing inhibitors, SSA and TG003 can be seen more 
clearly in nascent RNAs  
This chapter addresses the difficulties of assessing the effects of splicing 
inhibitors on RNA transcripts. It was not possible to see the effects of SSA on a 
majority of pre-mRNAs by RT-PCR because RNA transcripts with long half-lives 
obscured detection of RNAs affected by SSA. The average time of RNA turnover 
in mammalian cells is ~ 7 hours where <0.5% of RNA transcripts have half-lives 
less than 1 hour (Sharova et al., 2009). A “short” half-life of RNA is defined at <4 
hours so the effects of treatment with splicing inhibitors after 2 hours is unlikely 
to be seen (Tani et al., 2012). We have shown that by isolating nascent RNAs 
from cells pre-treated with SSA, it is possible to visualise the global effects of SSA. 
This novel method for analysing the effects of SSA will be useful for future 
studies on the spliceosome and the potential of SSA as therapy for cancers. 
 
Once a working assay for SSA had been established, it became obvious that SSA 
had different effects on individual RNAs. This observation has been corroborated 
by a number other of studies (Kaida et al., 2007, Lo et al., 2007, Corrionero et al., 
2011). It is thought that targeting a single aspect of the splicing process can give 
rise to diverse effects on different RNA transcripts and it has also been noted that 
some genes are more sensitive to SSA than others, inducing alternative splicing 
and often inhibiting splicing completely (Bonnal et al., 2012).  
This can be verified in vivo where mutations in the SF3b1 subunit protein cause 
specific developmental defects in neural crest formation in zebrafish, supporting 
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the theory that different cell types and genes have different requirements of 
SF3b1 (An and Henion, 2012).  
 
Other examples substantiating the differential effects of SSA can be seen when 
observing the action of SSA on yeast intron-containing transcripts; which are 
simple and synonymous to one another compared to human mRNA. The effects 
in vitro showed that there is an unknown mechanism by which the spliceosome 
can distinguish between RNA transcripts, most likely due to co-factors (Kaida et 
al., 2007). Knocking down core spliceosomal components in flies results in 
differential effects on alternative splicing (Pleiss et al., 2007). Mutations of 
different spliceosomal components cause different effects on RNAs and can be 
validated in our results as some differences in the effect of TG003 and SSA on 
RNA transcripts can be observed (fig 5.2.2, fig 5.2.4 and fig 5.2.6). 
 
To conclude, a majority of nascent RNA transcripts are affected by SSA with the 
minority that are unaffected showing no change in expression (figure 5.2.6). Of 
the transcripts that were affected by SSA differential effects could be seen. A 
deeper understanding of the effect of different cofactors of the core splicing 
machinery could help achieve modulation of mis-splicing that leads to disease.  
 
5.3.2 The effects of SSA and TG003 differ 
During this study, we detected a difference between the effects of SSA and TG003 
on RNA processing. When observing the action of SSA and TG003 on RNA 
transcripts some transcripts were affected to the same degree by both inhibitors, 
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some differ depending on which inhibitor is used and some transcripts show no 
effect with one or both inhibitors. A majority of these results could be repeated 
confirming the role of each drug in causing different effects on RNAs.  In addition 
immunocytochemistry analysis revealed that although both SSA and TG003 
caused nuclear retention of RNA, it occurred to significantly different degrees 
with SSA being 1.5 times more potent.  
 
Pleiss et al 2007 investigated 24 different mutations of the spliceosome core 
components and mRNA processing in flies to observe their effect on intron 
removal in mRNA on a global scale. They discovered that splicing mutations have 
an effect on a broad range of transcripts resulting in accumulation of unspliced 
pre-mRNA; however not all transcripts followed the same pattern. Transcripts 
can be affected equally by all the mutations, some are affected to differing 
degrees and some transcripts that are only affected by specific mutations (Pleiss 
et al., 2007). This has implications that individual splicing components have 
different effects depending on the RNA substrate.  
 
Furthermore TG003 splicing inhibitor targets SR proteins presumably having an 
effect on both U2- and U12-dependent spliceosomes whereas SSA is thought to 
target the SF3b subunit of the U2 snRNP that specifically inhibits U2-dependent 
spliceosome.  
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5.3.3 Splicing inhibition causes nuclear retention of RNA transcripts  
Immunofluorescence studies show the effect of the splicing inhibitors on 
localisation of RNAs. RNA retention can be can be detected in cells treated with 
either SSA or TG003 to varying degrees; SSA-treated samples showed 1.5 times 
more RNA within the nucleus than TG003-treated samples. In SSA treated cells 
there was 56% colocalisation of nascent RNAs in the nucleus compared to 
control samples which show 12% colocalisation (Figure 5.2.8). This shows high 
levels of nuclear RNA retention in SSA-treated samples. Current literature 
similarly report accumulation of multiple transcripts with partial intron 
retention upon treatment with SSA (Bonnal et al., 2012).  
 
Accumulated pre-mRNAs after splicing inhibition can be very stable despite 
containing termination signals in introns which would normally result in 
degradation by the NMD pathway, therefore nuclear accumulation of unspliced 
RNAs is possible (Kaida et al., 2007). However, reports from Kaida et al., 2007 
show that the SF3b subunit has a dual function in the splicing and nuclear 
retention of pre-mRNA, therefore inhibition of this component actually causes 
pre-mRNA leakage. Furthermore they show accumulation of unspliced proteins 
upon SSA treatment, bypassing all checks of unspliced RNA including NMD 
(Kaida et al., 2007). The class of RNA that constitute the majority of RNAs 
retained in the nucleus upon treatment with SSA is still not known and initial 
hypotheses alluding to retention of intronless ribosomal RNAs have not yet been 
corroborated by RT-PCR.  
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CHAPTER 6 - GENERAL DISCUSSION 
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6.1 Post-transcriptional regulation of microRNAs in ESCs 
Our main focus was to characterise the mechanism behind the differences in 
global miRNA expression in ESCs and differentiated NPSCs. We discovered that 
the majority of miRNAs (~60%) investigated were regulated by transcription. Of 
the remaining ~40% of miRNAs, all of these were post-transcriptionally 
regulated in ESCs. Our data presents a lack of correlation between primary and 
mature miRNA expression levels in ESCs confirming that Drosha often regulates 
or blocks miRNA expression in early developmental stages. The prevalence of 
post-transcriptional miRNA regulation observed in ESCs has been previously 
reported  in mouse embryonic development (Thomson et al., 2006).  
 
It is possible that observed transcription of primary miRNAs that are not 
processed is a potential hallmark of ESCs, which contributes to their plasticity 
and allows for rapid and discrete expression of crucial miRNAs during 
differentiation. This idea is supported when investigating expression of primary 
miRNAs located on chromosome 1 and 2 (fig 3.2.7). Sixteen out of 37 miRNAs 
analysed were actively transcribed and turned-over in ESCs however further 
processing into mature miRNAs is inhibited in ESCs.  
 
The potential mechanisms behind extensive post-transcriptional miRNA 
regulation in ESCs include regulation by RNA binding proteins (RNA-bps) that 
are specifically expressed in ESCs e.g. Lin28. In future we aim to establish if RNA 
binding proteins regulate those miRNAs that we discovered to be post-
transcriptionally regulated (Chapter 3).  
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MicroRNA deep sequencing has contributed to the discovery of huge numbers of 
miRNAs. Out of 2578 human miRNAs recorded in miRBASE, only 300 miRNAs 
are highly sequenced with more than 1000 reads per million (RPM) (miRBase 
and miRGator). This suggests that only 19% of existing miRNAs are likely to have 
functional biological role. With this data we are able to infer that the highly 
expressed miRNAs which are post-transcriptionally regulated in ESCs are likely 
to have a biological role, potentially in early development.  
 
6.2 Alternative polyadenylation of miRNA clusters 
Our investigation of miRNA regulation led to the discovery of alternatively 
polyadenylated primary miRNA transcripts. Primary miR-let-7a/f transcripts are 
alternatively polyadenylated between ESCs and NPSCs, which could play a role in 
the differential expression of mature miRNA (fig 4.2.4). Further study showed 
that each alternatively polyadenylated transcript was able to undergo Drosha 
processing into precursor miRNA however this occurred in the absence of Lin28 
(fig 4.2.5).  
 
The effect of APA can be further investigated by generating primary transcripts 
with mutated PASs rendering them unrecognisable by the cleavage and 
polyadenylation specificity factor (CPSF). Altered primary miRNA transcripts 
could then be transfected into cell lines and the resultant mature miRNA 
expression can be quantitated. We hypothesise that in the case of miR-let-7a/f, 
mutating the PAS positioned between pre-miR-let-7a and pre-miR-let-7f would 
result in decreased production of both mature miRNAs.         
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Post-transcriptional regulation of miRNAs is very apparent in miRNA clusters; 
although clusters are transcribed together individual mature miRNA expression 
can be different within a specific tissue type or between tissues. Recent evidence 
points to the role of tertiary RNA structure as a scaffold for accessory RNA-bps 
which can cause structural remodelling, exposing new binding sites/motifs 
(Chakraborty et al., 2012, Chaulk et al., 2011). In mice, 3’ truncation of the pri-
miR 17-92 can lead to an overall increase in mature miRNA expression (He et al., 
2005) which was later shown to be caused by structural disruption of the cluster 
(Chaulk et al., 2011). In addition, Chakraborty et al. (2012) showed that changing 
the order of miRNA hairpins in the pri-miR-20a-19a cluster results in impaired 
tertiary structure. This leaves the pri-miR-20a-19a cluster exposed to RNA-bp, 
MPC, resulting in altered processing efficiency. APA could work to alter tertiary 
structures of primary transcripts potentially revealing or excluding binding sites 
for RNA-bps that can promote or impede miRNA processing.  
 
Chakraborty et al. (2012) show that organisation of the tertiary structure of 
primary miRNAs may be the first point of post-transcriptional regulation. We 
show that clustered miRNA transcripts undergo extensive alternative processing 
which has the potential to contribute to altering RNA tertiary structure thereby 
influencing RNA-bp-mediated regulation of miRNA processing.  
 
6.3 Effect of Spliceostatin A on nascent RNAs 
Like previous reports we found it difficult to assess the effects of splicing 
inhibitors because RNA transcripts with long half-lives obscured detection of 
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RNAs affected by SSA. We overcame this by isolating nascent RNAs from cells 
allowing us to visualise global effects of SSA. This novel method for analysing the 
effects of SSA will be useful for future studies on splicing inhibitors. 
 
Nuclear and cytoplasmic nascent RNAs treated with SSA and TG003 are 
currently undergoing mass RNA sequencing and analysis (in collaboration with 
Dr Rosenstiel at IKMB, University of Kiel). We hope that this sequencing data will 
help us uncover which RNA transcripts are retained in the nucleus under 
treatment. We would predict that inhibiting the spliceosome will have an effect 
on rRNAs and other intronless genes, however we are not certain if this would be 
due to a direct effect of inhibiting the spliceosome or an indirect effect on 
transcription and export. We will be able to analyse the effects of the two drugs 
and any differences might give insight into the function of the SF3b subunit of 
the spliceosome and the role of CLK1 and CLK7 in splicing which are inhibited by 
SSA and TG003.  Furthermore, identifying RNA transcripts that are not affected 
by the splicing inhibitors could lead to further studies into the role of gene 
sequence and associated binding proteins on spliceosome recognition. We will 
also establish if SSA can affect genes with U12-type introns as proteins of the 
SF3b complex is present in both spliceosomes (Turunen et al., 2012). In fact SSA 
action and binding to the different subcomponents of SF3b has not yet been 
established and perhaps any similarities with the U12-dependant spliceosome 
could help clarify SSA binding.    
 
The spliceosome is present in Saccharomyces cerevisiae spp, despite less than 5% 
of their genome containing introns (Parenteau et al., 2008). In addition deletion 
Figure _ Spliceostatin A and TG003 splicing inhibitors cause retention of RNA in 
the nucleus. A-F) Immunocytochemistry of HepG2 cells. A & D) No treatment. B & 
E) Treatment with 1mM 5-Flurouridine for 2 hours C) Pre-Treatment with 
200ng/ml SSA for 30 mins and then 1mM 5-Flurouridine for 2 hours . F) 
Pretreatment with 2ng/mlTG003 for 30 mins and then 1mM 5-Flurouridine for 2 
hours. Cells were then stained by immunocytochemistry using either anti-BrdU 
and Alexa Fluor 555 antibody or DAPI. Photographs were taken on an SP5 
confocal.  
Figure _ Spliceostatin A and TG003 splicing inhibitors cause retention of RNA in 
the nucleus. A-F) Immunocytochemistry of HepG2 cells. A & D) No treatment. B & 
E) Treatment with 1mM 5-Flurouridine for 2 hours C) Pre-Treatment with 
200ng/ml SSA for 30 mins and then 1mM 5-Flurouridine for 2 hours . F) 
Pretreatment with 2ng/mlTG003 for 30 mins and then 1mM 5-Flurouridine for 2 
hours. Cells were then stained by immunocytochemistry using either anti-BrdU 
and Alexa Fluor 555 antibody or DAPI. Photographs were taken on an SP5 
confocal.  
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of many of these introns proved they were not essential for growth (Parenteau et 
al., 2008). This implies that the spliceosome may have other potential functions 
in addition to splicing, such as mRNA export. Splicing inhibitors are a useful tool 
to elucidate any ulterior roles of the spliceosome, particularly in organisms 
where conditional splicing mutations are not available (Pleiss et al., 2007). 
Understanding the role of individual subunits of the macromolecular 
spliceosome will help uncover the exact role the spliceosome plays in the 
transcriptome; including effects on transcription, mRNA export, miRNA 
biogenesis and expression. 
 
6.4 Splicing and microRNAs 
There are many aspects of splicing and miRNA biogenesis that are 
physiologically linked. The fact that a majority of human miRNAs are located in 
the introns of other genes implies coordinated function of the spliceosome and 
the microprocessor (Rodriguez et al., 2004). Intronic pre-miRNA processing is 
known to occur prior to splicing catalysis (Kim and Kim 2006) and recently it has 
been shown that pre-miRNA transcripts can be immunoprecipitated with the 
spliceosome and Drosha can be immunoprecipitated with splicing intermediate 
introns (Kataoka et al., 2009). 
 
There is a strong evolutionary connection between the RNA splicing machinery 
and miRNA mediated gene silencing (Dumesic et al., 2013, Tabach et al., 2013) 
including a correlation between the expression of miRNA components and the 
number of introns within a species (Tabach et al., 2013). Based on evolutionary 
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analysis it is also thought that a number of proteins involved in intron removal 
are orthologues of proteins involved in miRNA processing (Tabach et al., 2013). 
 
As the microprocessing machinery and the spliceosome are linked in function 
and share components, inhibiting the spliceosome might cause inhibition of 
miRNA processing, potentially resulting in the rise of pri-miRNA expression and 
a decline in mature miRNAs (Dumesic et al., 2013). Janas et al., 2011 show that 
knockdown of the U1 splicing factors can in fact reduce intronic miRNA 
expression, again substantiating the link between splicing and miRNAs. A direct 
consequence of inhibition of the spliceosome will also be seen in mirtrons which 
are directly spliced by the splicing machinery, bypassing Drosha processing. In 
addition we observed alternative splicing of the miR-302 cluster, the 
consequence for which is unknown. It is possible that treatment of ESCs with SSA 
could reveal a potential change in miR-302 expression as a result of inhibiting 
alternative splicing of the transcript. 
 
Advances in sequencing technologies have led to the discovery of an abundance 
of circular RNAs (ciRNA) that arise by splicing of an exon which joins its 5’ and 3’ 
ends to form a lariat. CDR1as is a ciRNA that is known to target miR-7 and act as 
a miRNA sponge causing knockdown of miRNA expression that is 10 times 
greater than any known transcript (Memczak et al., 2013). It is thought that the 
role of ciRNAs could go beyond binding just miRNAs, with potential to also act on 
RNA-bps.  Inhibiting splicing may result in a reduction of ciRNAs which would 
directly affect miRNA activity (Hansen et al., 2013, Memczak et al., 2013). 
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Alteration of tertiary structure by alternative polyadenylation or otherwise can 
have a direct impact on the spliceosome (Chakraborty et al., 2012). As previously 
discussed, the spliceosome stalls at introns containing miRNAs to allow time for 
RNA to fold (Chakraborty et al., 2012). MPC is an RNA-bp that binds to the 
tertiary structure of pre-20a-19a in mice and inhibits its expression 
(Chakraborty et al., 2012). Chakraborty et al., 2012 show that MPC recruitment is 
linked to the spliceosome therefore it is possible that altered tertiary structure 
could lead to increased binding of MPC leading to increased splicing thereby 
impeding pri-miRNA processing. It would be interesting to investigate the effect 
of inhibiting splicing on miRNA targeting; with the inclusion of introns it is 
possible that many miRNAs are able to target the intronic sequences for 
transcript degradation, potentially preventing the production of aberrant 
proteins. 
 
6.5 Conclusion 
We established a novel method to distinguish primary miRNA expression from 
confounding overlapping genes in ESCs and NPSCs. Using the method of 3’RACE 
we were able to identify a significant number of primary miRNAs that were 
inhibited from further processing in ESCs. Furthermore we revealed that miRNA 
gene clusters generated several primary transcripts by alternative 
polyadenylation. This may serve to regulate individual miRNAs independently 
from the rest of the cluster.  
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MicroRNAs have a huge role in early development across many species therefore 
post-transcriptional regulation of miRNAs is likely to be an important biological 
mechanism in human ESCs (Lee et al., 1993, Olsen and Ambros, 1999, Aravin et 
al., 2003, Bernstein et al., 2003). Subsequently further research into the control 
of miRNA expression promises a greater understanding of how the 
differentiation of stem cells can be regulated for the purpose of regenerative 
medicine.  
 
Human ESCs and cancer cell types are known to share miRNA expression profiles 
adding to their repertoire of other shared properties namely, self-renewal and a 
block in differentiation (Kim and Orkin, 2011, Thomson et al., 2006). As a result, 
further study into the regulation of ESC-specific miRNAs may prove useful in 
treating disease.  
 
Finally, we implemented a novel method for isolating nascent RNAs in order to 
establish an improved assay of the splicing inhibitor, SSA. This is likely to 
contribute to our understanding of splicing mechanisms and regulation, with 
potential for aiding the discovery of novel splicing drugs for cancer therapy.  
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Supplementary Material 
Supplementary Table S1 ESC and NPSC miRNAs and their host mRNAs. List of all microRNAs 
cloned from ESCs and NPSCs. Overlapping host mRNA (Host) ID and average expression levels 
(ave. signal) as detected by microarray are given where relevant, na = not applicable, U = 
unclassified EST. Cloning, sequencing and microarray were performed by Dr Elcie Chan. 
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Supplementary Table S3 Genes upregulated by IFNa. The arbitrary numbers represent 
expression levels of the genes in untreated HT1080 cells (Untreated expression) and IFNa 
treated HT1080 cell (IFNa induced expression) Fold difference shows how many times more 
the genes are expressed when induced by IFNa. Identified by GENECHIP array analysis by Der 
et al., 1988.  
Supplementary Table S2 List of verified poly(A) signal motifs (Kalkatawi et al., 2012) 
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Supplementary figure S1 Alternative polyadenylation of miR-21. A) A Schematic of the genomic position 
of pre-miR-21 (blue line) and the 3’RACE sequencing results illustrating the two 3’ends of pri-miR-21 
(black lines). B) Sequence of pre-miR-21 (underlined), the sequences in red indicate the position of the 
two poly(A) tails and the yellow sequence represents the PASs that aid the use of each poly(A) site. C) 
and D) the gels of the two 3’RACE reactions using different primers – show transcripts with two 
different poly(A) sites in primary miR-21 (the sequence of the bands is shown below the gels – the red 
sequence represents the primers used for the 3’RACE and the yellow sequence highlights the putative 
PAS which could cause polyadenylation).     
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Supplementary figure S2 Human and mouse miR-302 cluster sequence alignment. Matching conserved 
sequences are indicated by the “*” below the nucleotides. The underlined sequences indicate the 
precursor miR-302b, 302c, 302a, 302d and 367 (top to bottom respectively). Sequences in yellow 
represent potential PASs (predicted by web-based tool: https://github.com/coggy/signals_in_sequence) 
and the red sequence annotate the multiple 3’ends established by 3’RACE and ABI 3730xl DNA 
sequencing. 
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Supplementary figure S4 PCR of miR-let-7f primary transcript, digestion of this insert post ligation into 
pTRIPz and sequencing of the insert and vector A) shows a PCR gel with miR-let-7f product, this DNA is 
then expressed in pTRIPz vector B) Shows the gel after digestion of the pTRIPz vector with BamH1, the 
miR-let-7f insert is represented by the smaller band. C) The sequence of a portion of the pTRIPz vector 
and the DNA insert.  
A 
B 
C 
Supplementary figure S3 PCR of miR-let-7a primary transcript, digestion of this insert post ligation into 
pTRIPz and sequencing of the insert and vector A) shows a PCR gel with miR-let-7a product, this DNA is 
then expressed in pTRIPz vector B) Shows the gel after digestion of the pTRIPz vector with BamH1, the 
miR-let-7a insert is represented by the smaller band. C) The sequence of a portion of the pTRIPz vector 
and the DNA insert.  
A 
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Supplementary figure S5 PCR of miR-let-7af primary transcript, digestion of this insert post ligation into 
pTRIPz and sequencing of the insert and vector A) shows a PCR gel with miR-let-7af product, this DNA is 
then expressed in pTRIPz vector B) Shows the gel after digestion of the pTRIPz vector with BamH1, the 
miR-let-7af insert is represented by the smaller band. C) The sequence of a portion of the pTRIPz vector 
and the DNA insert.  
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